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Clostridium difficile infection (CDI) was 
discovered in 1978 as an important 
cause of antibiotic-associated diar-
rhoea and pseudomembranous colitis 
[ 1 ]. CDI became the most common 
healthcare-associated infection in 
Northern-America and Europe during 
the antibiotic era, especially after 
global spread of a fluoroquinolone- 
resistant ribotype 027 strain originat-
ing from the Canadian province 
Quebec in 2003 [ 2, 3 ]. The rise of CDI in 
Northern-America and Europe urged 
the use of epidemiological surveil-
lance systems to monitor disease dy-
namics and rapidly detect outbreaks 
[ 3 ]. In Europe, national surveillance 
activities were supported by the Euro-
pean Centre for Disease Prevention 
and Control (ECDC) gradually moving 
towards standardised epidemiologi-
cal surveillance with molecular typ-
ing systems for CDI [ 4 ]. However, valid 
estimations of the infection burden of 
CDI in Europe were hampered by the 
heterogeneity and insufficiency of 
diagnostic algorithms for CDI, lack 
of standardised typing systems and 
incomplete surveillance methodolo-
gies. This thesis includes two studies 
conducted within a project named ‘the 
European CDI Surveillance Network’ 
(ECDIS-Net) focussing on enhancement 
of CDI surveillance and laboratory 
capacity for CDI in Europe. In the 
Netherlands, a sentinel epidemiologi-
cal surveillance system monitors the 
incidence of CDI and the occurrence 
of outbreaks in hospitals, but not in 
other healthcare facilities or in the 
community. This thesis describes (spa-
tial) trends in the epidemiology of CDI 
in the Netherlands according to senti-
nel surveillance, in particular for 
children and the potentially zoonotic 
C. difficile ribotype 078. Data of a com-
munity-based case-control study to 
estimate the burden of CDI in the 
community, was used to apply spatial 
scan statistics to detect CDI clustering 
beyond the hospital setting. Finally, 
this thesis provides directions for 
future epidemiological surveillance 
systems of CDI, both in the Nether-
lands and Europe.
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Clostridium difficile
COMMENSAL AND PATHOGEN
Clostridium difficile is a ubiquitous gram-positive, spore-forming, rod-shaped bacte-
rium, firstly observed in the bacterial flora of meconium from healthy neonates 
in 1935 by Hall and O’Toole [ 5 ]. The bacterium was called “Bacillus difficile” for its 
difficulty to be cultured, growing exclusively under anaerobic conditions. The 
bacterium did not cause any symptoms in the neonates studied, but appeared to 
be highly pathogenic in animal models due to production of an exotoxin [ 5 ]. It 
was not just a matter of chance that C. difficile was firstly isolated from neonates; 
C. difficile colonisation is the highest during early life in humans (prevalence of 
26%, with a range of 18-90%) [ 6, 7 ]. 
C. difficile did not appear to be an important cause of disease before the antibiotic 
era [ 8 – 11 ]. The introduction of antibiotics, especially clindamycin in the 1960s, led 
to an increase of antibiotic-associated colitis [ 11 – 13 ]. In 1978, Bartlett et al. recog-
nised toxins of C. difficile to be the cause of antibiotic-associated pseudomembra-
neous colitis in adults [ 1 ]. The bacterium was renamed “Clostridium difficile” 
(κλωστήρ: Greek for rod) [ 14 ]. Recently, the bacterium has been reclassified as 
Clostridioides difficile [ 15 ]. Subsequent studies confirmed antibiotic use to be the 
foremost risk-factor for C. difficile infection (CDI) [ 11 ]. Antibiotics create a niche for 
C. difficile growth and toxin production in the gut due to loss of other microbial 
communities that compete for nutrients and/or interfere with more specific met-
abolic pathways (e.g. bile acid metabolism) [ 16, 17 ]. During or soon after antibiotic 
use, the odds for getting CDI increase a 7–10-fold, and gradually normalise dur-
ing a period of 3 months [ 18, 19 ]. The risk is dose dependent [ 20 ] for and the high-
est for (third-generation) cephalosporins and clindamycin [ 21, 22 ]. Disruption of 
the gut microbiota is not the exclusive preserve of antibiotics; also other drugs, 
such as proton pump inhibitors, affect the gut microbiota and increase the risk 
for CDI [ 23 ].
C. difficile belongs to the Peptostreptococcaceae family [ 15, 24 ] within the genus of 
Clostridia with more than 150 species. Around 15 of these species, including C. 
difficile, C. perfringens, and C. tetani, are capable to produce toxins, and thereby 
cause infection in humans [ 14 ]. C. difficile is known for its potential to produce a 
toxin A (tcdA), a toxin B (tcdB), and a binary toxin (C. difficile transferase; CDT) [ 25 ]. 
Some C. difficile subspecies carry one or more toxin genes (‘toxigenic’ strains) and 
these toxin genes can be acquired and lost though time [ 26 ]. Toxin A and B inac-
tivate regulatory proteins (Rho-GTPases) of the cytoskeleton, and thereby cause 
apoptosis of the epithelial cells in the gut [ 27, 28 ]. Binary toxin is a ADP-ribosylat-
ing toxin that induces formation of microtubule-based protrusions that might 
facilitate adherence and colonisation [ 29, 30 ]. Its role in C. difficile virulence is a 
topic of debate [ 31 ]. C. difficile contains many other factors to invade and survive 
hostile circumstances [ 32 ]. For example, specific adhesion molecules on the cell 
surface of C. difficile were found to facilitate the binding and release from target 
cells [ 33 ]. The ecological fitness of C. difficile –linked to its ability to cause disease 
0 1 1C H A P T E R  0 1
0
1
and emerge– varies per genotype [ 34 ]). The exceptional ecological fitness of a gen-
otype named PCR ribotype 027/NAP1 facilitated its worldwide transmission since 
2003 and ability to cause outbreaks [ 2, 34 ]. 
Like other clostridia, C. difficile sporulates to survive the aerobic conditions out-
side the hosts gut, indispensable for transmission to other hosts ( Figure 1 ) [ 35 ]. 
C. difficile spores are metabolically dormant and have a spore coat covered by an 
exosporium, causing resistance to other environmental stress-factors (e.g. anti-
septics) as well [ 35, 36 ]. Besides, sporulation helps the bacterium to resist antibiot-
ics and the host immune system after digestion [ 35 ]. C. difficile spores are excreted 
by both symptomatic as asymptomatic humans and animals [ 37, 38 ]. Yet, sympto-
matic patients have higher levels of skin and environmental contamination than 
asymptomatic carriers (Risk Difference 20%) [ 39 ]. 
  Stages of the Clostridium dif-
ficile life cycle in the human gastrointestinal 
tract. (copyright Smit 2017).
Figure 1
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PREVENTION OF CDI
The presence of toxigenic C. difficile in the gut does not lead to infection in hosts 
with an adequate colonisation resistance and may even protect against CDI (Risk 
Ratio 0.3) [ 40, 41 ]. CDI occurs when growth and toxin production of commensal or 
recently acquired C. difficile surpasses the host resistance. The host resistance is 
influenced antibiotic use, age, underlying diseases and other drugs that affect 
the gut microbiota or immune system; the most well-described risk factors for 
CDI [ 42 ]. In hospitalised patients whom usually have a reduced colonisation re-
sistance for CDI, exposure to symptomatic CDI patients and/or environmental 
contamination increases the risk for CDI (Hazard Rate 1.2) [ 43, 44 ]. Environmental 
C. difficile exposure in hospitals can be significantly reduced by daily and/or termi-
nal bleach disinfection, and multifaceted campaigns to improve hand hygiene 
[ 45 ]. Restrictive antibiotic stewardship programmes (aiming to persevere the 
patient resistance for CDI) can reduce the incidence of CDI by 48-49%, although 
the evidence for this finding is weak [ 46, 47 ]. The largest preventative effects has 
been shown for daily and terminal bleach disinfection, antibiotic stewardship, 
and bundled interventions (e.g. improved hand hygiene, contact precautions, 
environmental cleaning, and antibiotic stewardship) [ 45, 48 ]. During an outbreak, 
these measures are usually intensified [ 49 ]. Recent developments in the field of 
high resolution molecular typing methods (whole-genome sequencing) resulted 
in a shift of previously generally accepted hypothesis on nosocomial CDI trans-
mission. It was found that only 20-45% of hospital CDI results from direct trans-
mission from other symptomatic patients [ 50 – 52 ]. Alternative reservoirs –within 
and beyond healthcare facilities– were not elucidated and need further investiga-
tion. Reservoirs include ‘one or more epidemiologically connected populations or envi-
ronments in which the pathogen can be permanently maintained and from which infection 
is transmitted to the target population’ [ 53 ]. Reservoir populations of C. difficile include 
several animal species (e.g. pets) and asymptomatic infant and adult carriers [ 54 ]. 
Besides, the living environment is widely contaminated with C. difficile spores; 
25% of the parks, 17% of the households and 17% of the hospitals contains spores 
of toxigenic C. difficile (in southern United States) [ 55 ]. In addition, C. difficile spores 
are isolated from water and food in varying percentages [ 36, 37 ]. Therefore, 
tracing the attribution of different C. difficile sources to CDI is extremely complex 
but would be useful to reduce exposure, especially in those with a decrease of 
colonisation resistance. Antibiotic stewardship in the outpatient setting is impor-
tant as in hospitals; e.g. a 10% reduction of antibiotic use could prevent 17% of the 
community-acquired CDI cases [ 56 ].
DIAGNOSING CDI
The range of symptoms caused by toxigenic C. difficile is wide and overlaps other 
gastrointestinal infections. Severe damage of the colon by C. difficile toxins results 
in elevated yellow-white nodules or plaques consisting of neutrophils, nuclear 
debris and other inflammatory elements on the mucosal surface (“pseudomem-
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branes”) observed by endoscopy [ 57 ] potentially leading to ileus, toxic megacolon, 
septic shock and death. The majority of the outpatients diagnosed with CDI has 
persistent diarrhoea, watery stools, weight loss, abdominal pain, and watery or 
slimy stools [ 58 – 60 ]. About 4-8% of the outpatients are hospitalised because of CDI 
and death due to CDI is rare (<1%) [ 58, 59, 61 ]. In contrast, hospital patients with CDI 
more often have systemic signs of infection indicative of severe disease [ 62 ] such 
as leucocytosis (29-50%) and fever (37-56%) [ 63, 64 ]. Within 30 days, 13% of the 
hospital patients with CDI decease, and 10% of these deaths were found to be 
related to CDI [ 65 ]. Children tend to have milder disease compared to adults [ 66 ]. 
Laboratory diagnosis of CDI is one of the most discussed topics in CDI surveil-
lance. The main problem is the absence of a single diagnostic test that has opti-
mal test characteristics (high sensitivity and specificity) and is easy and quick to 
perform. Besides, research and communication on CDI diagnostics is complicated 
by the presence of two golden standards; a cell cytotoxicity assay detecting free 
toxin in faeces and a cytotoxigenic culture detecting toxigenic C. difficile. In 2009, 
a two-step laboratory algorithms was recommended for diagnosis of CDI by the 
ESCMID diagnostic guideline for CDI [ 67 ]. Moreover, the guideline endorsed CDI 
laboratory testing of merely unformed stool samples using the ‘3-day rule’ (test-
ing samples of all diarrhoeic patients ≥72 hrs admitted to a healthcare facility). A 
revised ESCMID diagnostic guideline was published in 2016, e.g. abandoning use 
of toxin EIAs (without detection of GDH) as a first step of the diagnostic algorithm 
for CDI and adding an optional third step for indistinct cases (CDI or carriage of 
toxigenic C. difficile) [ 68 ]. 
CDI TREATMENT
CDI can resolve by discontinuation of the inciting antibiotic. When specific treat-
ment is indicated, it is recommended to treat a first CDI with an oral ten-day 
course of metronidazole in mild cases, or a ten-day course of vancomycin in 
severe cases [ 69 – 71 ]. Metronidazole produces free radicals that break DNA strands 
and cause cell death of several anaerobic bacteria [ 72 ], whereas vancomycin 
inhibits cell-wall synthesis in gram-positives by binding to the peptidoglycan pre-
cursor [ 73 ]. Vancomycin has a higher symptomatic cure rate than metronidazole 
(79 vs. 72%; Risk Difference 7%) but is more expensive [ 74 ] and has more profound 
negative effects on the microbiota [ 75 ]. C. difficile resistance to both antibiotics is 
rare [ 76 ], but needs further clinical evaluation. Nine other antibiotics are available 
for CDI [ 74 ], among them fidaxomycin that has a lower recurrence rate compared 
to vancomycin in cases other than C. difficile ribotype 027 [ 69, 77 ] and mainly has 
its place for treatment of recurrent CDI [ 69 ]. Decision-making (supported by pre-
diction models), involves consideration of disease severity, disease recurrence, 
causative factors, feasibility of oral treatment, C. difficile type and antibiotic sus-
ceptibility [ 69 ]. 
The antithesis of treating an antibiotic-induced disease with antibiotics [ 78 ] stimu-
lated the development of new CDI treatments. The most striking ‘novel’ treatment 
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of CDI includes transfer of a healthy donors stool sample into the gut of an infect-
ed patient (faecal microbiota transfer; FMT) effective in 94% of the patients with 
recurrent CDI [ 79 ]. In 2015, a National Donor Feces Bank (NDFB) was initiated to 
provide FMT for Dutch hospitals in a standardised manner [ 80 ]. Alternative pre-
ventative or treatment modalities in development that focus on the host resist-
ance against CDI are vaccination, human monoclonal immunotherapy [ 81 ], toxin 
binders, administration of non-toxigenic C. difficile strains [ 82 ] and microbiome-
based strategies (e.g. administration of Firmicutes spores) [ 83, 84 ]. 





Epidemiological surveillance systems originate from the mid-20th century and 
involve “the systematic collection, analysis, interpretation and timely dissemination of 
health data for the planning, implementation and evaluation of public health programmes” 
[ 85, 86 ]. Surveillance systems aim to generate “a public health response leading to the 
control and prevention of adverse health events, or to a better understanding of the process 
leading to an adverse outcome” (e.g. disease risk factors or transmission) [ 86 ]. Epide-
miological surveillance systems are categorised into disease-specific, syndromic, 
and event-based surveillance [ 87 ]. Sub classifications refer to the method of data 
collection, e.g. differentiating healthcare provider-based from laboratory-based 
surveillance, active from passive surveillance, and prospective from retrospec-
tive surveillance [ 88 ]. Yet, ‘retrospective surveillance’ seems like a contradiction-
in-terms that should be avoided. Another sub classification differentiates senti-
nel from national surveillance [ 89 ]. Sentinel surveillance refers to collection of 
data from a representative fraction of the population to monitor disease trends in 
a larger area. A sentinel approach is useful when high-quality data is needed that 
cannot be obtained through passive surveillance [ 89 ] and the workload and/or 
costs of national surveillance is too high. The methodology of an epidemiological 
surveillance system is adapted to its aim; control of an infectious disease with a 
high disease burden requires comprehensive national surveillance, whereas 
elimination of a rare infectious disease requires more detailed information [ 89 ]. 
A surveillance system can also be applied at a regional or local level, e.g. within a 
single hospital, to guide the local infection control measures.
INTRODUCTION OF NATIONAL SURVEILLANCE OF CDI
Historically, the use of epidemiological surveillance systems for CDI has been trig-
gered by the occurrence of outbreaks. One of the first publications on surveillance 
of CDI describes the implementation of active hospital-wide surveillance after the 
recognition of a CDI cluster in Belgium in 1988 [ 90 ]. Interestingly, the authors note 
that surveillance outcomes were initially biased due to unawareness and underdi-
agnosis of CDI. After addressing these issues, surveillance and molecular typing 
led to improved prevention of CDI. In the Netherlands, a first laboratory-based sur-
veillance study was conducted in 2005 [ 91 ]. This study coincided with the occur-
rence of PCR ribotype 027 CDI outbreaks in the Netherlands [ 92 ]. In 2006-2009, 
Dutch national surveillance was limited to severe cases of CDI and outbreaks and a 
three-year surveillance study [ 93 ]. In 2009, continued Sentinel Surveillance for CDI 
was implemented in a subset of hospitals in the Netherlands ( Figure 2 ). Aims are to:
 • obtain continuous incidence rates of CDI in hospitals in the Netherlands
 • identify and characterize new circulating PCR ribotypes
 •  correlate new circulating PCR ribotypes with changes of epidemiology, 
and clinical syndromes of CDI
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The Dutch Sentinel Surveillance for CDI is a disease-specific, healthcare-provider 
based surveillance system that targets acute care hospitals only. Inclusion of 
patients is based on the presence of clinical symptoms of CDI and laboratory con-
firmation. The surveillance system is exceptional in Europe for its unselective 
PCR ribotyping of all submitted C. difficile strains. Hospital participation in Senti-
nel Surveillance for CDI is voluntary. Outcomes of Sentinel Surveillance for CDI 
are used to prioritise and monitor national control of CDI, especially transmis-
sion and outbreaks of ribotype 027 and other C. difficile strains with an increased 
ecological fitness. Hospital get direct notification of molecular typing results in 
case of ribotype 027 and/or outbreaks and can receive additional support for local 
infection control measures. Healthcare facilities not participating in Sentinel 
Surveillance for CDI are able to submit samples for (free of charge) PCR ribotyp-
ing in case of severe CDI or suspected outbreaks.
  Flow chart of Sentinel Surveillance for CDI in the Netherlands. The National Reference 
Laboratory for C. difficile is a collaboration of the Department of Medical Microbiology of the Leiden 
University Medical Centre in Leiden and the National Institute for Public Health and the Environment 
(RIVM) in Bilthoven. aThe Orisis registration system of the RIVM is used for case registration with clinical 
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SURVEILLANCE OF CDI IN EUROPE
In Europe, national surveillance activities of European countries were supported 
by ECDC after recognition of the emergence of ribotype 027 in Europe in 2006, 
gradually moving towards standardised epidemiological surveillance and molec-
ular typing systems [ 4 ]. In the same year, ECDC and the ESCMID study group for C. 
difficile publised ‘interim’ surveillance definitions for CDI [ 3 ]. European countries 
were advised to adapt their national surveillance system to their local situation, 
selecting for laboratory-based surveillance or healthcare provider-based surveil-
lance in specific, targeted populations. In 2005, a first pilot of multicountry two-
month survey in Europe was conducted [ 94 ]. This study underlined the need for 
implementation of a standardised case-definition and harmonisation of laborato-
ry diagnostics for benchmarking. The need for routine surveillance was rein-
forced in the ESCMID guideline to control transmission of CDI in 2008, also in the 
absence of outbreaks [ 95 ]. In that year, a first periodic European surveillance for 
CDI illustrated the added value of multicountry surveillance in Europe [ 64 ]. How-
ever, the continued heterogeneity of diagnostic, molecular typing and surveil-
lance methodologies hampered implementation of European-wide surveillance.
By way of comparison, The Centers for Disease Control and Prevention (CDC) 
integrated CDI surveillance as separate component in the Healthcare-Associated 
Infections Community Interface (HAIC) of the Emerging Infections Program (EIP) 
in the United in 2009 [ 96 ]. Before that time, surveillance was implemented in the 
National Nosocomial Infection Surveillance System initiated in 1970 [ 97 ]. The CDI 
surveillance component of EIP is population-based and aims to estimate the 
burden of health-care associated CDI and in the community, describe other 
epidemiological aspects of CDI and characterize C. difficile strains [ 96 ]. 
In 2011, 14 of the 31 European countries (45%) had adopted CDI surveillance and 
methodologies were heterogeneous. Continued integration of microbiological 
data was limited [ 98 ]. A multistate CDI surveillance system, such as implemented 
in the United States[ 99 ], was considered the only viable option to monitor and 
control CDI in Europe. Objectives of such a European surveillance system of CDI 
were agreed to [ 100 ]: 
 • estimate the incidence of CDI in European acute care hospitals
 • assess the burden of CDI in European acute care hospitals
 •  provide participating hospitals with a standardised tool to measure and 
compare their own incidence rates with those observed in other partici-
pating hospitals
 • assess adverse outcomes of CDI including death
 •  describe the epidemiology of C. difficile at the local, national and European 
level, in terms of factors such as antibiotic susceptibility, PCR ribotype, 
presence of toxin A (TcdA), toxin B (TcdB) and binary toxin, morbidity and 
mortality of infection, and the detection of new/emerging types
The ‘European CDI Surveillance Network’ (ECDIS-Net) aimed to optimise and test the 
feasibility of a surveillance protocol for European Surveillance of CDI in 2010-2014.
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USE OF MOLECULAR TYPING FOR SURVEILLANCE
Molecular typing methods aim to identify relatedness of pathogens and are used 
to test epidemiological hypotheses on transmission events [ 101 ]. Hence, molecu-
lar typing is vital for outbreak investigations [ 102 ]. Molecular typing also supports 
monitoring of ‘outbreak-associated’ or more virulent genotypes in an endemic 
setting. Several typing methodologies for C. difficile were developed and imple-
mented all over the world, targeting different parts of the C. difficile genome [ 103 
– 105 ]. PCR ribotyping is the traditional typing method in Europe. It targets the 
intermediary region of the 16S and 23S rRNA genes with a variable length, present 
in multiple copies of the ribosomal operon in the genome [ 106, 107 ]. Identical PCR 
ribotypes have an equivalent banding pattern after visualising the DNA frag-
ments [ 106 ]. Currently, 219 PCR ribotypes can be discriminated by the national 
reference laboratory for C. difficile in the Netherlands [ 108 ]. Capillary gel-based 
electrophoresis ribotyping has an improved performance compared to conven-
tional (agarose gel-based) PCR ribotyping for inter-laboratory standardization 
[ 109 ]. Moreover, the electronic portability of capillary ribotyping results is consid-
ered to dissolve the current problem of limited reference/central databases and 
contribute to more rapid detection of internationally emerging PCR ribotypes 
[ 109 ]. C. difficile transmission events are hallmarked by identical PCR ribotypes, 
but far more discriminatory typing methods are required to confirm transmis-
sion events and to study outbreaks [ 103, 105 ]. One of these methods is Multiple-
Locus Variable-Number Tandem-Repeat Analysis (MLVA), targeting seven regions 
with short tandem repeats spread in the C. difficile genome [ 110 ]. The total number 
of differences in repeat copy number at each locus (summed tandem-repeat 
difference; STRD) describes the genetic relatedness of the studies isolates [ 111 ]. 
Whole genome sequencing –of which the application for C. difficile was firstly 
reported in 2010 [ 112 ]– has the capability to distinct strains at a single nucleotide 
level; single nucleotide variants (SNV) [ 103 ]. The application of whole-genome 
sequencing led to important insights in the evolution and (drivers of ) transmis-
sion of CDI [ 2, 50, 112 ].
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The burden of CDI in hospitals
After the discovery of C. difficile as a pathogen in 1978, CDI was soon recognised as 
the foremost cause of antibiotic-associated diarrhoea in hospitals, causing 15-25% 
of all cases [ 102 ]. The regional incidence rate of CDI ranged from 1.1-7.9 cases per 
10,000 patient-days in the United States according to data from the National 
Nosocomial Infections Surveillance System in 1978-2001 [ 97 ]. A gradual increase 
of the incidence of CDI was noted for IC units and smaller hospitals. In Canada, 
the incidence rate of CDI was estimated at 6 cases per 10,000 patient-days in 1997 
(corresponding to a prevalence of 13% among all diarrhoeic inpatients) by surveil-
lance part of the Canadian Nosocomial Infection Surveillance Program [ 113 ]. In 
2002, the incidence rate of CDI increased dramatically in the region of Quebec in 
Canada to 15 cases per 10,000 patient-days [ 114, 115 ]. Almost a quart (23%) of the 
affected patients died within 30-days compared to 7% of matched controls [ 115 ]. 
Continuing signs of increased severity of CDI and the occurrence of outbreaks led 
to the recognition of the emergence of an earlier uncommon ribotype 027/NAP 1 
strain in Canada and the United States in 2005 [ 116, 117 ].
In the Netherlands, the endemic incidence of CDI remained unreported until 2005 
but sporadic outbreaks were noticed [ 118 – 120 ]. In 2005, an excessive number of CDI 
outbreaks occurred with a high impact on the local incidence rates and mortality 
[ 91, 121 – 125 ]. Also other European countries, i.e. the United Kingdom, Belgium and 
France, were affected by CDI outbreaks [ 94 ]. These outbreaks were related to the 
global spread of the ribotype 027/NAP1 strain from Canada and the United States 
towards Europe [ 2 ]. Transmission of ribotype 027 had been reported by 11 and 16 
European countries in 2007 and 2008, respectively [ 126 ]. Introduction of ribotype 
027 could be linked to international travels in some countries. The exceptional 
virulence of ribotype 027 was attributed to increased toxin production (associated 
to its tcdC gene mutation) and altered antibiotic resistance [ 126 ]. Retrospective in-
vestigation using whole-genome sequencing demonstrated that fluoroquinolone 
resistance acquired by two separate ribotype 027/NAP1 lineages contributed to its 
emergence and undermined the role of the tcdC gene mutation [ 2 ]. 
The Netherlands was the first European country that reported a decrease of 
ribotype 027 in 2006 by national surveillance data [ 93 ]. The incidence rate of CDI 
in hospitals in the Netherlands stabilised at 3 cases per 10,000 patient-days and 
ribotype 027 caused not more than 3% of all CDI (virtually all relating to health-
care). However, transmission of ribotype 078 caused concern due it high abun-
dance, especially compared to other countries [ 93 ]. A European surveillance esti-
mated the incidence of healthcare-associated CDI at 4 cases per 10,000 patient- 
days in 2008. Ribotype 027 was isolated from 5% of CDI, and less prevalent than 
e.g. ribotype 078 [ 64 ] The United Kingdom had a remarkable high prevalence of 
ribotype 027, but succeeded to reduce the national incidence rate of CDI and prev-
alence of ribotype 027 by antibiotic stewardship (e.g. restricting fluoroquinolone 
prescribing) in additional to other infection prevention control measures in 2007-
2013 [ 127 ]. ECDC estimated the overall number of healthcare-acquired CDI at 
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  Infographic of the Centers for Dis-
ease Control and Prevention (CDC) on prevention 
of CDI.
Figure 3
123,997 (95% CI: 107,697-441,969) in 2011-2012 [ 128 ]. Yet, thereafter ribotype 027 
emerged in Eastern-Europe [ 129 ]. 
In the United States however, 31% of healthcare-associated CDI and 19% of communi-
ty-associated CDI was caused by ribotype 027/NAP1 in 2011 [ 99 ]. It was estimated that 
approximately 453,000 patients were affected by CDI in 2011 (95% confidence inter-
val: 397,100 -508,500) of which 29,000 succumbed ( Figure 3 ). CDC denoted CDI as one 
of the three urgent ‘antibiotic resistance threats’ in the United States in 2013 [ 130 ]. 




As hospitals, long-term care facilities (LTCF) host a population at high risk 
for developing CDI, due to frequent antibiotic consumption, advanced age, 
comorbidities and suboptimal infection prevention. LTCF residents can facilitate 
C. difficile transmission between hospitals and LTCF [ 111 ]. In the United States, the 
number of CDI cases in nursing homes in 2012 was estimated at 112,800 (95% 
confidence interval: 93,400-131,800), circa one quarter of all CDI cases [ 131 ]. These 
numbers may be biased due to the fact that C. difficile laboratory testing in nurs-
ing homes is not always part of daily routine. A large proportion of the patients 
(76%) had been hospitalised ≤12 weeks before CDI and the very old (>85 yrs) were 
at particular risk [ 131 ]. In Europe, the burden of healthcare-associated infections 
in LTCF is monitored by repeated point-prevalence surveys. CDI was not one of 
most common HAI or isolated microorganisms. The CDI-specific burden was not 
reported but approximated 37,900 (0.9% of all HAI) on the basis of available data 
[ 132 ]. There are no national estimates of CDI in LTCF in the Netherlands, but out-
breaks have been reported [ 3 ]. 
In the general population, the incidence of CDI in the community was estimated 
at 0.67 cases per 10,000 person years (95% CI 0.58–0.78) in the Netherlands in 2010-
2012, comparable to Salmonella spp. This corresponded to a prevalence of 1.5% 
amongst community residents that visit their general practitioner with diar-
rhoea and submit a stool sample for laboratory testing [ 59, 60 ]. In another Dutch 
study, 4.2% of community residents with gastro-intestinal complaints were 
positive for toxigenic C. difficile using PCR, higher than Salmonella spp [ 133 ]. In 
Denmark, the community incidence of CDI was 2.3 cases per 10,000 person years 
[ 58 ]. In Minnesota, United States, the incidence of community-acquired CDI was 
estimated at 0.96 cases per 10,000 person years in 1991-2005 in a population-
based study [ 134 ]. While recent literature underlines the increasing burden of CDI 
in the community, the substantial community burden of CDI has been confirmed 
decades ago –prior to the emergence of ribotype 027/NAP1–if tested for [ 135 ]. Yet, 
the minority of the diarrhoeic community patients were tested for CDI at that 
time [ 135, 136 ].
Community patients with CDI have a rather different risk profile compared to 
hospital patients [ 134, 137 ]. Antibiotic use is the foremost risk-factor for CDI as in 
hospitalised patients, but absent in a considerable proportion (30-60%) of the com-
munity patients [ 59, 60, 137, 138 ]. It was suggested that other disrupting factors of 
the microbiome cause CDI in this subpopulation of non-exposed patients (e.g. 
proton-pump inhibiters) [ 139 ]. As mentioned before, C. difficile reservoirs include 
asymptomatic infant and adult carriers, and animals (e.g. pets). Food, water and 
other environmental contamination can be considered as ‘sinks’ rather than res-
ervoirs, but may be part of CDI transmission paths. In previous years, molecular 
studies aimed to trace CDI sources. One of these studies showed that 13% of CDI 
in adults were genetically related to infants strains according to whole-genome 
sequencing [ 140 ]. Advanced age, breastfeeding and exposure to pet dogs were 
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found to be risk factors for C. difficile in children in the same study. Animal contact 
has been recognised to increase the risk of CDI in children <2 yrs old by others 
[ 138 ]. Phylogenetic results of other whole-genome sequence studies suggest that 
numerous long-range transmission events occur between pet dogs and humans 
[ 141 ], as well as pigs and humans [ 142, 143 ]. Transmission paths have not been 
elucidated. In the Netherlands, piglets are frequently colonised by C. difficile PCR 
ribotype 078 [ 144 ] and contamination of the farm environment has been demon-
strated [ 145 ]. Persons with daily contact with pigs had a 1:4 risk to be positive 
for C. difficile in a small study, virtually all ribotype 078 [ 146 ]. In Central North 
Carolina, one of the largest pig producing states in the United States, environ-
mental exposure to livestock farms increases the risk for community-acquired 
CDI [ 147 ]. Moreover, CDI complies with some criteria of foodborne disease. Yet, the 
attribution of food to CDI transmission is considered low, as illustrated for hospi-
talised patients [ 148 ]. C. difficile cannot germinate and grow in food, and outbreaks 
of CDI were never found to be food-related [ 37, 149 ]. Yet, regular consumption of 
beef was an imported risk factor (Odds Ratio 5.5) of community-acquired CDI for 
adults in Denmark in contrast to other food products [ 138 ]. Overall, a complex 
interplay of animal and human reservoir populations and environmental sources 
(‘sinks’) need to be considered for CDI transmission beyond hospitals.
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Outline of the thesis
This thesis aims to describe contemporary changes of the epidemiology of CDI 
in the Netherlands and Europe and the subsequent introduction of a new stand-
ardised epidemiological surveillance system for CDI in Europe. Findings will be 
used to guide future directions of epidemiological surveillance systems for CDI 
–in particular for Europe and the Netherlands. This will improve estimations of 
the infection burden and helps to understand C. difficile sources and transmission 
routes that are needed for appropriate infection prevention control interventions. 
The heterogeneity of existing epidemiological surveillance systems for CDI in 
Europe hampered a valid estimation of CDI burden and illustrated the need for a 
standardised European-wide surveillance system for CDI. However, suboptimal 
laboratory diagnostic capacity was considered as the foremost barrier for imple-
menting European-wide surveillance for CDI. Besides, application of various 
non-standardised molecular typing methodologies prevented their use for moni-
toring transmission and control. In 2010, ECDC supported a 4-year project named 
‘the European CDI Surveillance Network’ (ECDIS-Net) to enhance CDI surveil-
lance and laboratory capacity to test for CDI. This thesis incorporates two studies 
that were conducted within the framework of ECDIS-Net. CHAPTER 2 evaluates 
changes in local laboratory diagnostic and national typing capacity for CDI 
through cross-sectional surveys amongst ECDIS-Net participants in 33 European 
countries in 2011 and 2014. CHAPTER 3 explores the feasibility of implementing 
a standardised European surveillance protocol for CDI through a three-month 
pilot in 14 countries in 2013. This study also illustrates the added value of 
collecting detailed epidemiological and microbiological data on CDI at European 
level. ECDIS-Net activities resulted in initiation of European Surveillance of CDI 
in EU/EEA countries by ECDC in 2016. 
The Netherlands has a national reference laboratory in place to support 
epidemiological surveillance and molecular typing of CDI since the recognition 
of ribotype 027 outbreaks in 2005. A national Sentinel Surveillance for CDI was 
implemented for ongoing monitoring of the incidence of CDI and detection of 
new outbreaks in 2009. According to this surveillance, the incidence of CDI stabi-
lised at 3 cases per 10,000 patient-days. Yet, the burden of CDI in children was 
never examined in detail but has been reported to increase in other countries. 
CHAPTER 4 investigates changes of the number of reported CDI amongst children 
in the Netherlands. Additionally, the clinical and microbiological characteristics 
of CDI in hospitalised children are compared to adults to determine if additional 
strategies to prevent, diagnose, and treat CDI in children are needed. Overall 
ribotype 027 caused not more than 3% of all CDI, but the high incidence of 
ribotype 078 caused concern because of its potential relation to pig-farming. 
CHAPTER 5 assesses the association between hospital incidence rates or ribotype 
078 and provincial pig-farming. This study also incorporates the use of spatial 
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scan statistics to search for clustering of community-CDI that could indicate 
sources of CDI beyond hospitals. CHAPTER 6 extends the use of spatial scan statis-
tics in a community-based case-control study of CDI, with detailed data on envi-
ronmental exposure of community-acquired CDI patients. These data are used to 
test livestock exposure as a risk factor for community-acquired CDI.
CHAPTER 7 elaborates on how advanced insights in the epidemiology, sources and 
transmission of CDI challenge present surveillance systems and synthesises 
future directions for improved surveillance systems and control of CDI. 
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Suboptimal laboratory diagnostics 
for Clostridium difficile infection (CDI) 
impedes its surveillance and control 
across Europe. We evaluated changes 
in local laboratory CDI diagnostics 
and changes in national diagnostic 
and typing capacity for CDI during the 
European C.difficile Infection Surveil-
lance Network (ECDIS-Net) project, 
through cross-sectional surveys in 33 
European countries in 2011 and 2014. 
In 2011, 126 (61%) of a convenience 
sample of 206 laboratories in 31 coun-
tries completed a survey on local diag-
nostics. In 2014, 84 (67%) of these 126 
laboratories in 26 countries completed 
a follow-up survey. Among laboratories 
that participated in both surveys, use 
of CDI diagnostics deemed ‘optimal’ or 
‘acceptable’ increased from 19% to 46% 
and from 10% to 15%, respectively 
(p  < 0.001). The survey of national ca-
pacity was completed by national 
coordinators of 31 and 32 countries in 
2011 and 2014, respectively. Capacity 
for any C. difficile typing method in-
creased from 22/31 countries in 2011 
to 26/32 countries in 2014; for PCR 
ribotyping from 20/31 countries to 
23/32 countries, and specifically for 
capillary PCR ribotyping from 7/31 
countries to 16/32 countries. While 
our study indicates improved diagnos-
tic capability and national capacity 
for capillary PCR ribotyping across 
European laboratories between 2011 
and 2014, increased use of ‘optimal’ 
diagnostics should be promoted.
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Introduction
Since 2003, Europe has been affected by outbreaks of Clostridium difficile infection 
(CDI) associated with the emergence of PCR ribotype 027/NAP1 [ 1 ]. A decade later, 
C. difficile was the microorganism responsible for 48% of healthcare-associated 
gastrointestinal infections in acute care hospitals across Europe [ 2 ]. Despite be-
ing frequent, CDI remains underestimated in most European countries [ 3 ]. 
Underdiagnosis mainly results from a lack of awareness among medical doctors 
of when to suspect that patients may have CDI and use of suboptimal diagnostic 
algorithms at local microbiological laboratories [ 3 5 ]. Reference tests, i.e. toxigenic 
culture and cell culture cytotoxicity assay (CCA), are not suitable for routine 
application due to their complexity and long turnaround time [ 6,7 ]. Rapid enzyme 
immunoassays (EIAs) to detect C. difficile toxins in faeces lack sensitivity [ 6,8 ]. 
Highly sensitive tests such as EIA detecting glutamate dehydrogenase (GDH) – a 
C. difficile-specific enzyme [ 9 ] – or nucleic acid amplification tests (NAATs) have 
insufficient specificity [ 6,10 ]. To overcome underdiagnosis and suboptimal perfor-
mance of stand-alone tests, the European Society of Clinical Microbiology and 
Infectious Diseases (ESCMID) has recommended since 2009 testing loose stools 
using two-step algorithms that have a highly sensitive test as the first screening 
step and a highly specific test as the second confirmatory test [ 6,11 ]. The ‘Bristol 
stool scores’ [ 12 ] are commonly used to categorise stool consistencies and can be 
used to select samples for CDI testing. ESCMID recommended performing CDI 
testing not only upon request of a medical doctor, but also based on other indica-
tions such as the ‘three-day rule’, i.e. diarrhoea after three days of hospitalisation 
or when diarrhoea develops after antibiotic use [ 6,13 ].
The type of diagnostic algorithm applied influences not only clinical care [ 14 ], 
but also CDI surveillance’s sensitivity and specificity [ 3,14,15 ]. However, a consen-
sus on when and how to test for CDI has not been established among reference 
and local laboratories.
Additionally, typing of C. difficile to understand its local or wider transmission 
remains non-standardised in Europe [ 16,17 ]. Numerous typing methods have be-
come available for routine use in the last 30 years. For C. difficile, these include 
methods that use restriction enzymes (e.g. restriction endonuclease analysis, 
pulsed-field gel electrophoresis (PFGE)), PCR amplification of housekeeping genes 
(e.g. multilocus sequence typing (MLST)), of repetitive elements (repetitive- 
element PCR, multilocus variable-number tandem repeat analysis (MLVA)), of the 
pathogenicity locus (e.g. toxinotyping) or of 16S-23S rRNA intergenic spacer 
regions (e.g. PCR ribotyping) [ 16,18 ]. Whole genome sequencing, with its ultimate 
discriminatory power, can already be used for in-depth analysis of evolutionary 
patterns [ 19 ]. Nevertheless, PCR ribotyping still remains the standard typing 
method in Europe as it involves relatively simple technology and its low costs 
permits widespread application [ 16,18 ].
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In 2010, the European Centre for Disease Prevention and Control (ECDC) launched 
the European C. difficile Infection Surveillance Network (ECDIS-Net) project, an 
initiative to enhance and harmonise laboratory diagnostic and typing capacity 
for CDI, and to support surveillance of CDI in Europe. The project consortium 
consisted of a team of experts involved in the first European multicountry sur-
veillance study performed in 2008 [ 20 ]. Between 2010 and 2014, the ECDIS-Net 
project developed standard operating procedures for C. difficile culturing and PCR 
ribotyping, implemented a reference nomenclature database and compiled a set 
of reference strains to standardise PCR ribotyping. National reference laboratories 
were invited to participate in a workshop for culturing and typing of C. difficile and 
participated in an external quality assessment exercise.
The study presented here measured changes in capacity for diagnostic testing for 
CDI and typing of C. difficile isolates in Europe between 2011 and 2014, using 
surveys of European local laboratories and national coordinators participating in 
the ECDIS-Net project. Additionally, we aimed to obtain insight into barriers to 
optimal CDI laboratory diagnostics, to inform further activities of ECDC and of 
the ESCMID Study Group for C. difficile (ESGCD) in this field.
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Methods
STUDY DESIGN
The Dutch National Reference Laboratory for C. difficile (Leiden University Medical 
Centre, Leiden, and the National Institute for Public Health and the Environment 
(RIVM), Bilthoven, the Netherlands) coordinated data collection in 2011 and in 
2014 by cross-sectional surveys among two target groups: (i) local microbiology 
laboratories, in order to evaluate changes in routine laboratory diagnostics; and 
(ii) national coordinators, i.e. representatives of national or regional reference 
laboratories nominated by competent bodies for surveillance on the request of 
ECDC, to evaluate national changes in diagnostic and typing capacity for C. difficile. 
In 2011 and 2014, 32 and 33 countries participating in the ECDIS-Net project were 
invited to take part in the survey, respectively (in 2011, Serbia did not participate 
in ECDIS-Net). All surveys are available online [ 21 ].
SELECTION
There was no European register of microbiology laboratories to use for random 
sampling. Therefore, ECDIS-Net national coordinators were requested to invite a 
representative sample of the local clinical microbiology laboratories (about 10%) 
in each country to participate in the survey. In Austria and Norway, the laborato-
ries were selected by random sampling; all other countries used non-random 
convenience sampling [ 22 ]. Selected laboratories were emailed an initial survey 
in October 2011: some laboratories replied in 2012. All respondents to the initial 
survey received a follow-up survey in June 2014.
DATA COLLECTION
Data were collected through a centralised web-based system (Questback, New 
York, United States). In 2011, the initial survey contained questions on several 
aspects of local routine diagnostics, including indications for undertaking CDI 
diagnostics and methodologies. Laboratories were requested to report the type 
of screening test primarily used for CDI diagnostics and confirmatory test (if 
applicable). For both, they could report more than one test. In 2014, the follow- 
up survey listed 10 diagnostic algorithms each designated as either ‘optimal’, 
‘acceptable’ or ‘incomplete’ ( Table 1 ). Laboratories were requested to estimate the 
percentage of samples that had been tested according to each algorithm listed, or 
to describe their usual diagnostic algorithm and estimate the corresponding 
percentage. The categorisation of CDI diagnostic algorithms was made by some of 
the ECDIS-Net experts who were also involved in revising the ESCMID diagnostics 
guidelines for CDI [6]. Algorithms designated as optimal had high sensitivity and 
specificity (not specifically defined), detection of free toxins in faeces and a rapid 
turnaround time [ 23 ]. Acceptable algorithms met the same criteria but without 
detecting free toxins in faeces. Any other algorithm was designated as incom-
plete. The 2014 follow-up survey additionally contained questions on barriers to 
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apply optimal or acceptable diagnostic algorithms and changes in the indications 
for sending samples for CDI diagnosis by medical doctors.
DATA ANALYSIS
To allow comparison, data on diagnostics from the 2011 initial survey were 
distributed into the three categories of diagnostic algorithms defined in 2014. For 
each local laboratory, CDI diagnostics, i.e. CDI testing practices, were considered 
optimal if more than 80% of the samples followed an optimal diagnostic algo-
rithm, and acceptable if more than 80% of the samples followed either an optimal 
or acceptable algorithm. CDI diagnostics of all other algorithms were considered 
incomplete. When a laboratory reported a three-step algorithm by applying a 
third diagnostic test when the screening and confirmatory tests were contradic-
tory, this algorithm was allocated to the best-matching two-step algorithm. 
Changes in local laboratory diagnostic capacity were evaluated by the McNemar’s 
test [ 24 ], and changes in the use of optimal, acceptable and incomplete algo-
rithms in 2011 and 2014 were evaluated by a Bowker test for symmetry [ 24 ]. 
A sensitivity analysis was performed using two assumptions on missing data 
in 2014, i.e. CDI diagnostics one category inferior ( Table 1 ) than in 2011 and CDI 
diagnostics one category superior than in 2011. Data were analysed using IBM 
SPSS statistics 20 (SPSS Inc., Chicago, United States). 
Table 1. Criteria for categorisation of Clostridium difficile infection diagnostic algorithms, survey of 
European countries participating in the European Clostridium difficile Infection Surveillance Network 
(ECDIS-Net) project, 2011 (n = 31)a and 2014 (n = 26)a
Categorisation of CDI diagnostics
CDI diagnostic algorithm
Screening test Screening test
Optimalb 1c NAAT EIA toxin detection
2–3c GDH EIA and toxin detection NAAT or toxigenic culture
Acceptableb 4–5c GDH EIA detection NAAT or toxigenic culture
6c NAAT None
Incompleteb
7–10c All other algorithms
CDI: Clostridium difficile infection; EIA: enzyme immunoassay; GDH: glutamate dehydrogenase;  
NAAT: nucleic acid amplification test.
a  Laboratories in 31 countries responded to the 2011 survey: Austria, Belgium, Bulgaria, Croatia, Cyprus, Czech 
Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Latvia, Lichten-
stein, Lithuania, Luxembourg, the Netherlands, Norway, Poland, Portugal, Romania, Slovenia, Spain, Sweden, 
Switzerland, Turkey and the United Kingdom (not including Wales). Serbia did not participate in the European 
Clostridium difficile Infection Surveillance Network (ECDIS-Net) project in 2011. No laboratories in Slovakia 
and Wales were invited to participate by ECDIS-Net national coordinators in 2011. Laboratories in 26 countries 
responded in 2014 (no data from laboratories in Croatia, Iceland, Latvia, Slovenia and Switzerland). 
b  Categorisation of CDI diagnostic algorithms in the second survey, in 2014 [21].
c  Corresponding CDI diagnostic algorithms in the second survey, in 2014 [21].
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SURVEY OF ECDIS-NET NATIONAL COORDINATORS
DATA COLLECTION AND ANALYSIS
All ECDIS-Net national coordinators received an initial survey in May 2011 and 
a follow-up survey in June 2014. Both surveys contained questions on national 
typing capacity (defined as any laboratory in the country performing typing) and 
on molecular typing methods, asking which were available in their country from 
a list of common methods [ 18 ]. 






Questionnaires on local diagnostic and typing capacity for CDI were completed 
by 126 (61%) of 206 laboratories in 2011–12 and by 84 (67%) of these same 126 labo-
ratories in 2014 ( Table 2 ). A total 124 (98%) of the 126 responding laboratories in 
2011–12 provided microbiological services to hospitals, of which 103 (83% ) served 
at least one university, secondary or tertiary care hospital. In addition, 66 (53%) 
provided microbiological services to long-term care facilities, of which 45 pro-
vided services to nursing homes. Furthermore, 65/124 (52%; data were missing for 
two laboratories) provided medical services to other healthcare services (e.g. gen-
eral practitioners). In 2011 and 2014, 120/126 (95%) and 83/84 laboratories (99%, 
among responders to both questionnaires; p = 0.50), respectively, reported that 
they performed CDI laboratory diagnostics.
INDICATIONS FOR CLOSTRIDIUM DIFFICILE INFECTION DIAGNOSTICS
The indications for CDI diagnostics reported in 2011 are listed in Figure 1. In 2014, 
a change of indications for sending samples for CDI diagnosis by medical doctors 
was observed; 16 (19%) of 83 laboratories reported that one or two changes had 
occurred since 2011. Several laboratories introduced the use of Bristol stool scores 
to assess stool consistency for sample selection (n = 5). Also, patient populations 
that were previously not monitored for CDI (e.g. outpatients, high-risk popula-
tions) were later explicitly included in protocols (n = 3) and awareness and recog-
nition of CDI among clinicians had improved (n = 5). Other improvements of sam-
ple selection were also reported (n = 5), i.e. application of guidelines for sample 
selection (n = 3) and/or the three-day rule, i.e. diarrhoea after three days of hospi-
talisation (n = 1), and unspecified attempts to improve sample selection (n = 1).
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Table 2. Response of participating European countries to local laboratory (n = 31 and n = 26, respectively) 
and national/subnational surveys (n = 31 and n = 32, respectively) on Clostridium difficile infection diagnos-
tic and typing capacity, 2011 and 2014
Country Number of laboratories that responded 
to local questionnaire/number invited
Replied to 
national questionnairea
2011 2014 2011 2014
Austria 4/8 2/4 Yes Yes
Belgium 4/9 4/4 Yes Yes
Bulgaria 7/7 2/7 Yes Yes
Croatia 2/4 0/2 Yes Yes
Cyprus 3/3 3/3 Yes Yes
Czech Republic 9/11 7/9 Yes Yes
Denmark 3/3 1/3 Yes Yes
Estonia 2/2 1/2 Yes Yes
Finland 3/3 2/3 Yes Yes
France 5/37 2/5 Yes Yes
Germany 5/7 5/5 Yes Yes
Greece 3/3 2/3 Yes Yes
Hungary 8/8 8/8 Yes Yes
Iceland 1/1 0/1 No No
Ireland 3/5 2/3 Yes Yes
Italy 13/14 8/13 Yes Yes
Latvia 2/3 0/2 Yes Yes
Lichtenstein 1/1 1/1 Yes Yes
Lithuania 3/3 2/3 Yes Yes
Luxembourg 2/6 1/2 Yes Yes
Netherlands 4/6 3/4 Yes Yes
Norway 9/13 4/9 Yes Yes
Poland 6/6 4/6 Yes Yes
Portugal 4/5 4/4 Yes Yes
Romania 4/6 3/4 Yes Yes
Serbiab NA NA NA Yes
Slovakiac NA NA Yes Yes
Slovenia 1/3 0/1 Yes Yes
Spain 3/5 2/3 Yes Yes
Sweden 2/3 2/2 Yes Yes
Switzerland 1/1 0/1 Yes Yes
Turkey 2/7 2/2 Yes Yes
UK-England 2/6 2/2 Yes Yes
UK-Northern Ireland 1/3 1/1 Yes Yes
UK-Scotland 4/4 4/4 Yes Yes
UK-Walesc NA NA No Yes
Total 126/206 84/126 31 32
NA: not applicable; UK: United Kingdom.
a  For the UK, data were analysed separately for England, Northern Ireland, Scotland and Wales, but the UK was 
counted as one country.
b  Serbia did not participate in the European Clostridium difficile Infection Surveillance Network (ECDIS-Net) 
project in 2011.
c  No laboratories in Slovakia and Wales were invited to participate by ECDIS-Net national coordinators. 
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  Criteria for selection of faecal samples tested for Clostridium difficile among responding 
local laboratories that participated in the European Clostridium difficile Infection Surveillance Network 
(ECDIS-Net) project in 2011 (n = 120)a
a  Laboratories in 31 countries responded to the 2011 survey: Austria, Belgium, Bulgaria, Croatia, Cyprus, Czech 
Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Latvia, Lichten-
stein, Lithuania, Luxembourg, the Netherlands, Norway, Poland, Portugal, Romania, Slovenia, Spain, Sweden, 
Switzerland, Turkey and the United Kingdom (not including Wales). Serbia did not participate in the European 
Clostridium difficile Infection Surveillance Network (ECDIS-Net) project in 2011. No laboratories in Slovakia and 
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C. DIFFICILE INFECTION DIAGNOSTICS
In 2011, 17 (14%) of 120 laboratories had optimal CDI diagnostics, 12 (10%) accepta-
ble diagnostics and 91 (76%) incomplete diagnostics ( Table 3 ). Incomplete algorithms 
included use of EIA toxin detection for screening with or without a confirmatory 
test, or a combination of EIA GDH and toxin detection without other tests for con-
firmation. Among laboratories responding to both the 2011 and 2014 surveys and 
that performed CDI diagnostics at both time-points (n = 81), the percentage of 
laboratories with optimal CDI diagnostics increased from 19% to 46% and that 
with acceptable CDI diagnostics from 10% to 15% while the percentage of labora-
tories with incomplete CDI diagnostics decreased from 72% to 40% (p  < 0.001; 
Table 3 ). Two laboratories without any diagnostics in 2011 had optimal and incom-
plete CDI diagnostics, respectively, in 2014.
Table 3. Laboratories participating in the European Clostridium difficile Infection Surveillance Network 
(ECDIS-Net) project according to their diagnostics category, 2011 (n = 120)a and 2014 (n = 81)a
Categorisation of CDI 
diagnosticsb
All laboratories that 
provided data
Only laboratories that provided 







Optimal 17 (14) 15 (19) 37 (46)
Acceptable 12 (10) 8 (10) 12 (15)
Incomplete 91 (76) 58 (72) 32 (40)
Total 120 (100) 81 (100) 81 (100)
CDI: Clostridium difficile infection.
a   Laboratories in 31 countries responded to the 2011 survey: Austria, Belgium, Bulgaria, Croatia, Cyprus, Czech 
Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Latvia, Lichten-
stein, Lithuania, Luxembourg, the Netherlands, Norway, Poland, Portugal, Romania, Slovenia, Spain, Sweden, 
Switzerland, Turkey and the United Kingdom (not including Wales). Serbia did not participate in the European 
Clostridium difficile Infection Surveillance Network (ECDIS-Net) project in 2011. No laboratories in Slovakia and 
Wales were invited to participate by ECDIS-Net national coordinators in 2011. Laboratories in 26 countries re-
sponded in 2014 (no data from laboratories in Croatia, Iceland, Latvia, Slovenia and Switzerland).
b  CDI diagnostics were considered ‘optimal’ if > 80% of the samples followed an ‘optimal’ testing algorithm, and 
‘acceptable’ if > 80% of the samples followed either an ‘optimal’ or ‘acceptable’ testing algorithm. CDI diagnos-
tics of all other laboratories were considered ‘incomplete’. The diagnostic algorithms are described in Table 1.
c  Two laboratories that did not perform CDI laboratory diagnostics in 2011 were not included. These laboratories 
indicated in the 2014 questionnaire that they used optimal and incomplete CDI diagnostics, respectively. 
d The percentages in this column do not add up to 100 due to rounding.




Laboratories with optimal CDI diagnostics in 2011 were more likely to respond to 
the 2014 survey (15/17) compared with those with acceptable (8/12) or incomplete 
diagnostics (58/91). Under the negative assumption that all non-responding labo-
ratories in 2014 applied CDI diagnostics one category inferior in 2014 compared 
with that of 2011, the percentage of laboratories with optimal diagnostics would 
have increased from 14% to 31%, that with acceptable diagnostics would have 
increased from 10% to 12%, and that with incomplete diagnostics would have 
decreased from 76% to 58% between 2011 and 2014 (p  < 0.001). Conversely, if all 
non-responding laboratories had CDI diagnostics one category superior in 2014 
compared with 2011, the percentage of laboratories with optimal diagnostics 
would have increased from 14% to 36%, that with acceptable diagnostics would 
have increased from 10 to 38%, and that with incomplete diagnostics would have 
decreased from 76 to 27% between 2011 and 2014 (p  < 0.001).
BARRIERS TO OPTIMAL/ACCEPTABLE DIAGNOSTICS FOR C. DIFFICILE INFECTION
Barriers to applying optimal or acceptable algorithms were examined in 2014. Of 
the 33 laboratories with incomplete CDI diagnostics, 17 indicated that materials 
or tests were too costly, six indicated receiving insufficient reimbursement for 
tests from insurers and five had insufficient availability of trained staff. Of the 50 
laboratories that had optimal or acceptable CDI diagnostics, 10 also indicated 
that materials or tests were too costly, seven indicated receiving insufficient 
reimbursement from insurers and five had insufficient availability of trained 
staff. Ten laboratories that responded in 2014 indicated that they disagreed with 




The national coordinators of 31 and 32 countries responded to the national survey 
in 2011 and 2014, respectively ( Table 2 ). Data were collected separately for the 
four countries within the United Kingdom (UK), i.e. England, Northern Ireland, 
Scotland and Wales, but the UK was counted as one country.
CHANGES IN NATIONAL DIAGNOSTIC CAPACITY
In 2014, eight of the 32 responding countries (France, Germany, Greece, Latvia, 
Luxembourg, Sweden, Switzerland, Turkey) reported no change in national/ 
subnational laboratory diagnostics for CDI. Conversely, 24 countries reported one 
or more changes in national/subnational laboratory diagnostics for CDI since 
2011 ( Figure 2 ). Specifically, 16 countries had experienced a change in availability of 
commercial diagnostic tests (Bulgaria, Czech Republic, Estonia, Hungary, Ireland, 
Italy, Lichtenstein, Lithuania, the Netherlands, Norway, Poland, Portugal, Romania, 
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Serbia, Slovenia, UK), 10 countries had new or revised guidelines for CDI diagnos-
tics (Austria, Czech Republic, Denmark, Estonia, Hungary, Ireland [ 25 ], Italy, 
Lithuania, Romania, UK) and three countries had changes in relevant legislation 
(Hungary, Poland, Romania). Three countries (Belgium, Croatia, Czech Republic) 
had implemented changes in reimbursement policies for diagnostic tests. Greece 
had limited access to and reimbursement of materials in both 2011 and 2014. 
In 2012, the UK implemented ‘harmonised’ diagnostics using GDH screening (or 
NAAT) and EIA toxin detection (or CCA) in all its laboratories [ 26 ].
Number of countries





Change in reimbursement of diagnostic tests
0 2 4 6 108 12 14 16
  Reported changes affecting national/subnational laboratory diagnostic capacity for  
Clostridium difficile infection between 2011 and 2014 in participating European countries (n = 32)a
a  Austria, Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, 
Greece, Hungary, Ireland, Italy, Latvia, Lichtenstein, Lithuania, Luxembourg, the Netherlands, Norway, Poland, 
Portugal, Romania, Serbia, Slovakia, Slovenia, Spain, Sweden, Switzerland, Turkey and the United Kingdom 
(data were analysed separately for England, Northern Ireland, Scotland and Wales, but counted as one country). 
No data were available for Iceland.
b  Seven countries reported other changes in national laboratory diagnostics: Slovenia was developing new 
national guidelines for CDI at the time of the second survey; Romania started a national surveillance study 
in 2014; Spain published an opinion document on CDI [32]; Slovakia was in the process of implementing new 
diagnostic methods due to an increased interest in CDI; in Cyprus, the central diagnostic laboratory for C. diffi-
cile implemented a two-step diagnostic algorithm; in Finland, CDI diagnostics were subcontracted to laboratory 
consortia that applied nucleic acid amplification tests more often; and Hungary relocated its national reference 
laboratory to expand its laboratory capacity but still had limited resources.
Figure 2
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C. DIFFICILE NATIONAL TYPING METHODS
The capacity for various C. difficile typing methods in participating countries in 
2011 and 2014 is depicted in Figure 3. The number of countries able to perform any 
method of typing increased from 22/31 countries in 2011 to 26/32 countries in 
2014. Only six countries (Croatia, Cyprus, Estonia, Lichtenstein, Lithuania, Serbia) 
reported that they did not have any national typing capacity in 2014 (none of 
these countries had typing capacity in 2011); however, Lichtenstein sent samples 
to another country (Austria) for typing.
 
Several typing methods were implemented by the countries ( Figure 3 ). PCR 
ribotyping (either capillary-based or conventional agarose gel-based), the current 
European standard for C. difficile typing, was available in 20/31 countries in 2011 
and in 23/32 countries in 2014. Two of the countries that acquired ribotyping 
capacity (Ireland and Romania) use it for national surveillance. Capillary PCR 
ribotyping was applied by 7/31 countries in 2011 and by 16/32 countries in 2014. 
In 2014, nine of the 32 participating countries applied MLVA, six PFGE and seven 
MLST. In 2014, whole genome sequencing was available in Germany, the Nether-
lands, Norway, Slovenia and England.
Some countries reported specific changes in national molecular typing capacity 
between 2011 and 2014. Greece, which previously did not have typing capacity, 
introduced MLST in January 2014. At the time of the 2014 survey, Estonia was 
capable of ribotyping for research projects, although there were no such projects. 
Turkey performed PCR ribotyping but lacked software to analyse the data. 
Denmark stopped using PCR ribotyping and only applied tandem repeat sequence 
typing. Hungary reported limited typing capacity for financial reasons although 
PCR ribotyping remained available at the national reference laboratory. Finland 
restricted the indications for ribotyping to severe CDI or outbreaks, which unin-
tentionally caused many laboratories to stop all culturing and/or sending isolates 
for typing.
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PFGE: pulsed-field gel electrophoresis; MLST: multilocus sequence typing; MLVA: multilocus variable-number 
tandem repeat analysis; WGS: whole genome sequencing. 
Other typing methods used in 2011 were: tcdC typing (Austria, Belgium, Finland, France, Italy, Latvia, Luxembourg 
(not shown), Spain, United Kingdom - Northern Ireland only), repetitive-element PCR (Belgium, Spain), toxinotyping 
(Italy, Spain), tandem repeat sequence typing (Denmark) and pathogenicity locus (PaLoc) multiplex PCR (Finland). 
Other typing methods used in 2014 were: tcdA/B (Belgium, Romania, Slovakia), CDT (Belgium, Slovakia), tcdC 
(Belgium), Δ117TcdC (Slovakia), and GyrAΔ detection (Belgium) detection, tandem repeat sequence typing (Den-
mark), and high molecular weight typing by MALDI-TOF (Sweden). 
  Clostridium difficile typing methods available in countries that participated in the European 
Clostridium difficile Infection Surveillance Network (ECDIS-Net) project in 2011 (n = 31)a and 2014 (n = 32)a
Figure 3
A.  2011
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a  In 2011, 31 countries responded: Austria, Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, 
Finland, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lichtenstein, Lithuania, Luxembourg, the 
Netherlands, Norway, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden, Switzerland, Turkey and 
the United Kingdom (not including Wales). No data were available for Iceland. In 2011, Serbia did not participate 
in the European Clostridium difficile Infection Surveillance Network (ECDIS-Net) project. In 2014, Serbia partici-
pated in the ECDIS-Net project and responded to the 2014 questionnaire, as did Wales, and so the number of 
responding countries in 2014 was 32.
Source of map: FreeVectorMaps.com (http://freevectormaps.com).
B.  2014
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Discussion
This study assessed changes in diagnostic testing and typing capacity for CDI in 
Europe between 2011 and 2014, using surveys of European local laboratories and 
of national coordinators participating in the ECDIS-Net project. Virtually all par-
ticipating local laboratories had implemented CDI diagnostics in 2011 and 2014, 
compared with 88% (186/212) of the local laboratories investigated in eight Euro-
pean countries in 2003 [ 27 ]. The percentage of laboratories with optimal CDI 
diagnostics increased from 19% to 46%, and that with acceptable diagnostics 
increased from 10% to 15%. Importantly, the ESCMID-recommended two-step 
diagnostic algorithm [ 6 ] became more common. Nevertheless, we still observed 
a considerable variation in CDI diagnostics within and between European coun-
tries, in line with another European study with 482 participating hospitals in 
2011–13 [ 3 ]. This variation in diagnostics can substantially affect CDI incidence 
rates obtained by surveillance [ 15,28 ]. Our survey showed that suboptimal CDI 
diagnostics may result from, for example, financial restrictions or limited avail-
ability of trained staff. As a consequence of the disagreement by a sizable minor-
ity of laboratories with the designation of diagnostic algorithms, the ESGCD 
undertook to revise its diagnostic guidelines [ 6 ] and propose an algorithm that 
can also be implemented in laboratories with limited numbers of trained staff 
and limited financial resources. These revised guidelines will be published in 
2016 on behalf of ESCMID. 
Among countries having national guidelines available, the UK was the only one 
that had succeeded in harmonising CDI diagnostics, by recommending a single 
two-test diagnostic algorithm (‘comprising a GDH EIA (or NAAT/PCR) followed by 
a sensitive toxin EIA’) [ 3,26 ]. The recommendations in the UK Department of 
Health guidance were supported by local study data and inclusion of frequently 
asked questions to allay objections of the laboratories to implementing the pro-
posed diagnostic algorithms [ 26 ]. Furthermore, the diagnostics guidance was one 
of many C. difficile-related activities in the UK, for example, implementation of 
mandatory CDI reduction targets with financial penalties for national health ser-
vices [ 29 ]. There probably are two possible ways to optimise testing: either to pro-
mote one national diagnostic algorithm or to promote the use of optimal testing 
strategies by local laboratories. However, the proposed algorithm in the UK was 
not fully compliant with the designation of diagnostic algorithms as optimal in 
this survey, highlighting the need for further discussion among experts to reach 
a consensus. Another example is Spain, where several national studies and meet-
ings were organised [ 30,31 ] that resulted in an opinion document to enhance 
optimal diagnostics for CDI [32]. We hope that the national reference laboratories 
that participated in the ECDIS-Net project will follow these examples and pro-
mote optimal diagnostics for CDI and its implementation in local laboratories.




Between 2011 and 2014, PCR ribotyping capacity and capillary PCR ribotyping 
increased among the participating countries. Capillary PCR ribotyping was vali-
dated in 2012–14 by four reference laboratories in England, the Netherlands, the 
United States and Canada, identifying a 98% consensus (195/200 cases tested) be-
tween the laboratories, which indicated the method’s suitability for standardised 
CDI surveillance [ 17 ].
We assume that ECDIS-Net activities during 2012–14, including a training pro-
gramme for C. difficile PCR ribotyping, contributed to the increased PCR ribotyp-
ing capacity. For example, Romania joined the training programme in 2012 and 
received a set of reference strains from the ECDIS-Net project and is now able to 
apply PCR ribotyping in their national surveillance. Poland reported having 
started their first national surveillance programme, stimulated by ECDIS-Net 
activities in 2012 [ 33 ]. A few countries (Hungary, Italy, Slovenia) had national sur-
veillance under development at time of the 2014 survey. Despite these positive 
trends, our study also indicates that some European reference and local laborato-
ries are affected by limited resources and budget reductions, which hamper 
implementation and technical improvements of molecular typing methods.
LIMITATIONS
This study has several limitations including the small, non-random selection of 
local laboratories for both surveys and the moderate response rate, limiting the 
degree to which conclusions can be extrapolated to all European microbiological 
laboratories. The representativeness of the invited and participating laboratories 
could not be assessed due to the absence of a suitably complete European register. 
Laboratories with better CDI diagnostics may have been more likely to participate 
in the original and follow-up surveys, leading to an overestimation of the num-
ber of laboratories with optimal CDI diagnostics in Europe. Additionally, the cat-
egorisation of CDI diagnostic algorithms into three levels, although made 
through a series of consultations with a team of international experts from the 
ECDIS-Net project, was based on expert opinion and some subjectivity cannot be 
excluded. Also, although the 2014 questionnaire for local laboratories requested 
quantitative data on the percentage of tests that followed each algorithm on a 
provided list, as the list had the subheadings ‘optimal’, ‘acceptable’ and ‘incom-
plete’, it is possible that those responding overestimated the proportion of desir-
able answers. We estimate that this reporting bias was minimal as for almost all 
laboratories, just one algorithm was used.
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CONCLUSIONS
We conclude that the ECDIS-Net project laid the foundations for Europe-wide sur-
veillance of CDI, although increased use of optimal diagnostic algorithms should 
be promoted, taking into consideration the limited resources and budget cuts in 
several European countries. The ESGCD revised the ESCMID diagnostics guide-
lines for CDI, which, once published, should contribute to standardisation of CDI 
diagnostics at local and national level in Europe. Typing capacity for CDI in 
Europe was acceptable overall; however, an internationally standardised capil-
lary PCR ribotyping protocol is now available [ 17 ] and requires further implemen-
tation in European countries. We would recommend that these important steps 
are considered as part of the integration of C. difficile molecular typing data 
in The European Surveillance System (TESSy), within the ECDC-coordinated 
Europe-wide CDI surveillance (since 1 January 2016) [ 34 ].
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OTHER MEMBERS OF THE ECDIS-NET PROJECT  F Allerberger, D Schmid (AGES, Austria); 
M Delmée, J van Broeck, (University of Louvain, Belgium); R Vatcheva-Dobrevska (National Centre of 
Infectious and Parasitic Diseases, Bulgaria); B Matica (Dr. Andrija Štampar Insitute of Public Health, 
Croatia); P Maikanti-Charalampous, D Pieridou- Bagatzouni (Nicosia General Hospital, Cyprus); 
O Nyč (Hospital FN Motol Prague, Czech Republic); KEP Olsen (Statens Serum Institut, Denmark); 
M Jyrna-Ellam, Anastasia Pavelkovich (North-Estonian Regional Hospital, Estonia); A Virolainen- 
Julkunen, O Lyytikäinen, (Institute of Health and Welfare, Finland); C Eckert (National Reference Labo-
ratory for C. difficile, France); B Coignard (Institut de Veille Sanitaire, France); L von Müller (University 
of Saarland Medical Centre, Germany); B Weiß (Robert Koch-Institut, Germany); E Petinaki (University 
Hospital of Larissa, Greece), A Kurcz, Z Barna, A Hajdu (National Center for Epidemiology, Hungary); 
L Kyne, L Fenelon (Health Protection Surveillance Centre and Beaumont Hospital, Ireland); F Barbanti 
(Istituto Superiore di Sanità, Italy), ML Moro (Agenzia Sanitaria e Sociale Regionale Emilia-Romagna, 
Italy); AO Balode (Rīga Stradiņš University, Latvia); J Miciuleviciene, R Valentiliene (Vilnius City Clinical 
Hospital, Lithuania); M Perrin, P Reichert, C Olinger (Laboratoire National de Sante, Luxembourg); SC 
de Greeff (National Institute for Public Health and the Environment (RIVM), the Netherlands); H Pituch, 
P Obuch-Woszczatynski (Medical University of Warsaw, Poland); M Oleastro, J Machado (Instituto 
Nacional de Saude Dr. Ricardo Jorge, Portugal); D Lemeni, I Macovei (‘Cantacuzino’ National Institute 
of Research and Development for Microbiology and Immunology, Romania); E Nováková (Jessenius 
Faculty of Medicine in Martin, Slovakia); M Rupnik (National Laboratory for Health, Environment and 
Food, Slovenia), J Kolman (National Institute of Public Health, Slovenia); E Bouza (Hospital General 
Universitario ‘Gregorio Marañón’, Spain), S Valdezate (Instituto de Salud Carlos III, Spain); T Åkerlund, 
O Aspevall (Public Health Agency of Sweden, Sweden); E Sheridan (Health Protection Agency, UK); 
P Rooney (Belfast City Hospital, UK); C Wiuff (Health Protection Scotland, UK); J Coia (Scottish Micro-
biology Reference Laboratories, UK); A Widmer (University Hospital Basel, Switzerland); M Ritzler (La-
bor RISCH, Liechtenstein); A Ingebretsen (Oslo University Hospital, Norway); J Bjørnholt (Norwegian 
Institute of Public Health, Norway); M Kroknes (St. Olavs Hospital, Norway); H Hardarson (Landspitali 
University Hospital, Iceland); B Levent (Refik Saydam National Hygiene Center, Turkey); M Jovanović 
(Clinical Center of Serbia, Serbia), M Drakulovic (Institute of Public Health of Serbia ‘Dr Milan Jovanović 
Batut’, Serbia).
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Clostridium difficile infection (CDI) 
remains poorly controlled in many 
European countries, of which several 
have not yet implemented national 
CDI surveillance. In 2013, experts 
from the European CDI Surveillance 
Network project and from the Euro-
pean Centre for Disease Prevention 
and Control developed a protocol 
with three options of CDI surveillance 
for acute care hospitals: a ‘minimal’ 
option (aggregated hospital data), 
a ‘light’ option (including patient data 
for CDI cases) and an ‘enhanced’ op-
tion (including microbiological data 
on the first 10 CDI episodes per hospi-
tal). A total of 37 hospitals in 14 Euro-
pean countries tested these options for 
a three-month period (between 13 May 
and 1 November 2013). All 37 hospitals 
successfully completed the minimal 
surveillance option (for 1,152 patients). 
Clinical data were submitted for 94% 
(1,078/1,152) of the patients in the 
light option; information on CDI ori-
gin and outcome was complete for 
94% (1,016/1,078) and 98% (294/300) of 
the patients in the light and enhanced 
options, respectively. The workload of 
the options was 1.1, 2.0 and 3.0 person-
days per 10,000 hospital discharges, 
respectively. Enhanced surveillance 
was tested and was successful in 32 of 
the hospitals, showing that C. difficile 
PCR ribotype 027 was predominant 
(30% (79/267)). This study showed that 
standardised multicountry surveil-
lance, with the option of integrating 
clinical and molecular data, is a feasi-
ble strategy for monitoring CDI in 
Europe.
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Introduction
After recognition of European outbreaks of Clostridium difficile infections (CDIs) 
associated with the emergence of PCR ribotype 027/NAP1 in 2005, CDI surveil-
lance at country level was encouraged by the European Centre for Disease Preven-
tion and Control (ECDC) [ 1 ]. In 2008, an ECDC-supported European CDI survey 
(ECDIS) identified large intercountry variations in incidence rates and distribu-
tion of prevalent PCR ribotypes, with the outbreak-related PCR ribotype 027 
being detected in 5% (range: 0–26) of the characterised isolates [ 2 ]. The surveil-
lance period was limited to one month and the representation of European hos-
pitals was incomplete; however, this has been the only European (comprising 
European Union (EU)/European Economic Area (EEA) and EU candidate coun-
tries) CDI surveillance study. The authors highlighted the need for national and 
European surveillance to control CDI. Yet, European countries were found to 
have limited capacity for diagnostic testing, particularly in terms of standard 
use of optimal methods and absence of surveillance protocols and a fully vali-
dated, standardised and exchangeable typing system for surveillance and/or 
outbreak investigation.
As of 2011, 14 European countries had implemented national CDI surveillance, 
with various methodologies [ 3 ]. National surveillance systems have since report-
ed a decrease in CDI incidence rate and/or prevalence of PCR ribotype 027 in some 
European countries [ 4 – 8 ]. However, CDI generally remains poorly controlled in 
Europe [ 9 ], and PCR ribotype 027 continues to spread in eastern Europe [ 10 – 12 ] 
and globally [ 13 ].
In 2010, ECDC launched a new project, the European C. difficile Infection Surveil-
lance Network (ECDIS-Net), to enhance surveillance of CDI and laboratory capac-
ity to test for CDI in Europe. The goal of ECDIS-Net was to establish a standardised 
CDI surveillance protocol suitable for application all over Europe in order to: (i) 
estimate the incidence rate and total infection rate of CDI (including recurrent 
CDI cases) in European acute care hospitals; (ii) provide participating hospitals 
with a standardised tool to measure and compare their own incidence rates with 
those observed in other participating hospitals; (iii) assess adverse outcomes of 
CDI such as complications and death; and (iv) describe the epidemiology of CDI 
concerning antibiotic susceptibility, PCR ribotypes, presence of tcdA, tcdB and 
binary toxins and detect new emerging types at local, national and European 
level.
The primary objectives of the present study were to: (i) test the pilot protocol 
for the surveillance of CDI in European acute care hospitals developed by ECDIS-
Net (methodology, variables and indicators); (ii) assess the feasibility and work-
load of collecting the required hospital data, case-based epidemiological and 
microbiological data; and (iii) evaluate the quality of data collected, whether in 
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the presence or absence of existing national CDI surveillance activities. A second-
ary aim was to assess the relationship between patient and microbiological char-
acteristics and in-hospital outcome of CDI to confirm the added value of collecting 
detailed epidemiological and microbiological data on CDI at European level.
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Methods
STUDY PROTOCOL AND DEFINITIONS  
A pilot protocol for the surveillance of CDI in European acute care hospitals was 
developed by ECDIS-Net participants (epidemiologists and medical microbiolo-
gists from various European countries) and ECDC experts in 2012–13. The pilot 
protocol version 1.2 specified three options for surveillance: ‘minimal’, ‘light’ 
and ‘enhanced’ [ 14 ]. In the minimal surveillance, aggregated numerator and 
denominator data were gathered on all CDI cases. In the light surveillance, basic 
case-based epidemiological data were included (e.g. age, sex, date of hospital 
admission and of CDI onset, CDI origin, recurrent CDI) on all CDI cases. In the 
enhanced surveillance, additional epidemiological data (e.g. comorbidities scored 
by the McCabe score [ 15 ] and the Acute Physiology and Chronic Health Evaluation 
II (APACHE II) chronic health points [ 16 ], in-hospital deaths) and C. difficile isolates 
were collected for the first 10 episodes of CDI per hospital. Outcome was not 
followed up after discharge from the hospital.
The case definitions for CDI (Box) were based on recommendations for CDI sur-
veillance, as proposed by ECDC and the United States Centers for Disease Control 
and Prevention (CDC) [ 1,17 ].  
Patients were included as a CDI case if symptom onset occurred within the hospi-
tals’ surveillance period, or if the patient was admitted during the surveillance 
period with symptoms present. Infants (children below two years-old) with 
‘compelling clinical evidence for CDI’ were also included.  
PARTICIPANTS AND STUDY PERIOD  
A total of 14 countries participated in this pilot study: they were selected by the 
project leaders given their various levels of ongoing surveillance activities and 
laboratory and typing capacity for CDI [ 18 ]. At the start of the ECDIS-Net project, 
nine countries (Austria, Belgium, Denmark, Finland, France, Germany, Hungary, 
the Netherlands and United Kingdom (Scotland only), hereafter referred to as UK-
Scotland) had already implemented national surveillance of CDI; five countries 
(Estonia, Norway, Poland, Romania and Serbia) had not. ECDIS-Net participants 
identified a convenience sample of two to four acute care hospitals per country to 
test the pilot protocol for a three-month surveillance period between 13 May and 
1 November 2013. Hospitals were encouraged, but not obligated, to test all sur-
veillance options in the protocol and to involve both hospital infection control 
personnel and microbiology laboratory personnel in data collection. It was agreed 
that the actual location of participating hospitals would not be disclosed for rea-
sons of confidentiality. We identified the proxy location of participating hospitals 
by mapping the median healthcare-associated CDI incidence rates obtained in 
this pilot study using the nomenclature of territorial units for statistics (NUTS) 
1 regions [ 19 ] that contained at least one participating hospital.
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Box. Definitions for surveillance of Clostridium difficile infections
CDI case
A patient to whom one or more of the following criteria applies:
1.  diarrhoeal stools or toxic megacolon, and a positive laboratory assay for C. difficile TcdA and/
or TcdB in stools or a toxin-producing C. difficile organism detected in stool via culture or 
other means;
2.  pseudomembranous colitis revealed by lower gastrointestinal endoscopy;
3.  colonic histopathology characteristic of CDI (with or without diarrhoea) on a specimen  
obtained during endoscopy, colectomy or autopsy.
Recurrent CDI
An episode of CDI (return of diarrhoeal stools with a positive laboratory test after the end of 
treatment) > 2 weeks and ≤ 8 weeks following the onset of a previous episode (CDI cases with 
onset later than 8 weeks after the onset of a previous episode were included as new CDI cases).
Healthcare-associated case
A case of CDI with onset of symptoms at least 48 hours following admission to a healthcare 
facility or with onset of symptoms in the community within 4 weeks following discharge from 
a healthcare facility.
Community-associated case
A case of CDI with onset of symptoms outside a healthcare facility or within 48 hours after 
admission to a healthcare facility, without residence in/discharge from a healthcare facility 
within the previous 12 weeks.
Complicated course of CDI
CDI leading to any of the following:
1.  admission to an intensive-care unit for treatment of CDI or its complications (e.g. for shock 
requiring vasopressor therapy);
2.  surgery (colectomy) for toxic megacolon, perforation or refractory colitis;
3.  death within 30 days after diagnosis if CDI is either a primary or contributing cause.
CDI : Clostridium difficile infection.
Source: [ 1,17 ].
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MICROBIOLOGICAL INVESTIGATION  
Local laboratories that serviced the participating hospitals used their own diag-
nostic procedures for CDI. Data on the algorithm used for CDI diagnosis was col-
lected for each patient included in light surveillance. In the enhanced surveillance 
option, 10 C. difficile isolates (or stool samples, if there was no possibility of anaero-
bic culture at the local laboratory) from samples from the first 10 episodes of CDI 
per hospital were sent to the national reference laboratory or appointed study labo-
ratory (collectively referred to as NRL) which performed PCR ribotyping and anti-
microbial susceptibility testing, performed according to national procedures. Most 
NRLs used conventional agarose gel-based PCR ribotyping [ 3 ] (Finland, France, 
Hungary, Poland, the Netherlands and UK-Scotland), some used capillary-based 
PCR ribotyping [ 3 ] (Austria, Belgium and Germany). Denmark, Estonia, Romania 
and Serbia did not perform PCR ribotyping and for Norway, the PCR ribotyping 
method used was not reported. NRLs were requested to send all C. difficile isolates 
to the coordinating laboratory (Leiden University Medical Centre, the Nether-
lands), which completed and confirmed microbiological results. The presence of a 
glutamate dehydrogenase (GDH) gene specific for C. difficile was confirmed in the 
coordinating laboratory by an in-house PCR [ 20 ], followed by PCR ribotyping [21]. 
Toxin genes (tcdA, tcdB, cdtA, cdtB) were detected by multiplex PCR [ 22 ]. In vitro 
susceptibility to metronidazole, vancomycin, and moxifloxacin was determined by 
measuring minimum inhibitory concentrations (MICs) by an agar dilution method 
[ 23 ] and interpreted using epidemiological cut-off values from the European 
Committee on Antimicrobial Susceptibility Testing (EUCAST). Isolates with a 
metronidazole MIC > 2 mg/L, a vancomycin MIC > 2 mg/L and moxifloxacin MIC > 4 
mg/L were interpreted as resistant [ 24 ].  
 
 
DATA HANDLING  
Data were entered in a web-based system developed for the current study (by the 
Institute of Hygiene and Environmental Medicine, Charité Universitätsmedizin 
Berlin, Germany, in 2013) and were analysed with SPSS version 20.0 and Stata soft-
ware version 12.1. 
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STATISTICAL ANALYSIS AND STUDY ENDPOINTS  
 
PRIMARY ENDPOINTS  
Variables and indicators  
For all variables in each surveillance option, frequencies and proportions were calcu-
lated, as appropriate. Hospital median incidence rates for healthcare-associated (HA) 
CDI and recurrent CDI were calculated per 10,000 hospital discharges and per 10,000 
patient-days using minimal surveillance protocol data. Dispersion around the 
median was described with the 25th and 75th percentile (interquartile range, IQR). 
We calculated 95% confidence intervals (CIs) for the incidence rates by Byar’s approx-
imation. 
Feasibility and workload  
Workload, defined as person-days per 10,000 hospital discharges required to com-
plete each surveillance option, and feasibility were measured using a question-
naire distributed to all participants.  
 
Data quality  
Epidemiological data quality was primarily assessed by data completeness. This 
was estimated by comparing each hospital’s minimal surveillance numerators 
(minimal option) with the number of available patient records (light option), and 
by calculating the proportion of patients for whom origin of the CDI (light option) 
and course of infection (enhanced option) were recorded, with less than 10% miss-
ing data being considered acceptable.
Microbiological data quality was assessed through comparison of each hospital’s 
testing rate per 10,000 patient-days and percentage of positive tests. Additionally, 
all NRLs’ ribotyping results obtained during the pilot study were compared with 
those of the coordinating laboratory. Additionally, in May 2013 and September 
2014, participation in two external quality assessments was offered by Public 
Health England to all ECDIS-Net NRLs that performed typing. NRLs in nine of the 
participating countries took part; on each occasion, 10 C. difficile strains were sent 
to the same eight NRLs and the coordinating laboratory of this study.  
 
Secondary endpoints  
Relationships between the risk of a complicated course of CDI or all-cause in-
hospital mortality in CDI cases (of any origin) and patient characteristics and 
microbiological results (as confirmed by the coordinating laboratory) were ana-
lysed by logistic regression. Correlations between incidence rates, testing rates 
and the proportion of PCR ribotype 027 were analysed by Spearman’s rank test.
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Results
PARTICIPATING HOSPITALS  
A total of 37 acute care hospitals from 14 European countries tested the minimal 
and light surveillance options for a three-month period between 13 May 2013 and 
1 November 2013. Of the 37 acute care hospitals, 21 were tertiary care hospitals, 
10 secondary care hospitals, five primary care hospitals and one was a specialised 
hospital for infectious and tropical diseases. A total of 36 hospitals included all 
wards; one hospital excluded a neonatal ward. Of the 37 participating hospitals, 
32, from 13 countries, tested the enhanced option as well ( Figure 1 ).
  Data collection in the pilot study for standardised surveillancea of Clostridium difficile infection 




Missing patient datad 
(n = 74)
>10th epsiode per hospital 
(n = 778)
No isolate or mismatch (n = 4) 






















No sample available for 





Samples collected by NRL (n = 281) 
(of which 201 were ribotyped by NRL)
Isolates ribotyped by 
coordinating laboratory (n = 267)
Analysed CDI epsiodes
CDI: Clostridium difficile infection.
a   Three surveillance options were tested: ‘minimal’ (aggregated hospital data), ‘light’ (including patient data for 
CDI cases) and ‘enhanced’ (including microbiological data on the first 10 CDI episodes per hospital).
b  Austria, Belgium, Denmark, Estonia, Finland, France, Germany, Hungary, the Netherlands, Norway, Poland, 
Romania, Serbia, United Kingdom (Scotland only). Enhanced surveillance including PCR ribotyping was carried 
out by Austria, Belgium, Finland, France, Germany, Hungary, the Netherlands, Norway, Poland and United King-
dom (Scotland only); Denmark, Romania and Serbia participated in enhanced surveillance, but did not perform 
PCR ribotyping at the national reference laboratory or appointed study laboratory. 
c  Three-month assessment during this time period.
d Clincial patient data missing, for reasons unknown.
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MINIMAL SURVEILLANCE: INCIDENCE RATE OF CLOSTRIDIUM DIFFICILE INFECTION  
A total of 1,152 CDI episodes were recorded by minimal surveillance in 37 hospitals 
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After exclusion of recurrent episodes, the incidence rate of healthcare-associated 
CDI by hospital ranged from 4.2 to 131.8 per 10,000 hospital discharges (median: 
16.4; IQR: 10.1–29.5) and from 0.6 to 18.5 per 10,000 patient-days (median: 3.7; IQR: 
2.0–6.6). The incidence rate of recurrent CDI varied between 0 and 118.6 per 
10,000 hospital discharges (median: 2.0; IQR: 0.2–5.2) and between 0 and 9.0 per 
10,000 patient-days (median: 0.3; IQR: 0.04–1.2).  
 
LIGHT SURVEILLANCE: PATIENT CHARACTERISTICS AND DIAGNOSTICS  
Patient data were submitted for 1,078 CDI episodes in 37 hospitals ( Figure 1 ). Most 
CDI cases were diagnosed by toxin enzyme immunoassay (EIA), confirmed by 
toxigenic culture (n = 220) or toxin EIA alone (n = 188). Other cases were diagnosed 
by GDH detection and confirmed by toxin PCR (n = 101) or toxin EIA (n = 88), by 
toxin PCR alone (n = 91), toxin PCR and toxigenic culture (n = 72) or other diagnos-
tic algorithms (n = 318).
The median age of patients was 72 years (IQR: 59–80); 38 (4%) CDI episodes were 
in those younger than 18 years, of whom 13 were younger than two years. The 
current hospital was reported as being the origin of infection for 66% (n = 673), 
another hospital for 18% (n = 178), a long-term care facility for 1% (n = 13) and an-
other healthcare facility for 2% (n = 21) of the 1,016 CDI episodes of known origin 
(for 62 episodes, the origin was unknown). Other patient characteristics are 
shown in Table 2. 
Table 2. Patient characteristics from ‘light’ (n = 1,078) and ‘enhanced’ surveillancea (n = 300) of Clostridium 
difficile infection in participating acute care hospitals in selected European countriesb, with putative deter-
minants of a complicated course of infection and all-cause in-hospital mortality, 13 May–1 November 2013c













Age in years 
< 65 370/1,077 (34) 104/299 (35) ref. ref.
65–84 549/1,077 (51) 152/299 (51) 3.4 (1.0–12.2) 1.6 (0.7–3.7)
≥ 85 158/1,077 (15) 43/299 (14) 6.6 (1.6–26.9) 2.1 (0.7–5.9)
Sex 
Female 573/1,078 (53) 157/300 (52) ref. ref.
Male 505/1,078 (47) 143/300 (48) 0.8 (0.3–1.8) 1.0 (0.5–2.1)
Recurrent infection 
No 862/978 (88) 240/277 (87) ref. ref.
Yes 116/978 (12) 37/277 (13) 0.7 (0.1–3.0) 0.9 (0.3–2.7)
CDI at admission 
No 505/984 (51) 153/276 (55) ref. ref.
Yes 479/984 (49) 123/276 (45) 1.7 (0.7–4.2) 0.3 (0.1–0.7)
Days of hospital stay to hospital-onset CDI
Number (IQR) 11 (IQR: 6–21) 9 (IQR: 6–17)  NA NA 




HA 885/1,078 (82) 249/300 (83) ref. ref.
CA 131/1,078 (12) 37/300 (12) 1.0 (0.3–3.7) 0.4 (0.1–1.6)
Unknown 62/1,078 (6) 14/300 (5) 2.0 (0.4–9.4) 1.1 (0.2–5.1)
Ward speciality 
Medicale NC 194/299 (65) ref. ref.
Surgical NC 53/299 (18) 0.9 (0.3–2.8) 0.8 (0.3–2.3)
ICU NC 29/299 (10) 1.8 (0.6–5.8) 2.5 (1.0–6.5)
Other NC 23/299 (8) NA 0.7 (0.2–3.4)
Healthcare admission < 3 months 
No NC 84/287 (29) ref. ref.
Hospital NC 194/287 (68) 1.0 (0.4–2.5) 1.3 (0.6–2.9)
Other NC 9/287 (3) 1.6 (0.2–14.5) 1.0 (0.1–9.3)
Antibiotic treatment < 3 monthsf 
No NC 34/254 (13) ref. ref.
One course NC 111/254 (44) 1.4 (0.4–5.2) 1.3 (0.4–4.1)
Multiple courses NC 109/254 (43) 0.7 (0.2–3.0) 1.0 (0.3–3.3)
Expected survival in years (McCabe score)
> 5 NC 171/285 (60) ref. ref.
1–4 NC 83/285 (29) 2.2 (0.9–5.5) 1.8 (0.7–4.5)
< 1 NC 31/285 (11) 2.5 (0.7–8.7) 12.0 (4.7–30.5)
Severe comorbidity (APACHE II CHP)g 
Liver cirrhosis NC 16/295 (5) 0.7 (0.1–5.8) 1.7 (0.5–6.1)
NYHA class IV heart failure NC 29/295 (10) 2.2 (0.7–7.0) 3.4 (1.4–8.3)
Pulmonary disease NC 38/297 (13) 3.3 (1.2–8.5) 1.7 (0.7–4.3)
Chronic dialysis NC 18/299 (6) 1.4 (0.3–6.7) 2.2 (0.7–7.2)
Immunocompromised status NC 92/291 (32) 0.8 (0.3–2.2) 1.3 (0.6–2.7)
C. difficile clade 
Clade 1, 3, 4 and 5 NC 187/267 (70) ref. ref.
Clade 2 (ribotype 027/176) NC 80/267 (30) 0.9 (0.4–2.5) 1.0 (0.4–2.3)
C. difficile binary toxin genes 
No NC 165/264 (63) ref. ref.
Yes NC 99/264 (38) 0.8 (0.3–2.1) 1.0 (0.4–2.1)
APACHE II CHP: Acute Physiology and Chronic Health Evaluation II chronic health points; CA: community-
associated; CDI: Clostridium difficile infection; HA: healthcare-associated; ICU: intensive-care unit; IQR: 
interquartile range; NA: not applicable; NC: not collected; NYHA: New York Heart Association; OR: odds 
ratio; ref.: reference group.
a   The ‘light’ surveillance option included patient data for CDI cases; in the ‘enhanced’ option, microbiological data 
on the first 10 CDI episodes per hospital were included.
b   All 37 hospitals in 14 European countries (Austria, Belgium, Denmark, Estonia, Finland, France, Germany, Hungary, 
the Netherlands, Norway, Poland, Romania, Serbia and United Kingdom (Scotland only)) tested the light option; 32 
hospitals in 13 countries (Austria, Belgium, Denmark, Finland, France, Germany, Hungary, the Netherlands, Norway, 
Poland, Romania, Serbia and United Kingdom (Scotland only)) tested the enhanced option.
c   Three-month assessment during this time period.
d   Number of episodes/total number of episodes for which data were available, unless otherwise indicated.
e   ‘Medical’ included several subspecialties of internal medicine (see protocol [ 14 ]).
f   Antibiotic treatment in past 3 months was the only variable with > 10% missing data.
g   The reference group consisted of patients without the comorbidity listed.
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ENHANCED SURVEILLANCE: COMPLICATED CDI AND IN-HOSPITAL MORTALITY  
For 300 CDI episodes in 32 hospitals, enhanced surveillance data were also sub-
mitted ( Table 2 ). The course of CDI was known for 98% (n = 294) of cases; 8% (n = 24) 
experienced a complicated course of infection (as defined in the Box). In univari-
able analysis, a complicated course was associated with age of 85 years or older 
and severe pulmonary disease, but not with CDI origin, presence of PCR ribotypes 
027 or 176, or of binary toxin genes ( Table 2 ). A total of 12% (n = 37) of CDI cases 
died during hospitalisation. Six deaths (2% of all CDI episodes) were related to 
CDI, 23 deaths (8% of all CDI episodes) were unrelated to CDI, and the relationship 
between CDI and death was unknown for the remaining eight episodes (3% of all 
CDI episodes). Patients with a complicated course had a 42% risk of in-hospital 
death (of which 25% were CDI-related) compared with 9% among patients with an 
uncomplicated course. All-cause in-hospital mortality was associated with a low-
er number of years of expected survival (a high McCabe score), healthcare-onset 
CDI and severe heart failure, but not with CDI origin, presence of PCR ribotypes 
027 or 176, or of binary toxin genes ( Table 2 ). 
ENHANCED SURVEILLANCE: MICROBIOLOGICAL DATA  
C. difficile was cultured and characterised in the coordinating laboratory for 
267 (89%) of the 300 CDI episodes registered during enhanced surveillance. The 
presence of toxin A and B genes was confirmed in 99% (263/265) of the cultured 
isolates; binary toxin genes were present in 38% (99/264) of the isolates. A total of 
51 different PCR ribotypes were characterised. The predominant PCR ribotype 
was 027 (30%; n = 79), followed by the highly related PCR ribotypes 014 and 020 
(15%; n = 40), and PCR ribotype 001 (6%; n = 15). PCR ribotype 027 was identified in 
isolates from eight European countries in 4–85% of all characterised samples, 
depending on the country ( Figure 2 ).
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CDI: Clostridium difficile infection; NUTS: nomenclature of territorial units for statistics.
The pilot study was based on a non-representative sample, thus the rates and distributions presented in this figure 
cannot be interpreted as being representative of any NUTS region.
a  The ‘minimal’ surveillance option comprised aggregated hospital data; the ‘enhanced’ option included micro-
biological data on the first 10 CDI episodes per hospital.
b  The NUTS 1 region indicates the geographical location of each participating hospital, rather than that of the 
hospital’s catchment area. The incidence rate per 10,000 patient-days in each NUTS 1 region is the median for 
all hospitals that participated within that same region. 
c  The number of PCR ribotyped strains varied by country: Austria (34), Belgium (26), Denmark (38), Finland (10), 
France (9), Germany (28), Hungary (17), the Netherlands (27), Norway (18), Poland (16), Romania (13), Serbia (22) 
and United Kingdom (Scotland only) (9). 
d Three-month assessment during this time period.
Source of map: FreeVectorMaps.com (http://freevectormaps.com).
  Incidence rate of healthcare-associated Clostridium difficile infection using ‘minimal’ 
surveillancea, by region (n = 22)b and distribution of PCR ribotypes identified using enhanced surveillance, 




>3 to 4 
>2 to 3 
















0 6 8 C H A P T E R  0 3
PCR ribotype 176, which is highly related to 027, was found in one CDI case in a 
country where no PCR ribotype 027 isolates were identified. The proportion of 
PCR ribotype 027 isolates correlated with the incidence rate of HA-CDI per 10,000 
patient-days (Spearman’s rho: 0.64; 95% CI: 0.36–0.81) ( Figure 3 ).
  Incidence rate of healthcare-associated Clostridium difficile infection in relation to the 
proportion of PCR ribotype 027 isolates, from ‘enhanced’ surveillancea in acute care hospitals in 13 Euro-
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CA: community-associated; CDI: Clostridium difficile infection; CI: confidence interval; HA: healthcare-associated.
Whiskers indicate the 95% CI around the incidence rate of HA-CDI per 10,000 patient-days per hospital. The pro-
portion of PCR ribotype 027 isolates correlated with the incidence rate (Spearman’s rho: 0.64; 95% CI: 0.36–0.81).
a The ‘enhanced’ surveillance option included microbiological data on the first 10 CDI episodes per hospital.
b  Austria, Belgium, Denmark, Finland, France, Germany, Hungary, the Netherlands, Norway, Poland, Romania, 
Serbia and United Kingdom (Scotland only).
c  Three-month assessment during this time period. 
All isolates that were investigated for antimicrobial susceptibility (n = 251) were 
susceptible in vitro to metronidazole. Eight PCR ribotype 027 isolates from Austria, 
Germany and Hungary showed reduced susceptibility to metronidazole, with a 
MIC just below the EUCAST epidemiological cut-off value [ 24 ]. Two PCR ribotype 
027 isolates from Denmark showed reduced susceptibility to vancomycin, with a 
MIC just below the EUCAST epidemiological cut-off value [ 24 ]; however, resist-
ance to vancomycin was not detected. In vitro moxifloxacin resistance was identi-
fied in 37% (n = 92) isolates, of which 77% (n = 71) belonged to PCR ribotype 027.
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FEASIBILITY AND WORKLOAD  
Participating hospitals reported a median of seven CDI episodes (IQR: 4–12) per 
month through both minimal and light surveillance. The feasibility question-
naire was completed by 26 of the 37 participating hospitals. Completion of the 
light and enhanced options were found to be ‘not difficult’ for 23/26 and 21/24 
respondents, respectively. The remaining respondents found them ‘quite difficult’.
The median workload for the ‘minimal’, ‘light’ and ‘enhanced’ surveillance op-
tions was 1.1, 2.0 and 3.0 person-days per 10,000 hospital discharges, respectively 
( Table 3 ).
The highest workload was reported by countries with the highest aggregated CDI 
incidence rates during the pilot (Serbia and Hungary). There were no differences 
in surveillance indicators by pre-existing surveillance activities, or when consid-
ering laboratory or typing capacity for CDI in the pilot study ( Table 3 ).  
 
 
DATA QUALITY  
Completeness of data was 94% (1,078/1,152) for patient data in the light option and 
98% (294/300) for data on the course of CDI in the enhanced option. Testing fre-
quency (range: 17–308 tests per 10,000 patient days) and the proportion of positive 
tests (range: 2–46%) varied between countries ( Table 3 ). The testing frequency cor-
related with the overall CDI incidence rate per 10,000 patient days (Spearman’s 
rho: 0.45; 95% CI: 0.15–0.68). PCR ribotyping results from the NRLs obtained dur-
ing enhanced surveillance were concordant with the coordinating laboratory’s 
results for 77% (128/166) of the isolates. Discordant results were either due to a 
mismatch in the identified PCR ribotype (n = 19; 11%), or because a PCR ribotype 
pattern result was not recognised by a NRL (n = 17; 10%) or by the coordinating 
laboratory (n = 2; 1%). External quality assessment demonstrated 75% and 86% 
accuracy of PCR ribotype allocation by the NRLs in 2013 and 2014, respectively.























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































0 7 2 C H A P T E R  0 3
Discussion
CDIs are a major concern for hospitals in Europe. The first ECDC point prevalence 
survey in 2011–12 estimated that 123,997 patients (95% CI: 107,697–441,969) devel-
oped a HA-CDI within the European Union each year [ 9 ]. In the United States, CDI 
has been declared an ‘urgent threat’ [ 25 ], with an estimated 80,400 HA-CDI cases 
in 2011 [ 26 ]. Establishing Europe-wide surveillance of CDIs is a pre-requisite to con-
trolling these infections in Europe. In 2011, 14 European countries had national 
CDI surveillance, but methodologies varied, and only four countries regularly 
linked C. difficile microbiological results to epidemiological data [ 3 ]. Therefore, a 
standardised protocol was proposed for periodical or continuous CDI surveil-
lance in European acute care hospitals, allowing direct interhospital and inter-
country comparison of surveillance results.
 
FEASIBILITY  
Results of our study in which we piloted a standardised surveillance protocol for 
CDI for European acute care hospitals suggests that all three surveillance options 
were manageable in participating countries, regardless of the countries’ pre- 
established level of CDI surveillance and microbiological typing capacity. 
Completeness of data was high, and hospital participants reported that the work-
load was manageable. Nevertheless, modifications were made on the surveillance 
methodology and forms to further optimise data collection. The finalised proto-
col version 2.2 is now available on the website of ECDC [ 27 ].
 
EPIDEMIOLOGICAL AND MICROBIOLOGICAL FINDINGS  
Using the pilot protocol, participating hospitals could obtain detailed informa-
tion on the local epidemiology of CDI at their respective facilities that could 
be used to target and reinforce infection prevention and control measures and 
resources. This pilot study had an important impact on certain national CDI- 
related activities as well: three of five participating countries that did not have 
national CDI surveillance at start of the ECDIS-Net project reported a high per-
centage of PCR ribotype 027 isolates in this study, and two of these countries 
(Poland [ 28 ] and Romania) decided to continue with intensified CDI surveillance. 
Interest in the surveillance and completeness of results also suggests that wide-
scale implementation at national and European level would be successful in 
acute care hospitals.
Although the non-representative selection of hospitals does not allow for interho-
spital or intercountry comparisons in the pilot study, patients enrolled in the 
enhanced option permitted a more in-depth analysis of the pilot data collected, 
allowing us to assess the relationship between patient and microbiological char-
acteristics and in-hospital outcome of CDI, our secondary objective. Similar to the 
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findings of a European study performed in 2008 [2], the majority of the patients 
in our pilot study had risk factors for CDI (e.g. median age of 72 years and 87% had 
used antibiotics in the previous three months). We found plausible associations 
between certain comorbidity variables and a complicated course of CDI or all-
cause in-hospital mortality of CDI cases; however, the presence of PCR ribotypes 
027 and 176 was not associated with a higher risk of all-cause in-hospital death, 
as found in a larger study in the United Kingdom in 2006–11 [29]. In contrast, the 
proportion of PCR ribotypes 027 isolates correlated with a higher incidence rate 
of HA-CDI, thus corroborating existing evidence on the high potential of this 
C. difficile PCR ribotype to spread. Indeed, this fluoroquinolone-resistant strain 
that emerged in Europe in 2004 [13] was the most frequently isolated ribotype, 
particularly in participating hospitals of eastern European countries. This find-
ing is in line with the ‘European, multicentre, prospective, biannual, point-prev-
alence study of C. difficile infection in patients admitted with diarrhoea’ (EUCLID) 
study (2011–13) that found PCR ribotype 027 to be most prevalent, clustering in 
Germany, Hungary, Poland and Romania [12].
Resistance to antibiotics that are routinely used to treat CDIs such as metronida-
zole and vancomycin was not detected in our study. Two PCR ribotype 027 isolates 
from one hospital showed a decreased susceptibility to vancomycin (MIC = 2 mg/L), 
but the clinical relevance of this finding is uncertain.  
DATA QUALITY  
We found varying frequencies of testing for CDI and percentages of positive tests 
in participating hospitals and countries, primarily indicating the need for an 
update of the European diagnostic guideline [ 30 ] and for promotion of optimal 
ascertainment of CDI. In addition, there is a need to address local or national 
variations in CDI case finding, ascertainment and reporting, which may be sub-
stantial across Europe, due to probable differences in clinical and laboratory 
awareness, practices of specimen collection from diarrhoeic patients and speci-
men transport, clinical and laboratory indications, requests from physicians and 
CDI testing methods, local epidemiology (e.g. intensified testing during out-
breaks), financial resources to test for CDI, data sources for surveillance, and 
reporting incentives or disincentives. Therefore, we suggest that in CDI surveil-
lance programmes the possibility of adjusting CDI incidence rates at least for key 
factors related to sampling and testing methods should be investigated. We rec-
ommend that validation studies accompany national surveillance to estimate 
sensitivity and specificity, in order to correct national and European CDI infec-
tion rate estimates.
Furthermore, standardisation of PCR ribotyping is essential for implementation 
of the enhanced surveillance option, as results show suboptimal concordance 
between results of national and external laboratories. Agarose-based ribotyping 
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results are more difficult to interpret and to exchange between laboratories than 
capillary-based results [ 31 ]. The increase, from 23% in 2011 to 50% in 2014, in the 
percentage of ECDIS-Net participating countries that use capillary-based PCR 
ribotyping [ 18 ] was the most likely explanation for the better performance in the 
external quality control exercise in 2014 [ 31 ]. Further standardisation of PCR 
ribotyping will likely be achieved by regular exchange of new C. difficile strains 
and build-up of a consistent reference database. The first steps have already been 
taken by concerted action of ECDIS-Net members with reference laboratories 
from CDC and the Public Health Agency of Canada [ 31 ]. At the same time, new 
developments in DNA sequence analyses should be monitored closely for applica-
tion in ribotyping modifications and considered for implementation in surveil-
lance activities of C. difficile [ 32 ]. In our pilot study, PCR ribotyping of the first 10 
strains per hospital in the enhanced option was performed to balance effort, 
costs and benefits, such as in the national surveillance programme of Belgium 
[ 5 ]. Despite these positive experiences, further evidence for this approach should 
be obtained and evaluated at European level.  
OTHER LIMITATIONS  
The results of our pilot study are not generalisable to all European acute care 
hospitals as it was based on a non-representative convenience sample, as also 
indicated by the disproportionally high number of tertiary care hospitals (21/37) 
in our sample. Similarly, our analytical epidemiological results and country- 
specific results are based on very small numbers of hospitals and should not be 
considered as representative. Specifically, the number of events allowed for 
univariable analysis only when exploring associations between covariables and 
outcome of CDI. Assessing the local context in more details (e.g. gathering infor-
mation on clinical practices and/or policies related to specimen collection and 
CDI testing in the participating hospitals) or covering all CDC surveillance evalu-
ation attributes [33] was beyond the scope of this pilot study. Local audits to deter-
mine surveillance sensitivity, in both case finding and collection of denominator 
data, could have helped to elucidate some of the larger observed variations.




We conclude that continuous or periodical surveillance with collection of differ-
ent levels of epidemiological and microbiological data following a standardised 
protocol is a feasible strategy to monitor CDIs in European acute care hospitals. 
Ideally, national and international validation studies, regular and comprehen-
sive evaluation of the surveillance protocol, as well as CDI case finding, ascertain-
ment and reporting should complement the surveillance activity.
ECDC has used the final protocol version 2.2 to initiate CDI surveillance in EU/
EEA countries in 2016, and will gradually incorporate enhanced surveillance 
data in The European Surveillance System (TESSy) [ 27,34 ]. Importantly, the sur-
veillance of CDI in European acute care hospitals will be the first Europe-wide, 
hospital-based surveillance of a primarily healthcare-associated infection with a 
distinct microbiological component. The protocol can be used as a tool to guide 
local CDI surveillance and ultimately contribute to reducing CDI incidence rates 
in acute care hospitals. Finally, aggregated data from nationally representative 
samples should allow an estimation of the true incidence rate of CDIs in Europe.
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STUDY COORDINATORS  F Allerberger, E Simons (AGES, Austria); M Hell (Paracelsus Medical 
University, Austria); J van Broeck, (University of Louvain, Belgium); R Vatcheva-Dobrevska (National 
Centre of Infectious and Parasitic Diseases, Bulgaria); B Matica (Dr. Andrija Štampar Insitute of Public 
Health, Croatia); P Maikanti-Charalampous, D Bagatzouni (Nicosia General Hospital, Cyprus); O Nyč 
(Hospital FN Motol Prague, Czech Republic); HM Holt (Odense University Hospital, Denmark); 
J Engberg (Slagelse Hospital, Denmark); L Søes (Hvidovre Hospital, Denmark); B Olesen, I Brock 
(Herlev Hospital, Denmark); V Adamson (Tartu University Hospital, Estonia), M Jyrna-Ellam, M Altmets 
(North-Estonian Regional Hospital, Estonia); O Lyytikäinen (National Institute for Health and Welfare, 
Finland); K Chami (Institute for Public Health Surveillance, France); C Eckert (National Reference 
Laboratory for C. difficile and Hôpital Saint Antoine, France); V Lalande (Hôpital Saint Antoine, France); 
I Poilane (Hôpial Jean Verdier, France); B Coignard (Institut de Veille Sanitaire, France); EO Glocker 
(Medical Center–University of Freiburg, Germany); C MacKenzie (Heinrich Heine University Düssel-
dorf, Germany); L von Müller (University of Saarland Medical Centre, Germany); B Weiß (Robert 
Koch-Institut, Germany); E Petinaki (Hospital of University of Thessalia, Greece), K Antmann 
(Semmelweis University, Hungary); A Kertész (Merged ‘Szent István’ and ‘Szent László’ Hospital and 
Policlinic); K Böröcz, A Kurcz, Zs Barna (National Center for Epidemiology, Hungary); L Kyne (University 
College Dublin, Ireland); L Fenelon (Health Protection Surveillance Centre and Beaumont Hospital, 
Ireland), P Spigaglia (Istituto Superiore di Sanità, Italy), ML Moro (Agenzia Sanitaria e Sociale 
Regionale Emilia-Romagna, Italy); AO Balode (Rīga Stradiņš University, Latvia); J Miciuleviciene, 
R Valentiliene (Vilnius City Clinical Hospital, Lithuania); M Perrin, P Reichert, C Olinger (Laboratoire 
National de Sante, Luxembourg); GA Kampinga, HAJ Hooijer (University of Groningen, University 
Medical Center Groningen, the Netherlands), SC de Greeff (National Institute for Public Health and 
the Environment, the Netherlands); E Lingaas (Oslo University Hospital, Norway); P Karpinski, 
D Lachowicz, P Obuch-Woszczatynski (Medical University of Warsaw, Poland); A Mikucka (Ludwik 
Rydygier Collegium Medicum, Nicolaus Copernicus University in Toruń, Dr Antoni Jurasz University 
Hospital No.1, Poland); G Szulencka (Provincial Hospital Wloclawek, Poland); M Oleastro, J Machado 
(Instituto Nacional de Saude Dr. Ricardo Jorge, Portugal); D Lemeni (‘Cantacuzino’ National Institute 
of Research and Development for Microbiology and Immunology, Romania); M Nica (Dr. Babes 
Clinical Hospital for Infectious and Tropical Diseased, Romania); E Nováková (Jessenius Faculty of 
Medicine in Martin, Slovakia); M Rupnik (National Laboratory for Health, Environment and Food, 
Slovenia); J Kolman (National Institute of Public Health, Slovenia); E Bouza (Hospital General Univer-
sitario ‘Gregorio Marañón’, Spain), S Valdezate (Instituto de Salud Carlos III, Spain); T Åkerlund, 
O Aspevall (Public Health Agency of Sweden; E Sheridan (Health Protection Agency, UK); P Rooney 
(Belfast City Hospital, UK); J Coia (Scottish Microbiology Reference Laboratories, UK); A Widmer (Uni-
versity Hospital Basel, Switzerland); M Ritzler (Labor RISCH, Liechtenstein); J Bjornholt (Norwegian 
Institute of Public Health, Norway); M Kroknes (St.Olavs Hospital, Norway); H Hardarson (Landspitali 
University Hospital, Iceland); B Levent (Refik Saydam National Hygiene Center, Turkey); M Drakulović 
(Institute of Public Health of Serbia ‘Dr Milan Jovanovic Batut’, Serbia).
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Background. Little is known about 
paediatric Clostridium difficile infection 
(CDI) epidemiology. We describe the 
clinical and microbiological charac-
teristics of CDI among hospitalized 
children in the Netherlands.
Methods. Between May 2009 and May 
2015, 26 hospitals registered charac-
teristics of paediatric (aged 2–18 years) 
and adult (aged ≥18 years) CDI in a na-
tional sentinel surveillance study. 
Routine polymerase chain reaction 
(PCR) ribotyping and multiple-locus 
variable-number tandem-repeat anal-
ysis (MLVA) of selected strains was per-
formed. Paediatric and adult results 
were compared using proportion and 
95% confidence interval (CI). Time 
trend of paediatric CDI was evaluated 
using a mixed-effect Poisson model.
Results. Paediatric CDIs were reported 
in 17 of the 26 participating hospitals 
(n = 135; 3% of all CDIs); the monthly 
number was constant over time. The 
median age of paediatric cases was 
10 years (interquartile range, 4.7–14.5 
years). Fifty-five percent of the children 
had community onset and 31% had 
severe CDI. Compared with adults 
(n = 4,556), complication and morta-
lity rates were lower. Clostridium diffi-
cile PCR ribotype 265 (toxin A negative, 
B positive) was most prevalent in 
children (15%; 95% CI, 8.8%–24.0%) but 
rarely found in adults (1%; 95% CI, 
0.9%–1.6%). This strain was rarely 
found in other countries, except for 
Belgium. MLVA showed genetic relat-
edness between three-fourths of pae-
diatric and adult ribotype 265 strains, 
without a clear epidemiological link.
Conclusions. Paediatric CDI in hospi-
tals has remained stable over the last 
6 years and resulted in fewer compli-
cations than for adult CDI. Further 
studies are needed to elucidate the 
source and epidemiology of PCR ribo-
type 265, primarily found in children.
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Introduction
Clostridium difficile is a commensal bacterium in newborns (30%–35% positive) and 
infants aged up to 2 years (10%–15% positive) [ 1 – 3 ]. Infants are considered insensi-
tive to free C. difficile toxins in the intestinal tract for several reasons, including 
lack of mature toxin-binding receptors on epithelial cells and incomplete cellular 
uptake of the toxins and/or protecting microbiome composition [ 1, 4 ]; however, 
clear scientific evidence is lacking.
Clostridium difficile is potentially harmful for children aged >2 years [ 5 ], though 
the presence of toxin-producing C. difficile in stools is not conclusive for diagnoses 
[ 6 – 8 ]. Children with a presumed C. difficile infection (CDI) have a 1.2 – 2 times 
higher in-hospital mortality risk and prolonged hospitalizations compared with 
matched controls [ 9, 10 ]. However, the absolute mortality risk, primarily ranging 
from 0% to 1.5% [ 10 – 16 ] and from 3% to 5% in certain studies [ 9, 17, 18 ], is much 
lower than for adults [ 11 ].
In the last decade, the reported incidence of paediatric CDI in both community 
and hospitals settings in the United States increased [ 10, 14, 17, 19 ]. Most children 
who develop CDI have underlying comorbidities [ 9, 13, 17 ]. Recent use of anti-biot-
ic drugs, the presence of gastrointestinal feeding devices, prior hospitalization, 
and comorbidities, such as malignancies, inflammatory bowel disease, and organ 
transplantation, are the main risk factors [ 10, 20, 21 ].
Here, we describe the clinical and microbiological characteristics of CDI in 
hospitalized children in the Netherlands as part of a CDI national sentinel sur-
veillance study and compare these results to those of adult cases. Our aim is to 
determine the burden of paediatric CDI and to determine if additional strategies 
to prevent, diagnose, and treat CDI in children are needed.




STUDY DESIGN  
We included all CDIs reported between May 2009 and May 2015 by 26 Dutch hospi-
tals that participate in a national sentinel surveillance study (no ethical approval 
needed). Hospitals were requested to register all hospitalized patients who ful-
filled the clinical CDI definition listed below. Children aged <2 years were exclud-
ed. For each CDI patient, information on the history of CDI <8 weeks prior to the 
current infection, the location of onset (community or hospital), and CDI severity 
was collected. Antibiotic use prior to CDI onset (for treatment of infections other 
than CDI) at time of or during admission was registered. Polymerase chain reac-
tion (PCR) ribotyping was used to characterize C. difficile isolates. Thirty days after 
diagnosis, complications, including surgery and admission to an intensive care 
unit due to CDI and mortality, were assessed. Additionally, hospitals reported the 
primary CDI diagnostic test applied during participation (possibly limiting sur-
veillance sensitivity).   
DEFINITIONS 
A paediatric CDI was defined as the occurrence of diarrhoea (3 or more loose stools 
per day for 2 subsequent days) or a toxic megacolon and a positive test for a toxin-
producing C. difficile or presence of pseudomembranous colitis in children aged 
2–18 years. Other causes of diarrhoea were excluded (by chart review and/or results 
of diagnostic tests for other enteropathogens). Patients aged ≥18 years who fulfilled 
the same criteria were categorized as “adults” with CDI. A case was considered as 
healthcare-onset CDI (HO-CDI) if symptoms started in a hospital or long-term care 
facility and as community-onset CDI (CO-CDI) if symptoms started at home. Severe 
CDI (for both children and adults) was defined as either the presence of bloody diar-
rhoea and/or pseudomembranous colitis, and/or diarrhoea accompanied by dehy-
dration (as judged by the treating physician) and/or hypoalbuminemia (<20 mg), 
and/or fever (≥38.0°C) with leucocytosis (>15.0 × 109/L). Mortality was considered as 
“contributable to CDI” if other comorbidities would not have caused death or “part-
ly contributable to CDI” if both CDI and other comorbidities caused death.  
 
LABORATORY METHODS  
The primary (first) diagnostic test of each participating hospital was variable for 
many hospitals ( Supplementary Table 1 ). Positive samples were sent to the central 
laboratory (Leiden University Medical Centre, the Netherlands) for typing. Real-
time PCR was used to identify the GDH (glutamate dehydrogenase) gene specific 
to C. difficile [ 22 ], and PCR ribotyping was used to characterize the isolates [ 23 ].
To study relatedness of the predominant paediatric PCR ribotype 265 in more detail, 
multiple-locus variable-number tandem-repeat analysis (MLVA) was applied [ 24 ]. 
We selected all ribotype 265 strains from children with CDI included in this 
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study and from 2 preceding and 2 successive adult ribotype 265 cases in the same 
hospital (also from cases typed apart from the sentinel surveillance study). MLVA 
results were visualized in a minimum spanning tree using BioNumerics soft-
ware, version 7.1 (Applied Maths, Saint-Martens-Latem, Belgium). All ribotype 265 
isolates were tested for deletions in the TcdA gene using PCR [ 25 ]. The genetic 
relatedness of PCR ribotype 265/ sequence type 88 to other C. difficile types was 
visualized in a phylogenetic tree, using multilocus sequence typing (MLST) 
results of the Clostridium difficile MLST Databases. Further, we requested interna-
tional collaborators (eg, the ESCMID Study Group for Clostridium difficile, founders 
of the Clostridium difficile MLST Databases, Webribo, and the US Centers for 
Disease Prevention and Control) to verify the presence of ribotype 265 in their 
databases by sharing the capillary electrophoresis PCR ribotyping peak file. 
 
STATISTICAL ANALYSES  
Categorical or binary variables were reported as frequencies and percentages and 
compared based on their 95% confidence intervals (CIs). Continuous variables 
were reported as medians and the interquartile ranges (IQRs). Quantile regres-
sion was used to assess associations between age and covariables. To evaluate a 
time trend of paediatric CDI, the monthly number of reports was analysed using 
a mixed-effect Poisson model, allowing random effects per hospital, to account 
for clustered data. Additionally, we corrected for the type of primary diagnostic 
test applied (categorized in free toxin detection, tests including GDH detection, 
or Nucleic acid amplification test (NAAT)). Complete case analysis was performed, 
except for 1 sensitivity analysis on CO-CDI vs HO-CDI and prior antibiotic usage. 
Data were analysed using Stata software, version 12.1 (StataCorp LP, College 
Station, Texas).




PAEDIATRIC CDI REPORTING AND TIME TRENDS  
Between May 2009 and May 2015, 4691 CDIs were reported. A total of 135 paediat-
ric CDIs (3% of all CDIs) were reported by 17 hospitals (65%). There were large 
interhospital differences in the proportion of paediatric CDIs, especially when 
university hospitals (range, 1.8%–14.3%) were compared with nonuniversity hospi-
tals (range, 0%–7.7%; Supplementary Table 1). No CDI outbreaks on paediatric wards 
were reported. The number of paediatric CDIs per month was stable according to 
mixed-effect Poisson modelling (P = .578), also when correcting for the type of 
primary diagnostic test applied (P = .145).
 
CLINICAL CHARACTERISTICS AND 30-DAY OUTCOME  
The median age of children with CDI was 10 years (IQR, 4.7–14.5 years) and simi-
lar for children with CO-CDI and HO-CDI (11 vs 10 years [P = .84]). Fifty-three per-
cent of the children with CO-CDI received non-CDI antibiotics prior to CDI onset 
(28/53 [95% CI, 39.1%–66.6%]) compared with 81% of the children with HO-CDI 
(43/53 [95% CI, 70.4– 91.9%]), though information on antibiotic use was missing for 
29 cases. If we assumed that all children with missing information either used or 
did not use non-CDI antibiotics prior to CDI onset, the difference persisted (66% 
vs 84% and 38% vs 70%, respectively).
A total of 39 children (31%, data for 8 children missing) met the criteria for 
having severe CDI. Eighteen of these children were dehydrated or had hypo-
albuminemia (46%), 16 had bloody diarrhea (41%), 10 had fever and leucocytosis 
(26%), and 5 had pseudomembranous colitis (13%). Females had severe CDI more 
often than males (45% [95% CI, 31.8%–58.2%] vs 19% [95% CI, 9.5%–28.2%]).
A complicated course within 30 days after diagnosis was reported for at least 
3 children (3%, data of 37 children missing). One 6-year-old female was admitted 
to the intensive care unit suffering from CDI with dehydration/hypoalbumine-
mia and fever with leucocytosis. Two males died within 30 days after diagnosis 
due to causes other than CDI.
 
PAEDIATRIC CDI COMPARED WITH ADULT CDI  
In Table 1, clinical data of children are compared with those of adult CDI patients 
(n = 4556). CO-CDI was more com-mon in children than in adults (55% [95% CI, 
46.4%–63.2%] vs 33% [95% CI, 31.8%–34.6%]). Severe CDI was more frequently 
observed in children than in adults (31% [95% CI, 22.7%–38.8%] vs 23% [95% CI, 
22.1%–24.6%]. In contrast to adults, CDI-related mortality did not occur in children 
(0% vs 4% [95% CI, 3.0%–4.2%].
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PCR RIBOTYPING DISTRIBUTION  
For 113 of 135 paediatric CDIs (84%), a stool sample or C. difficile isolate was sent to 
the reference laboratory for PCR ribotyping. Clostridium difficile was detected in 98 
samples (n = 5 culture negative; n = 10 Clostridium species but not C. difficile). In 
total, 36 different C. difficile PCR ribotypes were identified. Table 2 illustrates the 
ribotyping distribution of paediatric CO-CDI and HO-CDI compared with adults 
(information on CDI onset and typing results for 3573/4556 adults available). 
Ribotype 265 was most prevalent in children (15% [95% CI, 8.8%–24.0%]) but rarely 
found in adults (1% [95% CI, 0.9%–1.6%]). Ribotype 014/020 was commonly found in 
both children and adults (12% [95% CI, 6.5%–20.4%] and 15% [95% CI, 13.9%–16.3%], 
respectively). Ribotypes 001 and 078/126 were less frequently isolated from 
children than from adults (5% [95% CI, 1.7%–11.5%] vs 15% [95% CI, 13.7%–16.1%] 
Table 1. Clinical Characteristics and 30-Day Outcome of Children With Clostridium difficile Infection  
Compared With Adults
Patient demographics and 
course of CDI
Paediatric cases, 
n = 135 (%)
Adult cases, 
n = 4556 (%)
Age category, y
2–5 41 (30.4) -
6–9 26  (19.3) -
10–13 30  (22.2) -
14–17 38  (28.1) -
Male gender 74  (54.8) 2209  (48.5)
Previous CDI
Yes, clinical presentation only 1a  (1.2) 173  (6.5)
Yes, clinical presentation and positive test 19a  (23.2) 474  (17.8)
No, no clinical presentation 42a  (51.2) 1408  (52.9)
No, negative test 20a  (24.4) 608  (22.8)
Days to diagnosis of hospital-onset CDIb 2 (1–8) 2  (1–6)
Community onset of symptoms 74  (54.8) 1480  (33.2)
Prior antibiotic usec 71d  (67.0) 2674  (70.2)
Severe CDI 39e  (30.7) 968  (23.3)
30-day outcome
Complicated course 3f  (3.1) 568  (15.4)
Overall mortality
2
f  (2.0) 507  (13.7)
CDI-related mortality
0
f  (0) 133  3.6)
Abbreviation: CDI, Clostridium difficile infection.
a  Data missing for 53 children.
b  Expressed as median number of days and the interquartile range.
c  At time of diagnosis or during admission for treatment of infections other than CDI.
d  Data missing for 29 children. 
e  Data missing for 8 children. 
f  Data missing for 37 children.
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and 5% [95% CI, 1.7%–11.5 %] vs 13% [95% CI, 12.3%–14.5%], respectively). Ribotype 
027 strain was not found in the paediatric population but was present in 3% of 
the adult population (n = 94 [95% CI, 2.1%–3.2%]). The differences in ribotype 
distribution were larger when HO-CDI was compared with CO-CDI ( Table 2 ).
PCR RIBOTYPE 265  
Paediatric ribotype 265 cases occurred in 7 hospitals located in different regions 
of the Netherlands ( Figure 1 ). Two-thirds of the cases occurred between March 2012 
and March 2013 (n = 10), dispersed over several months. Ribotype 265–infected 
children were younger than those infected by other ribotypes (median age of 4 vs 
11 years). Children and adults with a ribotype 265 CDI (n = 15 and n = 45) did not 
have more severe CDI com-pared with those infected by other ribotypes (29% vs 
31% and 28% vs 24%, respectively) and did not have a higher 30-day mortality risk 
(0% vs 4% and 14% vs 14%, respectively). None of the ribotype 265–infected adults 
deaths were partly related to CDI.
MLVA showed that three-fourths of the ribotype 265 strains isolated from chil-
dren and adults were genetically related (defined as ≤10 summed tandem-repeat 
difference [ 24 ]; Figure 1). Three clonal complexes (defined as ≤2 summed tandem-
repeat difference on ≤2 loci [ 24 ]) were found, of which 2 complexes included adult 
and paediatric isolates from different hospitals. Three children had a recurrent 
ribotype 265 infection ( Figure 1 ). Three ribotype 265 strains that were isolated in 
1 university hospital (U3) in October 2012–November 2012 were genetically, but 
not clonally, related.
Ribotype 265 had an intact toxin B production but lacked toxin A due to a TcdA 1.8 
kb deletion as ribotype 017 [ 25 ] and was negative for binary toxin genes. A phylo-
genetic tree of multilocus sequence types submitted to the Clostridium difficile 
MLST Databases illustrated the genetic relatedness of ribotype 265 (assigned as 
sequence type 88) and ribotype 017 (assigned as sequence type 37; Supplementary 
Figure 2). According to the survey in our international network, ribotype 265 
appears to be very uncommon or absent in other countries, except for Belgium 
( Supplementary Table 2 ). In Belgium, ribotype 265 was primarily found isolated 
from children aged <2 years.
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Table 2. Polymerase Chain Reaction Ribotype Distribution of Community Onset and Healthcare Onset 




CO, n = 53 (%) HO, n = 45 (%) CO, n = 1182 (%) HO, n = 2391 (%)
001 2 (3.8) 3 (6.7) 105 (8.9) 427 (17.9)
002 6 (11.3) 2 (4.4) 76 (6.4) 148 (6.2)
005 6 (11.3) 2 (4.4) 54 (4.6) 105 (4.4)
014/020 8 (15.1) 4 (8.9) 179 (15.1) 359 (15.0)
027 - - 24 (2.0) 70 (2.9)
078/126 4 (7.5) 1 (2.2) 176 (14.9) 302 (12.6)
087 2 (3.8) 2 (4.4) 18 (1.5) 34 (1.4)
106 1 (1.9) 2 (4.4) 6 (0.5) 6 (0.3)
265 4 (7.5) 11 (24.4) 14 (1.1) 31 (1.3)
Other types 20 (37.7) 15 (33.3) 405 (34.3) 748 (31.3)
Unknown - 3 (6.7) 125 (11.2) 161 (6.7)
The 8 most common ribotypes (n ≥3 isolates) in children were taken as a reference, and ribotype 027 was included 
for its clinical relevance. A dash indicates a zero.
Abbreviations: CO, community onset; HO, healthcare onset.
 
a   Two adults had a mixed infection, the polymerase chain reaction ribotype with the lowest number is reported in 
the table.
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  Minimum spanning tree of Clostridium difficile polymerase chain reaction ribotype 265 
strains isolated from children (in blue; n = 15) and adults (in green; n = 24), according to multiple-locus 
variable-number tandem-repeat analysis. The STRD is shown between the circles. Dark gray areas repre-
sent a cluster of genetically related strains (defined as ≤10 summed tandem-repeat difference), and light 
gray areas represent clonal complexes (defined as ≤2 summed tandem-repeat difference on ≤2 loci). Each 
circle specifies the code for the hospital where the patient was located and the month and year of isolation. 
Superscripts indicate samples that were isolated from identical patients (a, b, and c). Abbreviations: STRD, 
summed tandem-repeat difference; U, H (U indicates University hospitals and H primary and secondary 
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Discussion
We report the clinical characteristics and PCR ribotypes of paediatric CDI in a 
large sentinel surveillance study in the Netherlands during a 6-year period.
In contrast with several studies performed in the United States [ 10, 14, 17, 19 ] and 
Italy [ 26 ] but in agreement with a recent study in the United Kingdom [ 24 ], we did 
not find an increase in paediatric CDIs over time. The increase in the United 
States could be related to the high prevalence of NAP1/ribotype 027 or to an in-
creased awareness of the need to test children for CDI, though this is opposed by 
1 study [ 17 ]. The recent implementation of NAAT in many laboratories may have 
contributed to this increase [ 27 ] by possibly including C. difficile carriers as CDIs. 
It did have a significant effect on paediatric CDI reporting in our analysis and was 
incorporated into our model. However, both the unadjusted and adjusted models 
did not indicate an increase in paediatric CDIs.
We found large interhospital differences in the proportion of reported paediatric 
CDIs, especially between university hospitals and nonuniversity hospitals (5% vs 
0.3%). University hospitals indeed treat children with a higher CDI risk, such as 
those with cancer, as well as organ and bone marrow trans-plantation patients 
[ 21 ]. However, we questioned whether non-university hospitals actually did test 
for C. difficile in children. We contacted 9 hospitals that do not or rarely report 
paediatric CDI; 1 did not test for CDI in children, but 7 tested on clinical request 
in children of all ages, and 1 only in patients aged >2 years. There is no guideline 
for CDI testing in children in the Netherlands (or in Europe) in contrast to the 
United States [ 4, 28 ]. We assume that differing views among both paediatricians 
and microbiologists on CDI testing in children contributed to interhospital dif-
ferences.
The clinical characteristics of paediatric CDI found in our study resemble find-
ings of other studies, despite the higher median age of patients in our study [ 9, 13, 
17, 18, 20 ]. Approximately half of the paediatric cases had CO-CDI, which is in line 
with 2 studies that used different criteria (29% and 54%) [ 9, 18 ], while others found 
26% and 71% of paediatric CDI cases to be acquired in the community [ 13, 15 ]. 
Antibiotics are considered to be a risk factor but not a prerequisite for developing 
paediatric CDI [ 21 ]. In our study, 67% of the children received non-CDI antibiotics 
prior to CDI onset, which is similar to previous studies that showed rates of 61%–
74%, depending on the measured time period of exposure [ 14, 18 ]. As expected, 
the percentage exposed to non-CDI antibiotics was lower in paediatric CO-CDI 
than in HO-CDI.
Compared with adults, we found a high proportion of severe CDI (31%) in children 
but a lower complication and mortality rate 30 days after diagnosis. Possibly, chil-
dren are more capable than adults of recovering from severe CDI [ 21 ] or possibly 
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the current severity criteria do not fit the paediatric population [ 29 ]. This is sup-
ported by a study that revealed that 50% of children with CDI did not require 
specific CDI treatment, while 76% were classified as “severe CDI” [ 24 ]. However, 
the severity rate in that study was much higher than in our study, and as de-
scribed in literature [ 13 – 15 ].
PCR ribotype 265 (toxin A negative due to a TcdA 1.8 kb deletion, toxin B positive, 
and negative for binary toxin genes) was most prevalent in children and rarely 
found in adults. Epidemiological and molecular typing data could not elucidate 
ribotype 265 transmission routes. MLVA showed that three-fourths of the ribo-
type 265 strains isolated from children and adults were genetically related. There 
was no clustering according to host (children vs adults), date, or place of isolation. 
These results suggest ongoing (regional) transmission between the 2 populations, 
whereas this ribotype may favour younger hosts in particular. In Europe, ribo-
type 265 was initially observed in Leiden in 2006 and determined to be a new 
ribotype at the Anaerobe Reference Laboratory in Cardiff (personal communica-
tion, Dr Michael Perry) in 2010. In the United States, it was first isolated in 1988 
(personal communication, Dr Jane Marsh) using MLST and belongs to the same 
lineage as ribotypes 017, 047, 088, 130, and 172 ( Supplementary Figure 2 ) [ 30 ]. 
Our international survey showed that this ribotype was rarely found in North 
America and Europe, except for the neighbouring Belgium where most were iso-
lated from children aged <2 years. Although we did not include children aged <2 
years in our study (as many other studies), these findings support our hypothesis 
that the ribotype favours younger hosts and that transmission may be restricted 
to certain countries.
After ribotype 265, ribotype 014/020 was most often detected in children (12%), 
consistent with previous studies where NAP4/ PCR ribotype 014 was predominant 
in 26% and 24% [ 13, 31 ]. Another study showed PCR ribotype 014 to be predomi-
nant in infants (aged <2 years) in 25% in Spain [ 32 ]. Our study, as well as a German 
study [ 31 ], indicated an absence of ribotype 027 in children in contrast to adults, 
though both studies typed a limited number of children. In contrast, NAP1/ 
ribotype 027 was found in 11% and 23% of the paediatric CDI cases in the United 
States and Canada [ 13, 15 ], including community-acquired CDI [ 15 ]. In a different 
single-center US cohort, NAP1/ribotype 027 was found in <1% of the children, op-
posed to 31% of adults in the same area [ 33 ]. These geographical differences may 
be due to diverse antibiotic exposure (e.g., fluoroquinolones), infection preven-
tion measures, or infection pressure in the community.
Our study has several limitations. CDI testing of children was not as well stand-
ardized as for adults and may have resulted in a general underestimation of the 
burden of paediatric CDI. Our definition of community-onset CDI, which was in-
troduced in 2009 for feasibility reasons, differs from international guide-lines 
and hampers benchmarking. Our sample size was relatively small, hampering 
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multivariate analysis, and we had high levels of missing data for some variables. 
Age-specific denominator data to calculate age-stratified incidence rates were not 
available, though we evaluated the monthly number of paediatric CDIs using a 
mixed-effect Poisson model, corrected for the primary diagnostic method applied, 
and showed that no variation in time was present. In addition, the number 
of paediatric admissions in the Netherlands [ 34 ] did not change over time. The 
absence of epidemiological links between ribotype 265 cases may be caused by 
incomplete sampling (eg, nondiagnosed children and asymptomatic carriers) and 
the lack of detailed patient data, although a dispersion in time and location was 
evident.
In conclusion, we did not observe an increase in the monthly number of reported 
paediatric CDIs over a 6-year period. Clostridium difficile ribotype 265 was more 
prevalent in children than in adults, without a clear explanation. Future prospec-
tive paediatric studies are needed to obtain more detailed information on CDI 
risk factors, transmission, and treatment in children and to confirm and eluci-
date why some PCR ribotypes are more or less abundant compared with adults.
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  Number of reported paediatric CDIs per 12-month time period,   
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Supplementary Table 1. Numbers of reported paediatric CDIs per total number of CDIs, stratified by 
12-month time period (May 2009-April 2015) and hospital, and primary CDI diagnostic test(s) applied.
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  Phylogenetic tree of the genetic relatedness of PCR ribotype 265 (sequence 
type 88) to other C. difficile types. To include as many sequence types (STs) for the phylogenetic analysis as 
currently described, we downloaded (20-04-2016) the STs from the online C. difficile multilocus sequence 
typing (MLST) database (http://pubmlst.org/cdifficile/ ). In total, 319 STs were included in the phylogenetic 
analysis (Last updated: 2016-04-04). Nucleotide sequences of the seven housekeeping genes used for C. 
difficile MLST (Griffiths et al.) were concatenated; 219 SNPs were identified for the 319 STs. A maximum 
likelihood phylogeny was reconstructed using RaxML (ref: Stamatakis) with a general time reversible (GTR) 
model and gamma correction for among-site rate variation combined with 100 random bootstrap repli-
cates (default). The STs numbers were removed to improve readability, only STs and corresponding PCR 
ribotypes (RTs) were kept for commonly found C. difficile types. The dashed window is enlarged to improve 
resolution for the lineage in which RT265 (ST-88) was located.
Supplementary Figure 2
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Background. It has been suggested 
that the high incidence of ribotype 
078 Clostridium difficile infections (CDI) 
in the Netherlands is related to pig 
farming. 
Methods. We used data of hospital-
ised CDI patients (>2yrs of age) diag-
nosed between May 2009 and May 
2015 in 26 hospitals participating in a 
national sentinel surveillance. We 
compared clinical and geographical 
characteristics of 078 CDI to other 
CDI. We investigated the association 
between 078 CDI incidence and four 
indicators of pig farming (piglet, pig, 
piglet farm and pig farm density) by 
mixed-effects Poisson regression. We 
used a space-time permutation model 
to search for community-onset 078 
CDI clusters (using SaTScan). 
Results. A total of 4,691 CDI were iden-
tified. Ribotype 078 was isolated in 
493 of 3,756 patients (13.1%) including 
a typing result. These patients had 
slightly higher community-onset dis-
ease and a 35% increase of 30-day 
mortality compared to non-078 CDI 
patients. The pooled overall and 078 
incidence rates were 2.82 (95% CI, 
2.42-3.29) and 0.26 (95% CI, 0.21-0.31) 
CDI per 10,000 patients-days respec-
tively. Hospital 078 CDI incidence was 
not associated with provincial pig 
(IRR, 0.98; 95% CI, 0.89-1.08), piglet 
(IRR, 0.95; 95% CI, 0.75-1.19), pig farm 
(IRR, 1.08; 95% CI, 0.84-1.39), or piglet 
farm density (IRR, 1.00; 95% CI, 0.56-
1.79). No clusters of community-onset 
ribotype 078 CDI were found.
Conclusions. Our results do not indi-
cate that the ribotype 078 CDI inci-
dence in hospitals is related to pig 
(farm) or piglet (farm) density. How-
ever, transmission beyond provincial 
borders or in non-hospitalised patients 
cannot be excluded.
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Introduction
The Gram-positive spore-forming bacterium Clostridium difficile emerged as an im-
portant cause of infectious diarrhoea and diarrhoeic outbreaks in hospitals in 
the Netherlands [1]. Hospitalised patients are considered to be primarily infected 
by other C. difficile infection (CDI) patients, possibly mediated through healthcare 
personnel or the hospital environment [2]. Yet, in at least 45% of the cases the 
source of infection is unknown [3]. Animals might be an alternative source of C. 
difficile infection [4, 5]. Several animal species are colonized by similar C. difficile 
subtypes as found in humans [4]. More in-depth genomic studies have suggested 
C. difficile transmission between pigs and humans of ribotype 014 in Australia [6] 
and ribotype 078 in the Netherlands [7]. Ribotype 078 is the predominant ribotype 
in pigs and piglets in the Netherlands [5, 8]. About 50%-80% of piglets are colonised 
by C. difficile and can develop disease [8 – 10]. At slaughter age, 1%-9% of pigs are 
positive [10,  11]. C. difficile spores can subsequently contaminate farm environ-
ments and pig-derived manure [12, 13] and can be found in meat [4, 5]. Considering 
the fact that 12 million pigs coexist with nearly 17 million inhabitants in the 
Netherlands [14], the impact of pig-farming on ribotype 078 transmission can be 
significant. Pig farming is concentrated in specific provinces in the Netherlands.
Since mid-2006, ribotype 078 is one of the most common ribotypes to cause CDI 
in hospitalised patients in the Netherlands [1]. Ribotype 078 appeared to be associ-
ated to community-acquired disease [15, 16] and more abundant in areas of con-
centrated pig farming in 2005-2008 [16]. In other European regions with high 
ribotype 078 rates, such as Northern Ireland and Scotland, the link between 
ribotype 078 and pig-farming was not extensively investigated [17, 18]. 
We hypothesise that if C. difficile ribotype 078 shedding by pigs and/or piglets 
leads to enhanced regional human exposure, we would find a relation between 
pig farming and the ribotype 078 CDI incidence in our country. In the present 
study, we use data of a national C. difficile infection sentinel surveillance in the 
Netherlands (May 2009 – May 2015). We investigate the association between hos-
pital incidence rates of ribotype 078 CDI and pig(let) density and pig(let) farm 
density at a provincial level. Second, we compare clinical characteristics of ri-
botype 078 compared to other CDI. Third, we use a space-time permutation mod-
el to identify the location of clusters of community-onset 078 CDI followed by 
hospitalisation.




SENTINEL SURVEILLANCE SYSTEM  
Prospective national C. difficile infection sentinel surveillance (SeS) was initiated 
in the Netherlands in May 2009 by the National Reference Laboratory for C. diffi-
cile (Leiden University Medical Centre, Leiden and the National Institute for Pub-
lic Health and the Environment (RIVM), Bilthoven). Hospitals were included in 
SeS according to their geographical location, with the aim to obtain a geographi-
cally representative sample of all hospitals in the Netherlands (Figure 1a). SeS 
hospitals prospectively submitted anonymous patient forms of all included 
CDI episodes to a web-based system (ethics approval not required). Subsequently, 
the National Reference Laboratory for C. difficile received the samples (faeces, or 
C. difficile isolates) of CDI episodes included in SeS for PCR ribotyping [19], and 
performed data analysis. For the current study, CDI SeS data from May 2009 to 
May 2015 was used. In that time period, surveillance was conducted at 26 hospi-
tals (8/75 primary care hospitals, 12/23 secondary care hospitals, and 6/8 univer-
sity hospitals), representing 25% of all hospitals in the Netherlands [14]. 
  Location of SeS hospitals and pooled CDI incidence rates in relation to average provincial 
pig density (no. of pigs per hectare) in 2009-2015. 
Figure 1A Locations of SeS hos-
pitals (n=26) and the average 
provincial pig density per hectare 
(Source of map: ArcGis, Environ-
mental Systems Research Insti-
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Figure 1B Pooled provincial CDI 
(all ribotypes) incidence rates 
and 95% CI (bars) in relation to 
average provincial pig density 
per hectare (line).
Figure 1C Pooled provincial ri-
botype 078 CDI incidence rate 
and 95% CI (bars) in relation to 
average provincial pig density 
per hectare (line). 
DR: Drenthe, FL: Flevoland, FR: Friesland, GE: Gelderland, GR: Groningen, LI: Limburg, NB: North Brabant, 
NH: North Holland, OV: Overijssel, UT: Utrecht, ZE: Zeeland, ZH: South Holland. 
No data
< 0.25
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DATA COLLECTION AND DEFINITIONS  
Hospitalised CDI patients (>2yrs of age) were eligible to be included in SeS. Chil-
dren aged <2 yrs were excluded for reasons described earlier [20]. A case was de-
fined as the presence of clinical symptoms (an abnormal stool frequency, >3 times 
per day diarrhoea during two subsequent days, or radiological or clinical signs of 
a toxic megacolon), and either the presence of a toxin-producing C. difficile in the 
faeces, or a confirmed pseudomembranous colitis (by endoscopy or by histopa-
thology after colectomy or autopsy) [20, 21]. Participating hospitals applied their 
own diagnostic procedures to test for the presence of toxin-producing C. difficile 
in the faeces. 
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The patient form included information on the location of CDI onset (i.e. commu-
nity or healthcare), the presence of CDI in the prior 8 weeks (‘recurrence’), CDI 
severity, CDI-related and all-cause 30-day mortality, as has been described previ-
ously [20]. Community-onset CDI included all cases with a reported onset of symp-
toms in the community, whereas healthcare-onset CDI related to cases with a re-
ported onset of symptoms in a hospital, nursing home or other healthcare 
institution (e.g. care home). Four-digit postal code data was requested from pa-
tients with community-onset CDI. Severe CDI was defined by the presence of 
bloody diarrhoea and/or pseudomembranous colitis and/or diarrhoea with either 
dehydration and/or hypoalbuminemia, and/or fever (>38 ºC) and leucocytosis 
(>15.0 X 109/L). 30-day mortality was considered ‘CDI-related’ if other comorbidi-
ties would not have caused death.   
 
 
HOSPITAL INCIDENCE RATES   
Yearly hospital incidence rates of CDI were calculated per 10,000 inpatient-days 
[22]. Numbers of inpatient-days of participating hospitals were extracted from a 
website of the CIBG of the ministry of Health, Welfare and Sport, to ensure stand-
ardised data collection [23]. Children below the age of two could not be excluded 
from these denominator data, which was not considered to have a large impact 
on incidence rates of CDI. We calculated Poisson rate 95% CIs for all incidence 
rates. Overall and provincial incidence rate of CDI were generated by inverse-
variance weighting.   
 
 
PROVINCIAL PIG AND PIGLET DENSITY  
The StatLine database of the Dutch National Bureau of Statistics [14] was used to 
calculate four indicators of provincial pig-farming; (i) the number of pigs per hec-
tare (‘pig density’), (ii) the number of piglets per hectare (‘piglet density’), (iii) the 
number of pig farms per 1000 hectare (‘pig farm density’), and (iv) the number of 
piglet farms per 1000 hectare (‘piglet farm density’) for 2009-2015.   
 
 
STATISTICAL ANALYSIS  
Risk ratios (RR) and 95% confidence intervals (CI) were calculated to compare pa-
tient characteristics of ribotype 078 CDI, with CDI caused by other ribotypes. 
Highly genetically related ribotypes that were difficult to discriminate by PCR 
ribotyping e.g. ribotypes 078/126 (as of now referred as ‘ribotype 078’) were clus-
tered. 
The association between four indicators of pig-farming (see Provincial pig and pig-
let density) and ribotype 078 hospital incidence rates at a provincial level was ana-
lysed by a multilevel mixed-effects Poisson regression model. We considered the 
outcome (incidence rate) to follow a Poisson distribution, and included ‘hospital’ 
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as a random effect to account for clustered data. We calculated incidence rate 
ratios (IRR) for each of the four indicators of provincial pig-farming, and adjusted 
for diagnostic testing and year. Diagnostic testing was categorised into algo-
rithms with ‘free toxin detection’, ‘PCR’ or ‘glutamate dehydrogenase detection’ 
since a variety of diagnostic algorithms were applied, and these categories are 
indicative for the sensitivity diagnostic testing for CDI. A similar analysis was 
performed for the hospital incidence of community-onset ribotype 078 infec-
tions. We performed two sensitivity analyses by (1) excluding university hospi-
tals, where relatively more patients are treated that originate from a different 
province to receive highly specialised care, and (2) excluding ribotype 126 CDI 
from the ribotype 078 subgroup, to avoid potential misclassification. STATA soft-
ware version 12.1 (StataCorp, College Station, USA) was used for data analysis.  
 
 
SPATIAL CLUSTER ANALYSIS OF COMMUNITY-ONSET CDI  
To identify clusters of community-onset CDI that might be missed while investi-
gating overall hospital incidence rates of CDI, we studied SeS postal code data of 
community-onset CDI by a retrospective space-time permutation model (SaTScan, 
M Kulldorff, Boston, MA, USA) [24]. This model does not require population-at-risk 
data, but data should derive from a stable population [24]. Therefore, we analysed 
data of two time periods (period I: September 2009-December 2013 and period II: 
December 2013-May 2015) of hospitals that continually participated in surveil-
lance. To select an appropriate spatial window setting, we initially used 50% pop-
ulation-at-risk as maximal spatial cluster size, and repeated the analysis with a 
maximal cluster size of 25 km radius, and compared our results [25]. We searched 
for clusters of community-onset CDI in general, as well as for ribotype 078 spe-
cific clusters, and assessed if they were located in provinces with a high pig and 
piglet density. We performed a sensitivity analyses by excluding ribotype 126 CDI 
from the ribotype 078 subgroup, to avoid potential misclassification.




REPORTED CDI EPISODES  
In total, 4,691 CDI cases were reported by 26 hospitals in a period of six years. A 
third (n = 1,554) was designated as community-onset and two-thirds as health-
care-onset CDI (n = 3,038). Of all healthcare-onset CDI episodes, 2,751 (90.6%) were 
reported to have started in a hospital, 148 in a long-term care facility (4.9%) and 
139 (4.6%) in other healthcare facilities. Healthcare-onset CDI was severe in 17.6% 
(n = 489) versus community-onset CDI in 34.9% (n = 517). Of patients with health-
care-onset CDI, 17.0% experienced a complicated course; 1 (0.04%) needed surgery 
for CDI, 37 (1.5%) had to be admitted to an intensive care unit for CDI, and 381 
(15.5%) died within 30 days. Eight of these patients died due to CDI (0.3% of all HO-
CDI), another 82 patients died from factors contributed to by CDI (3.3% of all HO-
CDI). Of patients with community-onset CDI 11.3% experienced a complicated 
course; 8 (0.6%) needed surgery, 16 (1.2%) were admitted to an intensive care unit 
for CDI, and 126 (9.5%) died within 30 days. Two of these patients died due to CDI 
(0.15% of all CO-CDI) and 41 (3.1% of all CO-CDI) patients died from factors contrib-
uted to by CDI. Of the remaining patients cause of death was indeterminate, not 
related to CDI or unknown. Supplementary Table 1 illustrates time trends of the 
characteristics and the outcome of all reported CDI episodes.   
 
 
MOLECULAR TYPING OF REPORTED CDI EPISODES  
For 3,755 CDI cases (80.0%) a PCR ribotyping result could be obtained and linked 
to the clinical data. Ribotype 014 (including ribotypes 020/295) was the most fre-
quently isolated ribotype (n = 570; 15.2%), followed by ribotype 001 (n = 547; 14.6%). 
The occurrence of ribotype 001 declined in time ( Table 1 ). Ribotype 078 (including 
ribotype 126) was the third most commonly found ribotype (n = 493; 13.1%). 
Its prevalence was constant over the study period. Ribotype 027 was occasionally 
found (n = 97; 2.6%). 
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CDI DUE TO RIBOTYPE 078 COMPARED TO OTHER RIBOTYPES  
The mean age of patients with a ribotype 078 infection was similar to those in-
fected by other ribotypes (69 vs.67 years), but the age distribution was marginally 
different (P = 0.039; Table 2). Community-onset CDI was slightly more common in 
078 patients than in non-078 patients (RR, 1.13; 95% CI, 0.99-1.28). CDI severity 
was higher in 078 cases compared to cases caused by other ribotypes (RR, 1.28; 
95% CI, 1.10-1.49). Further, patients with a ribotype 078 infection more often had 
a complicated course of disease (18.6% vs. 14.9%; RR, 1.25; 95% CI 1.00-1.56), a high-
er mortality (17.6 vs. 13.0%; RR, 1.35; 95% CI, 1.07-1.71), and higher CDI-related 
mortality (5.6 vs. 3.4%; RR, 1.65; 95% CI, 1.05-2.60) compared to those with CDI 
caused by other ribotypes. 
 078 CDI  (n=493) Non-078 CDI  (n=3,263) Risk ratio or P-value
% (95% CI) % (95% CI) RR (95% CI)
Age
     < 18 years 1.2% (0.2-2.2) 2.9% (2.3-3.4)
P = .039
     18-65 years 30.8% (26.7-34.8) 32.0% (30.4-33.6)
     65-85 years 56.4% (52.0-60.8) 51.2% (49.5-53.0)
     > 85 years 11.6% (8.8-14.4) 13.9% (12.7-15.1)
Female gender 50.7% (46.3-55.1) 51.2% (49.4-52.9) 0.99 (0.90-1.09)
Hospital service       
 Medical 68.8% (63.2-74.3) 71.6% (69.6-73.7)
P = .517 ICU 5.5% (2.8-8.2) 4.3% (3.4-5.2)
 Surgery 25.7% (20.5-30.9) 24.1% (22.1-26.0)
Previous CDI (>8 weeks) 29.6% (24.3-35.0) 23.1% (21.2-25.0) 1.28 (1.05-1.57)
Community-onset of symptoms 37.3% (32.9-41.6) 33.1% (31.5-34.7) 1.13 (0.99-1.28)
Antibiotic therapy prior to CDI 71.1% (66.7-75.5) 71.2% (69.5-72.9) 1.00 (0.93-1.07)
Severe CDI 30.3% (26.1-34.6) 23.7% (22.2-25.3) 1.28 (1.10-1.49)
CDI INCIDENCE RATES  
The pooled overall and ribotype 078 specific CDI incidence rates were 2.82 (95% 
CI, 2.42-3.29) and 0.26 (95% CI, 0.21-0.31) cases per 10,000 patients-days respec-
tively. There was no significant increase in time for all CDI (IRR, 1.00; 95% CI, 
0.94-1.07) or ribotype 078 CDI (IRR, 1.04; 95% CI, 0.84-1.29) adjusted for diagnostic 
category. Community-onset CDI increased in time (IRR, 1.03; 95% CI 0.93-1.15) 
while hospital-onset CDI remained stable (IRR 0.98; 95% CI 0.90-1.06) when adjust-
ing for diagnostic category (Figure 2). The overall CDI incidence rates were higher 
in secondary care hospitals (IRR, 1.44; 95% CI, 1.09-1.92) compared to primary 
care and university hospitals, as well as for ribotype 078 (IRR 1.44; 95% CI, 
0.78-2.67) when adjusting for year and diagnostic category. 
Table 2. Patient characteristics of PCR ribotype 078 CDIs compared to non-078 CDIs reported in C. difficile 
infection sentinel surveillance between May 2009 and May 2015.
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CDI RIBOTYPE 078 INCIDENCE RATES IN RELATION TO PIG DENSITY 
Fig 1b illustrates the pooled CDI incidence for each province with the correspond-
ing average provincial pig density and Fig 1c the pooled provincial 078 incidence 
with the corresponding average pig density. Hospital ribotype 078 incidence was 
not associated pig density (IRR, 0.98; 95% CI, 0.88-1.09) or piglet density (IRR, 0.95; 
95% CI, 0.75-1.21) of the province where the hospital was located. Further, ri-
botype 078 incidence was not associated with the number of pig farms per 1000 
hectare (IRR, 1.08; 95% CI, 0.84-1.39) and the number of piglet farms per 1000 
hectare (IRR, 1.00; 95% CI, 0.56-1.79). The incidence of community-onset ribotype 
078 CDI was not related to the annual pig density (IRR, 0.98; 95% CI, 0.82-1.16) as 
well. The first sensitivity analysis excluding university hospitals (IRR, 0.98; 95% 
CI, 0.87-1.10) confirmed our primary results. The second sensitivity analysis ex-
cluding ribotype 126 from the ribotype 078 subgroup (IRR, 0.99; 95% CI, 0.89-1.10) 
also supported our primary findings.   
 
 
SPATIAL ANALYSIS OF COMMUNITY-ONSET 078 CLUSTERS  
Of patients with community-onset CDI (n = 1,554) the postal code was registered. 
For period I postal codes of 792 CO-CDIs (of which n = 90 ribotype 078) were ana-
lysed. For period II postal codes of 490 CO-CDIs (of which n = 52 ribotype 078) were 
included. In the analysis restricted to 25 km radius three large clusters (28, 37 
and 49 km radius) of community-onset CDI were missed and five extra small clus-
ters were detected (2, 5, 7, 8 and 20 km radius). None of these clusters were found 
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to be statistically significant. We continued with the restricted model to detect 
smaller clusters that might be overlapped or non-significant in non-restricted 
settings [25]. In both time periods no clusters of community-onset CDI or commu-
nity-onset ribotype 078 CDI were found. Also, in our sensitivity analysis (exclud-
ing ribotype 126 infections from the 078 subgroup) no significant clusters were 
detected. 
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Discussion 
C. difficile ribotype 078 persists as one of the most common ribotypes in hospital-
ised patients in the Netherlands, causing 13.1% of the cases in the present study. 
CDI due to type 078 was found to be associated with a worse clinical outcome 
(35% increase of 30-day mortality and 65% increase of CDI-related mortality) as in 
other studies [26]. We investigated the association between the hospital incidence 
of ribotype 078 CDI and pig farming at a provincial level as suggested before [16]. 
However, our results did not indicate any association of ribotype 078 CDI inci-
dence in hospitals with provincial pig (farm) or piglet (farm) density. Besides, ri-
botype 078 did not cause spatial clusters of community-onset CDI followed by 
hospitalisation. Consequently we presume that C. difficile ribotype 078 shedding 
by pigs and/or piglets in our country does not lead to provincial excesses or local-
ised clusters of hospital ribotype 078 CDI.
Earlier reports showed an association of ribotype 078 with community-onset 
or community-acquired disease [15 – 18] as one would expect if transmission was 
driven by pig or other animal contact in the community. We found ribotype 078 
patients to have slightly higher community-onset disease compared to other pa-
tients. This could have been a result of the relatively low abundance of other en-
demic CDI strains (such as the healthcare-associated ribotype 027) taken as a ref-
erence to study ribotype 078 characteristics. Moreover, widespread transmission 
in the population may result in a change in clinical manifestation like for live-
stock-associated MRSA [27]. Previous studies in the Netherlands show that ri-
botype 078 was found in 11% of the CDI patients visiting their general practi-
tioner with diarrhoea (absolute prevalence 0.09%) [28] and in 13% of the healthy 
community residents living in the proximity of livestock farms (absolute preva-
lence 0.16%) [29] similar to our results of hospitalised patients. In asymptomatic C. 
difficile carriers admitted to three Dutch hospitals (one hospital located in the 
province with the highest pig density, North Brabant), ribotype 078 was not one 
of the foremost ribotypes found [30]. These findings challenge the hypothesis that 
ribotype 078 primarily is a community-related disease. 
This study is the first to search for clusters of community-onset ribotype 078 fol-
lowed by hospitalisation in relation to animal density, as has been done for other 
stock-related pathogens such as Q-fever [25]. No significant clusters were found, in 
line with the absence of community outbreak reports of ribotype 078 CDI [5]. Re-
markably, ribotype 078 rarely causes outbreaks in healthcare facilities (including 
those participating in the current study) despite its high virulence in infected 
patients. 




Our study has several limitations. This surveillance study targeted a geographi-
cally representative sample of hospitals, but selection bias may nonetheless have 
occurred. Not all pig farming areas were included in our data. Our analysis was 
based on the assumption that C. difficile ribotype 078 shedding by pigs and piglets 
leads to enhanced human exposure in the province [13]. Exposure may occur 
more localised, but we did not have data on individual exposure to pig-farming in 
this study. Ribotype 078 CDI not associated or followed by hospitalisation were 
not included. Besides, our provincial indicators for pig-farming did not differenti-
ate between areas of low and high intensive pig-farming. We only differentiated 
between community-onset and healthcare-onset CDI for feasibility, but commu-
nity-onset CDI could be related to previous healthcare exposure. Therefore, our 
results probably reflect an overestimation of CDI that is actually acquired in the 
community. Diagnostics for CDI were not standardised in the Netherlands during 
this study, which could bias incidence rates. We adjusted for three diagnostic 
categories in our models, but not for the specific testing strategy and diagnostic 
algorithm. Currently, 87% of the participants in the sentinel surveillance study 
apply a two-step algorithm to diagnose CDI [31]. CDI incidence rates were slightly 
underestimated due to the fact that children below the age of two could not be 
excluded from denominator data. The space-time permutation model was ham-
pered by a variable number of participating hospitals which would induce popu-
lation shift bias. To avoid this, we split the data in two time periods and selected 
hospitals that continually participated in surveillance (~80% all data) and thus 
might have missed clusters in the residual ~20% of the data.   
CONCLUSIONS  
According to the results of this study hospital incidence rates of ribotype 078 CDI 
in the Netherlands were not associated with pig-farming at a provincial level. 
Transmission beyond provincial borders (e.g. meat consumption) or in non-hospi-
talised patients cannot be excluded. No clusters of community-onset ribotype 
078 followed by hospitalisation were detected in provinces with higher pig densi-
ties, although we might be scratching the surface of the burden of CDI in the 
community. For prospective studies on the zoonotic potential of CDI, we suggest 
that multiple reservoir hosts and ‘sinks’ of CDI are considered and advanced 
molecular methods are used to prove transmission.  
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Objectives. Clostridium difficile infec-
tions (CDI) account for 1.5% of diar-
rhoeic episodes in patients attending 
a general practitioner in the Nether-
lands, but its sources are unknown. 
We searched for community clusters 
to recognise localised point sources of 
CDI. 
Methods. Between October 2010 and 
February 2012, a community-based 
prospective nested case-control study 
was performed in three laboratories 
in the Netherlands with a study popu-
lation of 2,810,830 patients. Bernoulli 
spatial scan and space-time permuta-
tion models were used to detect spa-
tial and/or temporal clusters of CDI. 
In addition, a multivariate condition-
al logistic regression model was con-
structed to test livestock exposure as 
a supposed risk factor in CDI patients 
without hospital admission within 
the previous 12 weeks (‘community-
acquired CDI’).
Results. In laboratory A, B and C, 1.3%, 
1.8%, and 2.1% of patients with diar-
rhoea tested positive for CDI respec-
tively. The mean age of community-
acquired CDI patients (n = 124) was 
49 years (SD, 22.6); 64.5% were female. 
No spatial or temporal clusters of 
CDI cases were detected compared to 
C. difficile negative diarrhoeic controls. 
Except for one false-positive signal, no 
spatio-temporal interaction amongst 
CDI cases was found. Livestock expo-
sure was not related to community-
acquired CDI (OR, 0.99; 95% confidence 
interval, 0.44-2.24). Ten percent of 
community-acquired CDIs was caused 
by PCR ribotype 078, spatially dis-
persed throughout the study area. 
Conclusions. The absence of clusters 
of CDI cases in a community cohort of 
diarrhoeic patients suggests a lack of 
localised point sources of CDI in the 
living environment of these patients. 
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Introduction
Clostridium difficile infection (CDI) occurs when its spores germinate in the intesti-
nal tract, and bacterial growth and toxin production surpass the host resistance. 
C. difficile toxins damage the intestinal epithelium causing symptoms ranging 
from diarrhoea to life-threatening colitis [1]. Although hospitalised patients have 
the greatest risk for CDI, the infection has been increasingly recognised in 
patients living outside healthcare facilities [2, 3].
The risk profile and transmission of community-acquired CDI (CA-CDI) are not 
fully understood. Fourteen to 17% of patients with CA-CDI have no evident risk 
factors that predispose for CDI, such as medication use, prior hospitalisation 
and underlying diseases [4, 5]. Transmission from infants, asymptomatic carriers, 
household members and pets has been suggested, but never thoroughly investi-
gated [6 – 8]. Livestock animals can acquire C. difficile as well, and may contribute to 
transmission of certain subtypes of C. difficile in the community [9]. In the Nether-
lands, piglets are typically infected by C. difficile ribotype 078 [10] and its spores 
contaminate the farm environment [11]. In-depth genomic studies indicate that 
C. difficile transmission between pigs and humans is likely [12, 13]. A publication 
from North Carolina, one of the largest pig producing states in the United States, 
suggested that environmental exposure to livestock farms increases the risk for 
CA-CDI, but calls for further spatial analysis that includes data of molecular 
strain typing [14].
The main objectives of the present study were to investigate i.) the spatial and/or 
temporal clustering of patients with CDI compared to difficile negative diarrhoeic 
controls in the community, ii.) the association of community-acquired CDI with 
livestock exposure, and iii.) the C. difficile PCR ribotypes and risk factors associat-
ed with spatial clustering of CDI in the community.




STUDY DESIGN   
We used data from a prospective community-based prospective nested case- 
control study on CDI, performed between October 2010 - February 2012 in the 
Netherlands. Details on the study design have been published previously [4]. In 
summary, three medical microbiological laboratories (A, B and C) tested all un-
formed stool samples of patients >2 yrs submitted by 832 general practitioners 
(with a population of 2,810,830 patients) for the presence of free C. difficile toxins 
in the faeces. Diagnostics of other enteropathogens were performed on request of 
the physician. The study area encompassed areas of varying levels of pig farming. 
Questionnaire data (e.g. on CDI risk factors and several environmental exposures, 
e.g. contact with livestock) were requested from all positive patients and a 
matched control group (on age, sex, and calendar time). PCR ribotyping was used 
to characterize all C. difficile isolates [15]. The study was approved by the LUMC 
Medical Review Ethics Committee.  
 
 
GEOCODING AND MAPPING  
Full residential postal codes were requested from both C. difficile positives (n = 194) 
and C. difficile negative patients with diarrhoea (n = 12,520). If the exact residential 
postal code was unknown (all patients of laboratory A, four patients of laboratory 
B, and two patients of laboratory C), the location of the general practitioners’ 
practice was used. Locations were obtained for 6,882 patients for laboratory A 
(83%), 3,009 patients for laboratory B (100%) and 1,367 patients for laboratory C 
(100%). Locations were geocoded to X- and Y-coordinates of the centroid of the full 
postal code. ArcGIS version 10.5 was used for mapping (Environmental Systems 
Research Institutes, Inc. Redlands CA).  
 
 
SPATIAL CLUSTERING ANALYSIS AND SPACE-TIME PERMUTATION MODEL  
Scan statistics were used to detect clusters of CDI in the community in temporal, 
spatial and space-time settings [16 – 18]. Likelihood ratio tests were used to detect 
the most likely clusters, while Monte Carlo simulation was used to correct for 
multiple testing [16, 18]. Bernoulli models were applied to assess if CDI cases were 
non-randomly distributed in space and time compared to C. difficile negative diar-
rhoeic controls [18]. Subsequently, we searched for space-time interaction of CDI 
and non-CDI diarrhoeic events by space-time permutation models [17]. For both 
models, we aggregated the data per week, used a standard maximal temporal 
cluster size of 50% of the population at risk, and a maximal cluster size of 25km, 
and scanned for high rates. As the three participating laboratories had slightly 
different study periods, we performed separate space-time permutation analyses 
for three laboratories. SaTscan (version 9.4.4, M Kulldorf, Boston, MA, USA) was 
used to perform all geospatial analysis. 
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LIVESTOCK EXPOSURE AS A RISK FACTOR FOR COMMUNITY-ACQUIRED CDI 
We tested livestock exposure as a risk factor for CA-CDI by multivariate condi-
tional logistic regression analysis. Patients were excluded if they were admitted 
to a hospital <12 weeks prior to onset of diarrhoea [19]. Livestock exposure in-
cluded professional contact and/or recreational contact with farm animals (e.g. 
visiting a children’s farm) <30 days before the onset of diarrhoea. Using data from 
the literature, putative confounders (other than matching variables) were antibi-
otic use [5, 20 – 23], hospital visits [22, 23], PPI use [24], CDI household contacts [8], 
and contact with infants [25]  and comorbidities [23]. Antibiotic exposure was 
categorized into 4C antibiotics (cephalosporins, clindamycin, ciprofloxacin and 
amoxicillin/clavulanic acid), non-4C antibiotics and antibiotics of unknown type 
[26]. We created a comorbidity score adapted from the chronic disease score 
for infectious diseases (CDS-ID), but scored reported illnesses in <1 year before 
diarrhoea [27]. Putative confounders were visualized in a directed acyclic graph 
( Supplementary Figure 1 ) [28] and incorporated in the multivariate model accord-
ingly. For the total effect of animal exposure we adjusted for age and gender 
(matching variables), comorbidities, and contact with infants. Odd ratios (ORs) 
were presented with a 95% confidence interval (95% CI). We used STATA version 
14.1 (StataCorp, College Station, TX, USA) for our analyses. 




C. DIFFICILE PREVALENCE   
The study covered a population of 2,810,830 patients inhabiting 3,848 postal code 
areas. In total, 194 of 12,714 patients (1.5%) tested positive for C. difficile toxins. Labo-
ratory A tested 111 of the 8,338 patients positive for C. difficile (1.3%) between October 
4, 2010 and October 28, 2011. Laboratory B tested 54 of the 3,009 patients positive for 
C. difficile (1.8%) between November 16, 2010 and January 31, 2012. Laboratory C test-
ed 29 out of 1,367 patients positive for C. difficile (2.1%) between September 30, 2010 
and September 30, 2011. The distribution of C. difficile positive and negative patients 
of all three laboratories is depicted in Figure 1. Of the 194 C. difficile positive patients, 
152 completed the questionnaire and 124 complied with the definition of CA-CDI. 
The mean age of CA-CDI patients was 49 years (SD, 22.6), and 64.5% were female.   
 
 
SPATIAL AND TEMPORAL CLUSTERS OF CDI  
According to Bernoulli modelling, no significant clusters of CDI (n = 179) were 
detected compared to C. difficile negative diarrhoeic controls (n = 11,258) for labora-
tory A, B and C. Furthermore, testing for purely spatial or temporal clusters did 
not yield significant results. One non-significant temporal cluster of 45 CDI cases 
(RR, 2.06; p = 0.051) was found between the October 23, 2010 and April 1, 2011 for 
laboratory A, and one of 11 cases (RR, 2.10; p = 0.89) between the November 30, 
2011 and January 24, 2012 for laboratory B.   
 
 
SPACE-TIME INTERACTION OF CDI  
One significant spatio-temporal cluster of six CDI cases (not caused by one ribo-
type) between December 11, 2010 - February 4, 2011 was found (15.31 km radius; 
p = 0.0066; Figure 1). However, this cluster was located in an area surrounded by 
large water surfaces ( Figure 1 ), not found by Bernoulli modelling, and interpreted 
as false positive. CDI patients were not clustered according to a space-time per-
mutation model for laboratory B and C.  
 
 
SPACE-TIME INTERACTION OF C. DIFFICILE NEGATIVE PATIENTS   
WITH DIARRHOEA  
Two clusters of C. difficile negative diarrhoeic controls were detected for laborato-
ry A ( Figure 1 ). The first consisted of 159 patients diagnosed between October 16, 
2010 – April 22, 2011 (22.25 km radius, p < 0.0001) of whom 9% were tested positive 
for a combination of infectious pathogens causing diarrhoea. The second cluster 
included 15 diarrhoeal patients without infectious pathogens detected between 
November 20, 2010 and January 21, 2011 (19.19 km radius, p = 0.0012; Figure 1). 
For laboratory B and C, C. difficile negative diarrhoeic controls were not clustered 
according to a space-time permutation modelling.
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RISK FACTORS FOR CA-CDI  
Table 1 shows the putative risk factors for community-acquired CDI cases (n = 124) 
and controls (n = 232). Comorbidities and antibiotic exposure were associated 
with CA-CDI, while there was no apparent association with environmental expo-
sures to livestock. In multivariate analysis, livestock exposure was not related to 
CA-CDI (OR, 0.99; 95% confidence interval, 0.44-2.24).  
 
 
PCR RIBOTYPES OF CA-CDI  
C. difficile isolates were available for PCR ribotyping of 120 patients with commu-
nity-acquired CDI. Of 25 different PCR ribotypes found, ribotypes 002 (11.4%), 015 
(10.1%), and 078 (10.1%) were most common. Since no CDI clustering was found, 
associations to specific PCR ribotypes could not be investigated. PCR ribotype 078 
cases and those caused by the highly related ribotype 126 were spatially dispersed 
throughout the study area. 
  Distribution of 179 community CDI cases (yellow circles) in contrast to density of C. difficile 
negative diarrhoeic controls (number per 5x5 km; blue) as detected by three medical microbiology laborato-
ries in the Netherlands. Red circles indicate spatial-temporal clusters of community CDI cases (dotted line; 
























C. difficile negative controls
number per 5x5 km
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Table 1. Putative risk-factors of community-acquired CDI, and multivariate conditional logistic regression 
analysis of livestock exposure as a risk factor for community-acquired CDI. aAdjusted for age and gender, 
bmatching variables. CA-CDI; community-acquired CDI; OR: Odds ratio; CI: confidence interval; MVA: multi-
variate analysis; sd: standard deviation.
CA-CDI (N=124) Controls (N=232)
n  N % n   N % ORa (95% CI) MVA OR (95% CI)
Age, mean (±sd)b 49.0 22.6 48.4 22.4
Femaleb 80 / 124 64.5 151 / 232 65.1
Comorbidities <1yr before diagnosis
 Diabetes 12 / 124 9.7 18 / 230 7.8 1.34 0.62 2.91
 Respiratory illness 20 / 124 16.1 20 / 230 8.7 2.03 1.06 3.87
 Kidney disease 5 / 124 4.0 4 / 230 1.7 2.49 0.58 10.70
 Transplant 1 / 124 0.8 0 / 230 0.0
 Cancer 3 / 124 2.4 3 / 230 1.3 1.76 0.24 12.73
 Gastro-intestinal illness 12 / 124 9.7 17 / 230 7.4 1.35 0.60 3.03
 Comorbidity score, mean (±sd) 0.78 1.17 0.49 1.04 1.29 1.05 1.58 1.27 1.03 1.56
Antibiotic use <90 days before diarrhoea
 4C antibiotics 19 / 122 15.6 3 / 228 1.3 43.42 8.43 223.64
 Non-4C antibiotics 27 / 122 22.1 6 / 228 2.6 24.33 7.08 83.55
 Unknown type of antibiotics 18 / 122 14.8 23 / 228 10.1 4.32 1.78 10.48
 Overall antibiotic use 64 / 122 52.5 32 / 228 14.0 10.87 5.14 22.96
Hospital visits <30 days 39 / 119 32.8 64 / 216 29.6 1.16 0.71 1.89
CDI household contacts 1 / 121 0.8 2 / 221 0.9 1.01 0.09 11.20
Diarrhoeic household contacts 6 / 121 5.0 18 / 222 8.1 0.62 0.24 1.56
Contact with infants <2 year old 35 / 121 28.9 89 / 246 36.2 0.76 0.46 1.28 0.87 0.51 1.49
Animal, manure, and meat exposure
 Livestock 10 / 121 8.3 22 / 231 9.5 0.94 0.42 2.07 0.99 0.44 2.24
 Pet(s) 79 / 119 66.4 137 / 228 60.1 1.36 0.82 2.23
 Gardening 34 / 119 28.6 85 / 219 38.8 0.59 0.35 0.99
 Working in food and beverage 4 / 123 3.3 4 / 229 1.7 1.84 0.46 7.40
 Eating meat
  never 2 / 121 1.7 4 / 231 1.7 ref.
  1-2 times a week 16 / 121 13.2 35 / 231 15.2 0.88 0.15 5.17
  3-6 times a week 54 / 121 44.6 113 / 231 48.9 0.94 0.17 5.24
  daily 49 / 121 40.5 79 / 231 34.2 1.32 0.23 7.49
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Discussion 
The incidence of CDI in the community in the Netherlands was estimated at 0.67 
per 10,000 persons per years (95% confidence interval, 0.58-0.78), comparable to 
Salmonella infections [4]. Our multicentre study of community CDI is the first to 
assess both spatial clustering and environmental risk factors for CA-CDI in com-
bination with molecular typing data. We did not find spatial clusters of CDI in a 
large community cohort of diarrhoeic patients. Correspondingly, there was no 
space-time interaction indicative for unusual increases of CDI in the community 
except for one false-positive signal. Our results support the hypothesis that CDI 
transmission in the community derives from widespread sources and not from 
localised environmental point sources, such as livestock farms [11]. 
Concerns that livestock farms –piglet and pig farms in particular– contribute to 
transmission of CDI to humans occurred for several reasons in the Netherlands 
[9]. High rates of C. difficile ribotype 078 have been found among piglets, farmers 
and the farm environments [10, 11, 29]. One out of four persons with daily contact 
with pigs was positive for intestinal carriage with C. difficile of which virtually all 
were ribotype 078 [29]. Application of whole-genome sequencing confirmed the 
presence of 100% identical ribotype 078 strains in pigs and humans [13]. In the 
current study, ribotype 078 cases accounted for 10% of CA-CDI, but its occurrence 
was not spatially clustered in areas of livestock farming. Other studies indicated 
that livestock farming does not lead to regional increases of CDI associated with 
PCR ribotype 078, or to a higher risk of C. difficile colonization in neighbouring 
residents [30, 31]. 
Our study incorporated spatial scan statistics. To our knowledge, two other stud-
ies assessed spatial clustering of CDI in the community in Australia [32] and North 
Carolina [14] respectively. In Australia, no spatial clusters were found among 1,792 
C. difficile cases deriving from 392 postal code areas in Queensland [32]. In con-
trast, clustering was found in 21% of the 1,895 CA-CDI cases analysed in 10 coun-
ties of North Carolina comprising an area of approximately 1.94 million residents 
[14]. CA-CDI was associated with living in proximity to a livestock farm, farming 
raw materials service and nursing home [14]. The latter finding may result from 
the fact that long term care facility residents were eligible for inclusion as CA-CDI 
patients. Both studies included several demographic and environmental factors 
in the constructed spatial models, but molecular typing data and detailed patient 
information on CDI risk factors and animal exposure was lacking. A comparison 
between these findings and our case-control data is not straightforward. Interest-
ingly, C. difficile PCR ribotype 014 was the most prevalent type in pigs in Australia, 
whereas ribotype 078/Toxinotype V was most prevalent in pigs in North Carolina 
[33] and the Netherlands [10]. In Australia, transmission of genetically identical 
ribotype 014 isolates was demonstrated between pigs and humans [12], similarly 
as for ribotype 078 in the Netherlands [13]. 
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Our study has several limitations. We were not able to use exact residential data 
for all patients and experienced overall 10% missing location data. In the spatial 
analyses of laboratory A, we used locations of the general practitioners’ clinics 
which may have caused a bias towards more clustering in this region. Second, our 
control group consisted of patients with diarrhoea due to other causes than 
C. difficile and not the total population-at-risk. Therefore we might have over-
looked CDI clusters that occurred at the same time and place as non-CDI diar-
rhoeic clusters. We assumed that CDI result in a different pattern of clustering 
than other (also non-infectious) causes of diarrhoea, but there is no literature to 
support this assumption. We compensated by use of a second spatial model 
(space-time permutation model), not requiring population-at-risk data. However, 
further exploration of the scale and spatial patterns to be incorporated in spatial 
models for CDI are needed. Finally, we have not included cases (and controls) that 
did not visit their general practitioner or did not submit a stool sample [34]. 
 
CONCLUSIONS  
Our study using spatial scan statistics did not find clusters of CDI in the commu-
nity. The lack of geographical and temporal clustering in the present study in 
combination with a lack of environmental risk factors (e.g. livestock exposure) 
suggest that widespread sources most likely are key in CDI infection and trans-
mission in the community.   
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Chapter 7
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CDI became the most common healthcare-associated infection (HAI) in Northern-
America and Europe during the antibiotic era, especially after global transmis-
sion of a fluoroquinolone-resistant ribotype 027 strain originating from Canada, 
2003 [ 1, 2 ]. The rise of CDI in Northern-America and Europe urged the introduc-
tion of molecular typing services and epidemiological surveillance systems to 
monitor disease dynamics and to detect outbreaks [ 2 ]. Surveillance data are used 
to direct and monitor the effect of local and national infection prevention 
controls interventions, facilitate education of hospital staff, setting priorities 
for research projects, and persuade national authorities to provide sufficient 
resources to combat CDI – as recommended by the WHO [ 3 ]. In the Netherlands, 
a national reference laboratory for molecular typing and ad-hoc surveillance of 
C. difficile has been set up to control transmission of ribotype 027 and other CDI 
in 2005 [ 4 ]. The Dutch national reference laboratory for C. difficile implemented a 
national Sentinel Surveillance for CDI for ongoing monitoring of the incidence of 
CDI and detection of new outbreaks in 2009. The Sentinel Surveillance helps to 
improve local infection prevention in participating hospitals, controls the trans-
mission of highly virulent types such as ribotype 027 and generates new hypo-
theses to understand and optimise the control of CDI [ 5 ].
The Dutch national reference laboratory achieved corporation with many other 
national or central reference laboratories in Europe. However, the heterogeneity, 
insufficiency and/or unavailability of diagnostic, typing and surveillance meth-
odologies across Europe impeded combined efforts to control CDI. Hence, the 
European Centers for Disease Control and Prevention (ECDC) supported a 4-year 
project named ‘the European CDI Surveillance Network’ (ECDIS-Net) to enhance 
CDI surveillance and laboratory capacity to test for CDI in Europe in 2010. 
This thesis aims to describe trends in diagnostic capacity and epidemiology of 
CDI in the Netherlands and Europe and determines requirements to optimise 
surveillance and control of CDI. The thesis incorporated two ECDIS-net studies 
(CHAPTER 2 AND 3) as well two studies using data of Dutch Sentinel Surveillance 
for CDI (CHAPTER 4 AND 5) complemented by a community-based case-control 
study in the Netherlands (CHAPTER 6). The studies’ implications for surveillance 
and control are discussed in the current chapter.   
In CHAPTER 2 of this thesis, we showed that 46% of the surveyed ECDIS-Net labora-
tories had optimal diagnostics for CDI in 2014. This was in line with a larger 
study, illustrating that 48% of the European laboratories used optimal diagnos-
tics for CDI in 2014 [ 6 ]. Our survey provided more insight in the barriers for opti-
mal CDI laboratory diagnostics (e.g. limited resources, budget cuts, and disagree-
ment on optimal CDI algorithms) informing the ESCMID study group for 
C. difficile throughout revision of the European diagnostic guidance document 
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for CDI [ 7 ]. We proposed strategies to promote optimal diagnostics for CDI at 
national level in Europe. These strategies included advocating a single national 
two-step algorithm for CDI like in the United Kingdom [ 8 ], or encouraging the 
use of one of the optimal two-step algorithms of the revised ESCMID diagnostic 
guideline for CDI [ 7 ]. Surveillance programs can stimulate the use of optimal 
diagnostics for CDI and explore statistical strategies to remove residual bias 
caused by diagnostic variability. Still, one should note that many other factors 
(e.g. clinical awareness and criteria for selection of faecal samples tested for CDI) 
bias detection of CDI besides laboratory diagnostics.   
 
Molecular typing of C. difficile can enhance the potency of surveillance systems 
by early detection and confirmation of outbreaks, monitoring the prevalence 
of endemic strains and source tracking, and complements investigation of 
C. difficile antibiotic resistance [ 9, 10 ]. Yet, the variety of applied molecular typing 
methodologies by (national) reference laboratories for C. difficile hampers data 
pooling to obtain an overall view of the European and worldwide molecular 
epidemiology of CDI. In CHAPTER 2 of this thesis we demonstrated that the 
typing capacity of CDI in Europe increased from 71 to 81% in the course of 
ECDIS-Net. PCR ribo typing – exploiting the variable 16S-23S rRNA interspacic 
region of C. difficile – is the standard typing method in Europe for its relative 
simplicity and low costs [ 10 ]. Capacity for PCR ribotyping (standard or capillary) 
increased from 65 to 72%, and capillary PCR ribotyping from 23 to 50%. 
Capillary PCR ribotyping has been preferred for its enhanced discriminatory 
power compared to standard PCR ribo typing and has been standardised by 
four reference laboratories in England, the Netherlands, the United States and 
Canada [ 11 ]. Despite these technical developments, use of PCR ribotyping has 
been restricted by limited resources and budget reductions in several countries. 
This underlines the need for more targeted application of molecular typing 
in epidemiological surveillance for outbreak detection and source tracking of 
CDI, and will also affect the implementation of more discriminatory typing 
methodologies (e.g. whole-genome sequencing). 
 
Implementation of national epidemiological surveillance systems for CDI 
has been recommended after the rise of CDI in Europe in 2003 to control its trans-
mission [ 2, 10, 12 ]. Only fourteen of the 31 European countries (45%) had adopted 
surveillance for CDI in 2011 and methodologies were heterogeneous. Continued 
integration of microbiological data was limited [ 13 ]. A multistate CDI surveil-
lance system, such as implemented in the United States [ 14 ], was considered 
the only viable option to monitor and control the burden of CDI in Europe. In 
CHAPTER 3 of this thesis, we tested a standardised European surveillance protocol 
aimed to monitor and estimate the burden of CDI in Europe in 14 countries with 
varying levels of implemented surveillance activities in 2013. This surveillance 
system had the option of integrating clinical and molecular data, and obtained 
important information on the high number of patients having CDI symptoms at 
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admission (49%) and the presence of PCR ribotype 027 (30%). Results of this study 
were used by ECDC to optimise and initiate European Surveillance of CDI in 2016 
[ 15 ]. A recent European survey illustrated that 20 out of 33 European countries 
had surveillance systems for CDI in place in 2017 and hospitals in at least 21 coun-
tries applied the European Surveillance protocol [ 16 ]. Standardisation of CDI 
diagnostics and molecular typing as described in CHAPTER 2 was considered part 
of integration of C. difficile data in The European Surveillance System (TESSy) 
within this project. Other challenges relate to representative sampling of health-
care facilities participating in surveillance, optimisation of CDI surveillance 
definitions and validation of surveillance data.
 
In the Netherlands, the national Sentinel Surveillance for CDI aims to describe 
trends of the incidence of CDI in participating hospitals, to estimate the total 
burden of CDI Dutch hospitals, and detect circulating and new emerging PCR 
ribotypes in relation to their clinical outcome for targeted control of highly 
virulent ribotypes affecting patient safety. Participating hospitals get direct noti-
fication after isolation of C. difficile ribotype 027 or when an outbreak is suspected. 
The main results of Sentinel Surveillance are annually published on the website 
of the National Institute of Public Health and the Environment (RIVM) and 
included in national reports on the ‘Consumption of antimicrobial agents and antimi-
crobial resistance among medically important bacteria in the Netherlands’ (Nethmap), 
and presented to hospital infection control personnel and microbiologists in the 
Netherlands [ 17, 18 ]. In this thesis, data of Sentinel Surveillance was used to study 
(spatial) trends in the epidemiology of CDI in the Netherlands, in particular for 
children and the potentially zoonotic C. difficile ribotype 078. 
During recent years, there have been concerns about the rise of CDI in children 
as observed in the United States [ 19, 20 ]. Although C. difficile rarely causes infec-
tion in children up to 2 years, the bacterium is potentially hazardous in older 
children [ 21 ]. Children above the age of two years have been included in Sentinel 
Surveillance since its start in 2009. In CHAPTER 4 of this thesis, we analysed clini-
cal and microbiological data of hospitalised children included in Sentinel 
Surveillance to investigate the time trend of CDI among children in our country. 
We did not find an increase of the number of CDI reports (n= 135, 3% of all CDIs) 
amongst children in 2009-2015 in twenty-six Dutch hospitals. There were no out-
breaks on paediatric wards. Approximately one-third of the children met the cri-
teria for severe CDI, but only 3% experience serious complications and none died 
related to CDI. PCR ribotyping showed a high prevalence of ribotype 265 (toxin A 
negative due to a TcdA 1.8 kb deletion, toxin B positive) compared to adults (15 
versus 1%). Multiple-locus variable-number tandem-repeat analysis (MLVA) 
showed that three-fourths of the ribotype 265 strains isolated from children 
were genetically related to those found in adults. According to our international 
survey, ribotype 265 was uncommon or absent in many countries except for 
neighbouring Belgium. Transmission routes could not be elucidated. Notably, 
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ribotype 027 was not isolated from children. We underlined the need for recon-
sideration of diagnostic testing and surveillance definitions for children, as well 
as studies to elucidate the observed differences in the prevalence of specific 
ribotypes of C. difficile compared to adults.
 
In the Netherlands, there have been concerns about the high burden of the poten-
tially zoonotic C. difficile PCR ribotype 078 and its link to pig farming [ 5, 22 ]. In our 
country, 12 million pigs coexist with nearly 17 million humans and pig farming 
is unevenly geographically distributed [ 23, 24 ]. Pigs and pig farm environments 
are commonly contaminated with C. difficile ribotype 078 [ 25 ]. A quarter of Dutch 
farmers tested positive for C. difficile ribotype 078 in a small study [ 26 ] alike live-
stock-associated MRSA [ 27 ] and clonal relatedness of ribotype 078 strains with 
those isolated from pigs and clinical patients has been confirmed by whole- 
genome sequencing [ 28 ]. In CHAPTER 5 of this thesis, we hypothesised that C. diffi-
cile ribotype 078 shedding by pigs (including piglets) leads to increased human 
exposure at a provincial level and consequently higher incidences of ribotype 078 
CDI in hospitals there situated. However, we found that the hospital incidence of 
ribotype 078 CDI was not related to the pig farming density of the province where 
the hospital was located. Nevertheless, the burden of PCR ribotype in the Nether-
lands was substantial (13.1% of all CDI), and these patients had an increased 
mortality risk compared to other CDI patients (Risk Ratio 1.35). We introduced 
the use of space-time statistics [ 29 ] to search for clusters of community-onset CDI 
followed by hospitalisation, but found no evidence for the presence of clustering. 
Our analyses was limited by the fact that not all hospitals in provinces with the 
highest farm density were included due to our sentinel approach and transmis-
sion beyond provincial borders or in outpatients could not be excluded. We 
suggested molecular investigation of multiple reservoir populations and sinks 
(e.g. One Health approach) to study zoonotic transmission of CDI in the absence of 
observed epidemiologic associations. 
 
In CHAPTER 6 of this thesis, we extended the use of spatial scan statistics to search 
for clustering of CDI in the community, using data of a prospective nested case-
control study of three laboratories in the Netherlands from 2010-2012 [ 30 ] in the 
absence of community-based CDI surveillance. CDI is a common cause of diar-
rhoea in the community with an incidence rate of 0.67 cases per 10,000 patient 
years comparable to Salmonella infection in the Netherlands [ 30 ]. CDI clusters in 
the community could potentially co-localise with undetected sources of CDI, that 
may also contribute to CDI in the hospital setting [ 31 ]. We did not detect any spa-
tial or temporal clusters of CDI cases compared to C. difficile negative diarrhoeic 
controls and no evident space-time interaction amongst CDI cases. Livestock ex-
posure was not related to community-acquired CDI (Odds Ratio 0.99). Ten percent 
of community-acquired CDI was caused by PCR ribotype 078, but its occurrence 
was spatially dispersed throughout the study area. Our findings supported the 
hypothesis that CDI transmission in the community derives from widespread 
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sources [ 32 ] and not from localised environmental community point reservoirs, 
such as livestock farms [ 25 ].
 
Lately, the combat on the increasing threat of antibiotic resistance was brought 
into national focus, in line with the worldwide action plan of the WHO [ 33 ]. Goals 
set are e.g. to reduce preventable HAI by 50% in 2015-2019 and to enhance and 
improve regional surveillance using a ‘One Health’ approach. In order to achieve 
a reduction of CDI additional efforts are needed to e.g.; i) Improve evidence-based 
infection prevention in hospitals, ii) evaluate the role of asymptomatic carriers in 
the transmission of CDI iii) provide full reporting of hospital incidence rates for 
CDI linked to indicators of antibiotic stewardship and patient safety, iv) applica-
tion of more discriminatory molecular typing methodologies and model-based 
(spatial) studies for source tracking within and beyond the healthcare setting.
In conclusion, this thesis provided several options for improving surveillance 
and control of CDI at a national and European level.
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Methodological and analytical challenges 
for CDI surveillance  
Compelling evidence how to design (inter)national surveillance systems is lack-
ing [ 34 ], but several studies including those incorporated in this thesis indicated 
the strengths and weaknesses of existing epidemiological surveillance systems 
for CDI. The following paragraphs discuss the main methodological and analy- 
tical challenges for CDI surveillance encountered during the realisation of this 
thesis and provide several options to improve future surveillance of CDI.  
 
 
CASE DEFINITIONS FOR CDI SURVEILLANCE  
Soon after recognition of the emergence of ribotype 027 outbreaks in Europe, 
‘interim’ surveillance definitions for CDI were publised by the ESCMID study 
group for C. difficile in collaboration with ECDC in 2006 [ 2 ]. Interim surveillance 
definitions included a case definition for CDI, recurrent CDI, healthare-associat-
ed and community-associated CDI, severe CDI and a CDI outbreak. The proposed 
surveillance defininitions were mostly based on clinical experience and consid-
ered to be subjected to evidence-based revisions. Most European countries imple-
mented the interim ESCMID definitions for national surveillance of CDI [ 13 ]. The 
ESCMID definitions were also adopted by the Clostridium difficile Surveillance 
Working Group in the United States in 2007, whom underlined the need for 
standardised CDI definitions for benchmarking of incidence rates among health-
care facilities and to direct surveillance activities [ 35 ]. The ESCMID surveillance 
definitions are now used for over one decade and have only slightly been adapted 
−presumably due to their usability, the shortage of validation studies and the 
need of stable parameters.   
 
CLINICAL CASE-DEFINITION  
Both Dutch Sentinel Surveillance and European Surveillance of CDI use the 
ESCMID case-definition for CDI as published in 2006 [ 2 ]. In contrast to the sur-
veillance module of the National Healthcare Safety Network in the United States 
[ 14 ], this definition includes clinical criteria (i.e CDI symptomatology) in addition 
to laboratory confirmation of toxin-producing C. difficile in the stools of the pa-
tient. The Dutch Sentinel Surveillance protocol additionally defines that other 
causes of diarrhoea should be excluded to be eligible for inclusion as CDI case. 
The use of clinical criteria contributes to the specificity of the case-definition 
compared to using laboratory criteria/events only, but goes with an increased 
surveillance workload [ 36 ] due to the need of chart review before patient inclu-
sion. However, this process may be supported by use of sophisticated computer 
algorithms [ 36, 37 ]. The added value of verifying clinical criteria in addition to 
laboratory events for case finding depends on the local criteria for selection of 
faecal samples and applied diagnostic algorithms for CDI. In Chapter 2 of this 
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thesis, we have illustrated the variety of criteria for selection of faecal samples 
tested for CDI in Europe as also illustrated by others [ 6 ]. Besides, the increased use 
of highly sensitive but potentially less specific diagnostics algorithms for CDI (see 
How to standardise laboratory diagnostics for CDI) emphasises the need to preserve 
clinical criteria in the case-definition of CDI [ 38 ]. Whether or not to use a similar 
case-definition for children and as for adults is unclear; a more stringent case-
definition for children seems plausible because of high rates of CDI colonization 
[ 39 ] as discussed in Chapter 4. The use of risk-factors (i.e. hospitalisation, comor-
bidities and antibiotic use) as previously proposed diagnostic criteria [ 40 ] hampers 
diagnosis of CDI in children in the community. Yet, compelling clinical evidence 
(e.g. exclusion of other causes of diarrhoea) and laboratory confirmation of the 
presence of free toxins in the faeces should at least be considered for inclusion of 
children in CDI surveillance. 
RECURRENT CDI  
In Chapter 3 of this thesis, we demonstrated that 12% of all patients suffered 
from recurrent CDI. The surveillance definition of recurrent CDI (“≤8 weeks follow-
ing the onset of a previous episode of CDI”) is based on the time interval between 
two episodes and not on microbiological molecular typing results [ 2 ]. The Dutch 
Sentinel Surveillance protocol specifies if the prior CDI episode was verified by 
laboratory diagnostic results or clinical symptomatology solely, possibly leading 
to higher rates of reported recurrent CDI (Chapter 4 and 5). Recurrent infection 
within 8 weeks can occur due to a relapse of the same or reinfection by another 
C. difficile strain [ 2 ]. The ESCMID definition for recurrent CDI has several advan-
tages. The simplicity of the definion allows its widespread and consistent use (not 
depending on the availibity and methodology of molecular typing for CDI). 
Further, there is no bias due to mixed infections present in 3-7% of the CDI 
patients troubling the confirmation of relapsing strains of C. difficile in one 
patient [ 41 ]. Reported recurrence rates of CDI underlined the high cumulative 
burden of CDI and urged the need for improved treatments stategies, such as 
fecal microbiota transfer [ 42 ]. The disadvantage of not distuiginging CDI relapse 
and reinfection by the current ESCMID definition is missing out the opportunity 
to investigate the separate contributions of reexposure and decreased host resist-
ance to C. difficile to direct infection prevention control measures. However, the 
question is to what degree these aspects can be dissociated from each other. 
Small studies using whole-genome sequencing showed that the majority of infec-
tions (within and beyond the 8-week cutoff) were caused by identical C. difficile 
strains, suggestive of persistance and outgrowth of C. difficile spores during and 
after antibiotic therapy for CDI [ 43, 44 ]. In a validation study, the cutoff of 8 weeks 
had a low sensitivity (56%) and specificity (74%) to indicate patients with a relapse 
due to a same PCR ribotype, and a 20-week cutoff was suggested [ 45 ]. Extension 
of the 8-week cutoff was also suggested by a whole-genome sequencing study on 
ribotype 027 tracking [ 46 ]. Overall, application of the ESCMID definion for recur-
rent CDI is important to highlight the cumulative burden of CDI for patients and 
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to monitor the overall effect of treatment and infection prevention control strate-
gies for recurrent CDI, but should not imply any conclusions on relapse and reinfec-
tion of CDI. The latter requires well-performed molecular typing (See Use of molecu-
lar typing for surveillance) that should be part of efficacy trials of CDI treatment 
modalities and enhanced surveillance. In the Netherlands, one should consider to 
simplify reporting of recurrent CDI in Dutch Sentinel Surveillance, or at least vali-
date the discrimination of two levels of case-ascertainment of the prior CDI.
HEALTHCARE-ASSOCIATED AND COMMUNITY-ASSOCIATED CDI  
As CDI has a variable ‘incubation’ time, not all CDI occurring during admission 
in healthcare facilities derives from transmission within healthcare facilities. 
Besides, a part of healthcare-acquired CDI have its onset after discharge. Clear 
cutoff levels are lacking. Discrimination of local transmission from imported 
CDI has important consequences for hospital infection control [ 47 ]. Whereas 
local transmission requires intensified measures to reduce the infection load in 
the hospital (i.e. cleaning) and interruption of transmission paths (e.g. hand wash-
ing and patient isolation), imported CDI requires investigation of community 
sources and may be an argument to screen for C. difficile at admission. In Chapter 
3, we specified 82% of CDI to be healthcare-associated CDI using the ESCMID sur-
veillance definition (“CDI with onset of symptoms at least 48 hours following admission 
to a healthcare facility or with onset of symptoms in the community within 4 weeks follow-
ing discharge from a healthcare facility”). Notably, half (49%) of the patients had symp-
toms present at admission, but 68% had been hospitalised in the prior 3 months. 
Another hospital than the one where the patient was located at time of diagnosis 
was reported to be origin of infection for 18% of CDI. The Dutch Sentinel Surveil-
lance does not practise the ESCMID definitions of healthcare-associated and com-
munity-associated CDI, but registers the location of onset of CDI. In the Nether-
lands, 65% of CDI in hospitalised patients started in a healthcare facility, in 91% 
of the cases an acute care hospital (Chapter 5). Hospital-onset CDI was less com-
mon in children (45%) than in adults (67%, Chapter 4). 
Proportions of reported healthcare-associated CDI contrast the findings of a 
benchmark whole-genome sequence study illustrating that only 55% of the hospi-
tal cases in Oxfordshire were considered to be locally transmitted by other symp-
tomatic CDI patients (≤10 SNVs difference) [ 31 ]. In another study performed in the 
United Kingdom, 20% of CDI was linked (≤1-2 SNVs difference to a CDI case in the 
prior 90 days (inter-hospital range 7-24%) [ 48 ]. Yet, these studies did not investi-
gate all potential transmission paths of CDI within healthcare facilities and cri-
teria for ‘direct’ transmission by other CDI patients (SNVs difference and time 
interval) need further analysis. One of the studies indicated large inter-hospital 
variations of hospital transmission [ 48 ], emphasising the need of confirmation 
studies in other countries and settings before global extrapolation. These studies 
should also focus on validation of the ESCMID definition of healthcare-associated 
CDI, as suggested by a smaller study [ 49 ].
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SEVERE CDI  
Severity criteria are used for choosing the best treatment strategy for individual 
patients and prediction of unfavourable outcomes of CDI [ 50 ]. Patients that were 
treated according to a guideline basing treatment decisions on CDI severity crite-
ria had a lower 90-day mortality (Risk Difference 31%) compared to other patients, 
although the study was limited by its observational design [ 51 ]. In surveillance 
systems, the use of severity criteria aims to detect signals indicative of increased 
virulence (as observed for PCR ribotype 027) or treatment failure, and data can be 
applied for burden estimations to guide local and national policy. Ribotypes that 
pose an increased threat for patient safety due to enhanced virulence need 
stronger, more timely and potentially tailored responses to prevent transmission 
[ 52, 53 ]. Although surveillance definitions are generally well-standardised across 
Europe, the largest variation has been observed for definitions of severe CDI [ 13 ]. 
There is some muddling of concepts in surveillance systems as some severity def-
initions include symptoms indicative of severe colitis of the gut at time of diagno-
sis, while other definitions include outcomes of CDI (e.g. mortality). The Dutch 
Sentinel Surveillance uses both severity criteria and distinguishes ‘severe’ CDI 
(i.e. bloody diarrhoea and/or pseudomembranous colitis, and/or diarrhoea accom-
panied by dehydration and/or hypoalbuminemia, and/or fever with leucocytosis) 
from ‘complicated’ CDI (leading to IC admission and/or surgery for CDI, or death). 
The ESCMID definition for ‘severe’ CDI [ 2 ] was adopted by The European Surveil-
lance of CDI but labelled as ‘complicated’ CDI. Reporting complication rates of CDI 
conceivably contributes to the readiness to prioritise and improve CDI treatment 
and infection prevention control at a local and (inter)national level. However, use 
of an additional definition for the severity of CDI at diagnosis as in the Nether-
lands provides the opportunity to use the same definition for treatment decisions 
improving patient care.
OUTBREAK DETECTION  
Detection of CDI clustering in space and time can curtail transmission of CDI e.g. 
by indicating shortcomings in infection prevention control and is one of the 
purposes of surveillance for CDI at an institutional level [ 35, 54 ]. There is no clear 
definition for a CDI outbreak. Outbreak definitions are usually based on the 
detection of ≥2 related CDI in a locally defined time period [ 2 ], or a relative or 
absolute increase of the CDI incidence rate [ 44 ]. In the Netherlands, we suspect an 
outbreak if ≥2 cases of the same PCR ribotype occur on one ward of a healthcare 
facility or if the incidence rate is higher than the background incidence (no clear 
cutoff level) [ 55 ]. Ward-based outbreak definitions are practicable but probably 
insufficient due to the fact that hospitals have a high flow of patient transfers 
between wards and procedural diagnostic locations. A recent paper from the 
United States illustrated the usefulness of ‘network graph displaying’ of such 
patient transfers registered by electronic health records tracking patients in 
space and time during admission [ 56 ]. On average, CDI patients moved to four 
different hospital locations between CDI diagnosis and discharge. The analysis 
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revealed the hospital location linked to increased risk of CDI and urged improve-
ment of cleaning practices for that particular location [ 56 ]. Yet, the model as-
sumptions on contamination of the hospital environment of C. difficile need local 
confirmation and molecular typing should confirm the transmission paths as 
found by spatial analysis. A Dutch study describing the largest reported ribotype 
027 outbreak so far, showed that 25% of the CDI patients were transferred ≥3 
times and the number of ward transfers was associated with the risk of CDI [ 57 ]. 
Hence, ward-based outbreak detection will therefore miss out other ways of CDI 
transmission important for infection prevention control. Monitoring hospital-
wide incidence rates of CDI to detect outbreaks does not have this disadvantage 
but requires valid cutoff levels with sufficient sensitivity to detect smaller out-
breaks [ 54 ]. Reliance on manual review of microbiological records by infection 
control personnel and epidemiologists may lead to errors [ 58 ]. In the recent years, 
spatial scan statistics [ 29, 59 ] were developed for automated outbreak detection 
not requiring pre-set cutoff levels. In Chapter 5 and 6 we introduced these models 
to search for spatial clustering beyond the hospital setting, but these models have 
been applied for hospital outbreak detection by others – using the same freely 
available software [ 58 ]. The models have several advantages, e.g. correction for 
random variability, time-trends, seasonality, and multiple testing [ 29, 54, 60 ]. Use 
of the models is feasible and some of its software is freely available, which ena-
bles its global application (also in countries with limited resources). To conclude, 
CDI outbreak detection should not be restricted to onward transmission but 
should be generated by locally validated models with clear thresholds, confirmed 
by molecular typing.   
SAMPLING POPULATION FOR SURVEILLANCE 
ACUTE CARE HOSPITALS  
The ECDC European Surveillance of CDI (Chapter 3) as well as the Dutch Sentinel 
Surveillance system (Chapter 4 and 5) target acute care hospitals. Ideally, for opti-
mal outbreak detection, all hospitals participate in surveillance. However, a rep-
resentative sample of institutions in surveillance suffice to monitor trends and 
reduce the efforts and costs of surveillance. The ECDC European Surveillance of 
CDI has no requirements of hospital sampling at a national level and encourages 
participation of every willing hospital. The Dutch Sentinel Surveillance system 
targets a geographically representative subset of participating hospitals and 
de-links initiation of surveillance from outbreak control. Sampling of healthcare 
facilities for sentinel surveillance has been described by the WHO [ 61 ]. Yet, both 
methodologies are prone to selection bias. In general, the ‘best’ sampling strategy 
depends on the main aim of the surveillance system. For valid national estimates 
on the burden of disease, regular epidemiological methodologies can be applied 
(aiming for high representativeness of the obtained data). However, if the main 
goal of surveillance is rapid detection of outbreaks or other deviations from the 
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background epidemiology for inciting additional infection control interventions, 
healthcare network modelling may be preferable to sample hospitals for partici-
pating in surveillance [ 34 ]. This model uses a ‘movement matrix’ describing 
direct and indirect transfers between hospitals and subsequently simulates trans-
mission of an infection within that network. Hospitals with the lowest detection 
time of the first infection are prioritised for participation in surveillance [ 34 ]. 
Yet, since both the Dutch Sentinel Surveillance and European Surveillance of CDI 
primarily aim to estimate the incidence and burden of CDI in the Netherlands 
and Europe respectively, regular epidemiological methodologies can be used to 
sample a subset of hospitals with a balanced population in relation to general 
patient characteristics, CDI risk factors, clinical course and outcome, and medi-
cal practices compared to all hospitals [ 62 ]. 
OTHER POPULATIONS   
Expanding CDI surveillance to long-term care facilities (LTCFs) as in the United 
States [ 63 ] should be considered for several reasons. LTCF residents have a high 
risk for CDI and liaise C. difficile transmission [ 54, 63 ]. In the Netherlands, several 
persisting ribotype 027 outbreaks occurred in the past. One of these outbreak 
occurred in one hospital and several LTCFs in the Southern part of the Nether-
lands between 2008-2011 [ 64 ]. Of LTCF residents, 23% of the patients tested posi-
tive for CDI and ribotype 027 was isolated from 58% of all samples were submitted 
for PCR ribotyping. MLVA proved clonal genetic relatedness of 027 strains in 
LTCF and hospital patients. Modelling of transmission of antimicrobial-resistant 
pathogens within healthcare networks of hospitals and LTCFs in the Netherlands 
illustrated that extension of surveillance to LTCFs could accelerate detection of 
outbreaks and support national infection control [ 65 ]. CDI surveillance in LTCFs 
could urge improved antibiotic stewardship and infection control in these 
settings, improving patient safety. The number of CDI in LTCF residents is signifi-
cant in the United Sates, about a quarter of all CDIs is found in LTCF patients [ 63 ]. 
The high burden of CDI in LTCFs in the United States was already suggested by 
the high number of LTCF-onset CDIs in hospital patients (36%) [ 14 ]. Results of 
Dutch Sentinel Surveillance indicate that only 5% of the healthcare-onset CDIs 
are related to LTCFs in the Netherlands (Chapter 5). In the European CDI surveil-
lance pilot, LTCFs were reported to be the origin of infection for 1% of the patients 
(Chapter 3). These numbers suggest that the burden of CDI in LTCF in European 
countries might be much lower than in the United States and CDI surveillance is 
these settings would be excessive. In our experience, collection of CDI surveil-
lance data in LTCFs in the Netherlands is challenging. Data collection of resident 
information and institutional parameters, as well as laboratory testing of diar-
rhoeic residents, is not part of daily routine (except for outbreaks) due to a lack of 
time and resources. Therefore, CDI surveillance data of LTCFs is very likely to be 
prone to bias due to underdiagnosis (much more than in hospitals) and missing 
data. Further research (e.g. large point-prevalence studies) is needed to indicate 
the burden of CDI in LTCFs and to indicate if implementation of CDI surveillance 
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in LTCFs outweighs the additional efforts and costs. In the Netherlands, we have 
initiated an ongoing repeated point-prevalence study on CDI and multidrug- 
resistant organisms in 2016-2017 in collaboration with the national reference 
laboratory from Ireland. Moreover, the National Institute of Public Health (RIVM) 
incorporated microbiological detection of colonization of toxin-producing C. dif-
ficile in a cross-sectional prevalence survey of the surveillance network for HAIs 
in nursing homes (SNIV) once [ 66 ]. 
Continued CDI surveillance in the community setting is less often suggested, al-
though being common [ 30, 67, 68 ]. According to the ‘One health’ approach further 
efforts are needed to link human and animal surveillance systems (see Control of 
CDI beyond healthcare-facilities; a one health approach) [ 69 ]. Community-based labora-
tory surveillance of CDI could indicate the currently unidentified time-trend of 
CA-CDI in the Netherlands, and would complement hospital-based surveillance. 
Yet more awareness of general practitioners and revision of the national guide-
line for ‘Acute diarrhoea’ is needed before introducing community-based labora-
tory surveillance in the Netherlands, since only 40% of the CDI patients in the 
community setting are diagnosed [ 30 ]. Surveillance of environmental sources is 
not recommended at present, but would be very useful to detect the attributable 
portion of these sources for human CDI [ 54 ].  
MICROBIOLOGICAL ASPECTS  
 
HOW TO STANDARDISE LABORATORY DIAGNOSTICS FOR CDI  
In Chapter 2 of this thesis, we have demonstrated the variety of laboratory diag-
nostics for CDI in Europe. In total, 19% and 46% of the ECDIS-Net laboratories 
used optimal diagnostics in 2011 and 2014, respectively. These percentages are 
probably an overestimation of the use of optimal diagnostics in all European 
laboratories caused by selection bias. Still, our findings accorded with a large 
European study indicating that 32% and 48% of the European laboratories used 
optimal diagnostics in 2010-11 and 2012-13, respectively [ 6 ]. Of all European hos-
pitals (n=117) that participated in start-up ECDC European Surveillance of CDI in 
2016, 70% used an optimal diagnostic algorithm [ 16 ]. In the Netherlands, 54% of 
the hospitals participating in Sentinel Surveillance used optimal CDI diagnostics 
in 2016-17 [ 70 ]. In Chapter 2 and 3, we stressed the need for further optimisation 
of laboratory diagnostics for CDI to improve clinical care, and s sensitivity and 
specificity of surveillance. Results of ECDIS-Net informed the ESCMID Study 
Group for C. difficile to revise their diagnostic guideline for CDI contributing to 
optimisation and standardisation of CDI diagnostics [ 71 ]. We anticipated that the 
updated guideline would end the debate on optimal laboratory diagnostics 
engaged in ECDIS-Net. Yet after publication of the updated guideline in 2016 [ 7 ] 
ongoing debate focussed on the importance of detecting free C. difficile toxins in 
the faeces compared to toxigenic C. difficile [ 72 ]. The ECSMID diagnostic guideline 
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provides the option of performing a third test (toxigenic culture or NAAT) of GDH 
EIA positive (step 1) but toxin A/B EIA negative (step 2) samples [ 7 ]. Patients with 
toxigenic C. difficile but without detected toxins in the faeces (potentially excre-
tors and not CDI) appear to have a similar 30-day mortality risk compared to 
C. difficile negative patients, whereas patients with C. difficile toxins in the faeces 
have an increased mortality risk  [ 73 ]. Yet, symptomatic patients with toxigenic 
C. difficile are as infectious as patients with C. difficile toxins in the faeces [ 48 ]. 
Besides the clinical consequences, whether or not to approve patients without 
detected toxins in the faeces as having CDI will have an impact on surveillance 
outcomes. Hospitals using algorithms that detect toxigenic C. difficile have higher 
incidence rates that those detecting free C. difficile toxins in the faeces (adjusted 
Incidence Rate Ratio 1.09) [ 72 ]. As the current European guideline did apparently 
not end the debate on optimal laboratory diagnostics for CDI, additional efforts 
are needed for standardisation. Probably the most viable option is to adopt one of 
the algorithms recommended by ESCMID on a regional or national level (incorpo-
rated in national guidelines and surveillance protocols), and to explore statistical 
strategies to remove residual bias caused by diagnostic variability for benchmark-
ing [ 72 ]. Additionally, the role of free toxin detection in the faeces in CDI diagnos-
tics needs further investigation, including the option to use of NAAT cycle thresh-
olds predictive for the presence of free toxins [ 74 ].
HOW TO ADJUST CDI INCIDENCE RATES FOR DIAGNOSTIC VARIABILITY   
Several statistical strategies could be explored to remove bias caused by diagnos-
tic variability for benchmarking of CDI incidence rates. Illustrating the need of 
these strategies, some hospitals participating in Dutch Sentinel Surveillance con-
sider their high CDI incidence rate compared to other hospitals to result from 
their highly sensitive diagnostic algorithm. Hospitals with a higher burden of 
CDI might be more aware and motivated to optimise their diagnostic capability 
exemplifying the chicken and egg situation. In Chapter 3 of this thesis, we stated 
that incidence rates derived from CDI surveillance systems should be adjusted for 
‘key factors related to sampling and testing methods’, i.e. by use of a standardized infec-
tion ratio (SIR) [ 75 ]. A SIR is a summary statistic to express the relative incidence 
of CDI compared to a reference population (e.g. national or European estimate) 
adjusted for biasing factors. For clarification, the proposed biasing factors in 
Chapter 3 do not relate to the patient population at risk (like used for Standard-
ized Mortality Rates in Dutch hospitals) but to the chance of a CDI to be accu-
rately detected and included for surveillance estimates. So how should such a SIR 
be calculated? The simplest approach would be to use a formula that replaces the 
sensitivity and specificity of the applied algorithm by the sensitivity and specific-
ity of the ‘reference’ algorithm [ 76 ]. However, other factors (e.g. clinical aware-
ness) that bias estimations of the CDI incidence cannot be incorporated in this 
formula. One multi-country study in Europe illustrated that three factors most 
significantly bias CDI incidence rates, i.e. diarrhoea sampling frequency, testing 
rate and the laboratory diagnostic algorithm [ 77 ]. Except for the number of all 
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tested diarrhoeal samples, these data are incorporated in European Surveillance 
of CDI (Chapter 3) and Dutch Sentinel Surveillance [ 70 ]. A hindrance to include 
the three factors in a formula is the variety of applied laboratory diagnostic algo-
rithms and uncertainty how to classify all these. In Chapter 3 and 4 while using 
data of Dutch Sentinel Surveillance, we adjusted for three categories of diagnos-
tic algorithms that we considered to have the most contrast in terms of sensitiv-
ity. We found that use of NAAT as a primary test for CDI did influence the inci-
dence of CDI in children, but their might be room for improvement. Another 
elegant approach is the use of place-specific risk-adjustment factors to adjust for 
diagnostic intensity, found by Finkelstein et al. for ‘balanced’ reimbursement of 
health care providers in the United States [ 78 ]. However, their approach requires 
data of migrating patients across states, and could be applicable within European 
countries or cross-border regions, but not for Europe. The use of a risk adjustment 
formulas seems more feasible though not fully accounting for all variations in 
diagnostic testing [ 79 ]. Further studies should validate the coefficients and other 
essential variables to be incorporated in risk adjustment formulas [ 79 ]. Above all, 
promotion of optimal and appropriate diagnostic testing may prevent bias in the 
first place [ 38 ].
USE OF MOLECULAR TYPING FOR SURVEILLANCE  
In Chapter 2 and 3 as well as the current chapter of this thesis, we stressed the 
implementation and standardisation of molecular typing methods for surveil-
lance of CDI (e.g. for detecting local transmission and outbreaks and discrimin 
ating relapse and reinfection of CDI), and demonstrated the improving typing 
capacity for CDI in Europe. A sequel survey in 2017 indicated further expansion 
of the capacity for capillary PCR ribotyping (25/32 European countries) and the 
use of Multilocus Variable Tandem-repeats Analysis (MLVA) by 15 countries [ 16 ]. 
The advantages and disadvantages of PCR ribotyping have been discussed else-
where [ 10, 54 ]. In summary, PCR ribotyping results can exclude the possibility of 
transmission when isolates are unrelated [ 54 ]. Yet, about 1:10 randomly chosen 
pairs of isolates has the same PCR ribotype by chance [ 54 ]. The use of capillary 
PCR ribotyping prevents some of the difficulties of conventional PCR ribotyping 
(e.g. improved discriminatory power and transfer of typing data) and was interna-
tionally standardised [ 11 ]. PCR ribotyping is useful for recognition of new emerg-
ing types, but always requires clinical alertness and knowledge. For example, 
PCR ribotypes evolving from ‘outbreak-related’ clades are not recognisable by 
their ribotype quotation (e.g. 826) [ 55 ] but can have the same properties and requ 
ire enhanced control measurements. Despite the relevance of PCR ribotyping as 
described in this thesis, there is only one trial performed that showed that 10% of 
the ribotyping results had a direct effect on infection control (and 45% for MLVA 
results) [ 80 ]. The use of molecular typing for discriminating false-positive from 
real CDI outbreaks was underlined by another study  [ 81 ]. More discriminatory 
typing methods, such as MLVA as applied in Chapter 4 of this thesis and whole-
genome sequencing can indicate transmission even when epidemiological links 
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are undetected [ 54 ]. In one study, use of MLVA led to a 95% similarity of outbreak 
detection compared to whole-genome sequencing [ 82 ]. Use of MLVA in Chapter 4 
led to the interesting finding that that three fourths of the ribotype 265 strains 
isolated from children and adults were genetically related but did not elucidate 
transmission paths. This may have resulted from incomplete sampling however 
also illustrated the need for linked enhanced epidemiological data on previous 
(healthcare) exposures and validation of MLVA for other ribotypes than 027 and 
078. A secondary outcome of our study was the knowledge that rapid exchange of 
a capillary PCR ribotyping peak patterns with other national reference laborato-
ries for C. difficile provided useful information to contextualize research findings.
The added value of molecular typing data for direct patient-care remains ques-
tionable. Genotypes of C. difficile have been causally linked (but not always [ 83 ]) to 
patient mortality [ 84 ]. In chapter 5, we again demonstrated the increased mortal-
ity risk of patients with ribotype 078 but we did not find an increased mortality 
risk for ribotype 027/176 patients in Chapter 3. Assessing the ‘virulence’ of specific 
genotypes is troubled by confounding host factors [ 83 ] and absence of standard-
ised control group (but a mix of other genotypes with variable virulence factors). 
Yet, whole-genome sequencing consistently showed that ribotype 027 was associ-
ated to higher odds of patient-patients transmission compared to other types 
[ 46, 48 ]. These results endorse the procedures of the Dutch national reference lab-
oratory to directly notify hospitals after isolation of C. difficile ribotype 027. This 
type should be referred to as ‘outbreak-associated’ rather than ‘hypervirulent’. 
In conclusion, the use of molecular typing for CDI surveillance is vital but the 
limited resources and budget reductions in several countries (Chapter 2) force the 
need for well-targeted application of molecular typing in epidemiological sur-
veillance systems, including more expensive and complex typing methodologies 
(e.g. whole-genome sequencing) needed for improved outbreak detection and 
source tracking of CDI. Additionally, the performance of these methodologies 
need a critical eye [ 30 ] and linkage with epidemiological data remains essential.  
 
 
VALIDATION AND EVALUATION OF SURVEILLANCE SYSTEMS  
The validity of a surveillance system needs to be periodically evaluated in relation 
to its goals (e.g. outbreak detection) [ 85 ]. The most well-established framework to 
systematically evaluate surveillance systems was published by the CDC in 2001 
[ 62 ]. The CDC framework focusses on public health surveillance systems in gen-
eral and comprehends ten evaluation attributes (simplicity, sensitivity, data qual-
ity, flexibility, acceptability, positive predictive value, representativeness, timeli-
ness, stability and usefulness) [ 62,  86 ]. Application of the framework needs 
prioritising and tailored use of the ten attributes for each surveillance system 
evaluation [ 62, 85 ]. Surveillance validation studies for CDI and HAI in general are 
rarely published [ 87, 88 ]. Moreover, there are no clear cutoff levels of acceptable 
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sensitivity and specificity for CDI surveillance [ 89 ]. In Chapter 3 of this thesis, we 
(partly) assessed the attributes simplicity, data quality, acceptability and useful-
ness of the CDC framework for Surveillance of CDI and stated that national and 
European Surveillance of CDI should be accompanied by validation studies. Most 
important evaluation attributes for CDI surveillance as highlighted earlier in this 
chapter are; data quality (intrinsic validity), representativeness and surveillance 
sensitivity and specificity. The intrinsic validity of collected surveillance data is of 
crucial importance for benchmarking of surveillance outcomes [ 89, 90 ]. The in-
trinsic validity of a surveillance data can be undermined by inter-hospital and/or 
international variability of the implementation and performance of a surveil-
lance system leading to ‘data quality bias’ [ 31, 36 ]. ECDC has illustrated the use of 
point-prevalence studies for validation of HAI surveillance to evaluate data qual-
ity, as well as surveillance sensitivity and specificity [ 88 ]. Warranting representa-
tiveness of surveillance is of particular importance while designing (see Sampling 
of healthcare facilities for Surveillance systems) [ 88 ]. Other options include e.g. 
comparison of different (electronically derived) datasets and capture-recap 
ture methodologies [ 85 ]. Representativeness of surveillance data should ideally be 
verified by comparison of ‘minimal’ surveillance data (Chapter 3) of the complete 
hospital population, and enhanced surveillance data of a subset of the hospital 
population. In view of the increased interest in HAI incidence rates for differenti-
ating healthcare safety between hospitals [ 36,  91 ] it is likely that reporting of 
hospital incidence rates of CDI will become normative in the coming years in 
the Netherlands and other European countries and these data can be used for 
validating the representativeness of (Sentinel) CDI surveillance.   
 
 
IMPLICATIONS FOR INFECTION PREVENTION CONTROL
OPTIMIZING CONTROL OF CDI WITHIN HEALTHCARE-FACILITIES  
CDI remains one of the most prevalent healthcare-associated infections in the 
United States and Europe despite the use of enhanced infection prevention 
control over the last decade [ 92, 93 ]. These infection prevention control measures 
include environmental disinfection, antibiotic stewardship and bundled inter-
ventions, usually intensified during outbreaks [ 94, 95 ]. Whereas outbreak control 
is achievable by using these measures, reduction of the endemic incidence of CDI 
remains challenging and acquires additional efforts. The CDC published an 
expanded roadmap for elimination of HAI including CDI in hospitals and LCTF in 
the United States in 2013 [ 96 ]. Notably, CDI was the only HAI that did not met the 
prior target (30% decrease in 2008-2013). To achieve subsequent targets, research 
projects to improve the knowledge of CDI transmission and a toolkit to support 
reduction of CDI by antibiotic stewardship were realised [ 96 ]. In fact, a recent 
meta-analysis showed that antibiotic stewardship can decrease CDI incidence 
rates with 32% [ 97 ]. Especially reduction of the use of fluoroquinolones have been 
linked to a decrease of CDI in England [ 53 ]. CDC currently aims for a 30% reduc-
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tion of the standardised infection ratio of CDI and hospitalizations due to CDI in 
2015-2020 [ 98 ]. The ECDC has not (yet) set targets for CDI reduction in Europe, but 
has several activities to support antibiotic stewardship [ 99 ] and infection preven-
tion control of CDI, in addition to the initiation of European Surveillance of CDI 
and support of microbiological molecular typing for CDI [ 15 ]. National guidelines 
for infection prevention control of CDI in Europe are accessible at the website of 
ECDC, illustrating that most of these are out-dated as for the Netherlands. The 
ESCMID/ECDC infection prevention guideline for CDI [ 100 ] is currently updated 
and will be published in 2018. Model-based studies are useful to anticipate on the 
effectiveness and target population of (novel) strategies to reduce CDI with 
in healthcare facilities [ 101 ]. For example, one model-based study evaluated the 
effectiveness of vaccinations under development for CDI in a dynamic hospital 
setting (43% reduction) [ 101 ]. Decontamination of food was considered to have a 
minimal effect on transmission of CDI in another study exploiting modelling 
[ 102 ]. In a comprehensive model-based study, the two most effective strategies to 
reduce the incidence of hospital-onset CDI were daily cleaning with a sporicidal 
disinfectant and screening at admission, endorsing the importance of asympto-
matic carriers for transmission of CDI in the hospital setting [ 103 ]. Isolating 
asymptomatic carriers of C. difficile at admission in a quasi-experimental study 
from Canada prevented 62% of the expected CDI [ 104 ]. Another model-based 
study confirmed the effectivity of screening at admission, but also illustrated 
this approach needs to complemented by bundled interventions [ 105 ]. Currently, 
a multicentre study is performed to disentangle the risk-factors of asymptomatic 
carriers of C. difficile at hospital admission and their role in hospital transmission 
of CDI in the Netherlands.  
 
 
CONTROL OF CDI BEYOND HEALTHCARE-FACILITIES;    
A ONE HEALTH APPROACH   
As mentioned before, growing evidence supports the concept that control of CDI 
also requires evaluation and management of C. difficile reservoirs beyond health-
care-facilities. The burden of CDI in the community is considerable (Chapter 6) 
especially in view of the number of patients that do not visit their general practi-
tioner with diarrhoea or submit a stool sample to search for infectious causes of 
diarrhoea [ 106 ]. There are no studies that tested infection prevention control 
strategies outside healthcare facilities. However, there has been an increased in-
terest in studying reservoirs and transmission paths in the community setting 
[ 107 ]. As said, reservoirs include ‘one or more epidemiologically connected popu-
lations or environments in which the pathogen can be permanently maintained 
and from which infection is transmitted to the target population (here: humans 
susceptible for CDI)’ [ 108 ]. Theoretically, blocking tactics of exposure to CDI reser-
voirs in the community – especially for high-risk patients – could result in further 
control of CDI. In practice, this would be easier to achieve if contributing source 
populations are piglets or pigs and not asymptomatic infants and adults carrying 
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C. difficile as suggested in the previous paragraph. Besides, the feasibility of such a 
blocking tactic will depend on the detected transmission paths (e.g. meat con-
sumption). It remains an anomaly that the community is not particularly inter-
ested in the rates of C. difficile contamination of food as for Salmonella species, 
given the same rates of these infections in the community. This is probably 
caused by the fact that CDI is still known as an healthcare-associated infection 
and is expected to change if the news on community-acquired CDI pervades in 
the community. Besides, healthy community residents that do use antibiotics or 
other drugs might consider themselves erroneously not at risk for CDI at all. The 
question is if that is correct. In the scientific community, C. difficile is now recog-
nised as one of the pathogens needing a ‘One Health’ approach. By this approach, 
three health domains (human, animal, and environmental) are evaluated to pro-
vide an comprehensive understanding of the infection and effective strategies 
for infection control [ 109 ]. A proposed One Health framework cites ‘directed acy-
clic graphs’, ‘risk models’ and ‘geographical information systems’ (GIS) as impor-
tant study methodologies [ 109 ]. In Chapter 6 of this thesis, we created a direct 
ed acyclic graph to visualise the relation between livestock exposure and CDI. 
Besides that, we introduced the use of geographical information systems viz. spa-
tial scan statistics [ 110 ] in Chapter 5 and 6. Spatial clustering can trace infection 
sources whereas spatial and temporal connectivity between the reservoir and 
target population can trace (indirect) transmission paths  [ 111 ]. In Chapter 6 
we have elaborated on the limited application of spatial analysis in the field of 
C. difficile research and the conflicting results of published studies [ 60, 112, 113 ]. 
We called for further exploration of spatial settings (scale, patterns) and control 
data to construct spatial models for CDI. In future spatial analysis studies, dis-
criminative molecular typing data and extensive epidemiological patient data 
should be integrated. 




In Europe, including the Netherlands, a variety of laboratory diagnostics for CDI 
were used of which around half is suboptimal. Consequently, the burden of CDI 
in Europe has been underestimated for years [ 6 ]. Optimisation of CDI diagnostics 
improves clinical care, and sensitivity and specificity of surveillance. Epidemio-
logical surveillance systems can endorse the use of optimal diagnostics for CDI 
and explore statistical strategies to remove residual bias. In the Netherlands, full 
adherence to European diagnostic guidelines should be strongly stimulated. 
After tackling the problem of underdiagnosis, future challenges relate to ascer-
tainment of the role of free toxin detection in the faeces in CDI diagnostics and 
optimal testing criteria for CDI in children. 
Surveillance data are used to direct and monitor the effect of local and national 
infection prevention control interventions, facilitate education of hospital staff, 
set priorities for research projects, and persuade local and national authorities to 
provide sufficient resources to combat CDI – as recommended by the WHO [ 3 ]. 
Facing the heterogeneity of European surveillance systems and a shortage of 
incorporation of microbiological molecular typing data [ 13 ], a standardised sur-
veillance protocol was tested and proved to be feasible for countries with varying 
levels of implemented surveillance activities. Standardised European Surveil-
lance of CDI is essential for benchmarking of CDI incidence rates (between facili-
ties and countries) and burden estimations, and was initiated by ECDC in 2016 
after completion of our study  [ 16 ]. Application of capillary PCR ribotyping and 
more discriminatory molecular typing methodologies (e.g. whole-genome 
sequencing) for improved outbreak detection and source tracking of CDI should 
be well-targeted, given the limited resources and budget reductions in several 
European countries. European Surveillance of CDI would benefit from periodic 
evaluation and clinical validation studies, as well as incorporation of spatial data 
(carefully considering the sensitivity of such data). 
In the Netherlands, national surveillance of CDI helps to improve local infection 
prevention in participating hospitals, controls the transmission of highly viru-
lent types such as ribotype 027 and generated new hypotheses to understand and 
optimise the control of CDI. In this thesis, data of the Sentinel Surveillance for 
CDI – initiated in 2009 – was used to study (spatial) trends in the epidemiology of 
CDI in the Netherlands, in particular for children and the potentially zoonotic 
C. difficile ribotype 078. CDI among children did not increase, but we illustrated 
notable differences in the prevalence of specific ribotypes (265 and 027) compared 
to adults. This thesis relativized the role of pig farming to the incidence of PCR 
ribotype 078 in the Netherlands. There was no association between hospital inci-
dence rates of ribotype 078 CDI and provincial pig farming density. No spatial 
clusters of community-onset CDI followed by hospitalisation were detected. Cor-
respondingly, no spatial or temporal clusters were found by a community-based 
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study and the distribution of PCR ribotype 078 was not linked to specific geo-
graphical areas. Livestock exposure was not related to community-acquired CDI. 
These findings supported the hypothesis that CDI transmission in the communi-
ty derives from widespread sources and not from localised environmental com-
munity point reservoirs, such as livestock farms. To identify the attribution of 
these reservoirs and transmission paths, ‘One Health’ studies incorporating high-
ly discriminative molecular typing and modelling are needed.
To conclude, CDI should be designated as an urgent treat in European and Dutch 
healthcare as in the United States [ 114 ].  Future activities should focus on; i) 
improving of evidence-based infection prevention in hospitals, ii) evaluating the 
role of asymptomatic carriers in the transmission of CDI iii) provide full report-
ing of hospital incidence rates for CDI linked to indicators of antibiotic steward-
ship and patient safety, iv) application of more discriminatory molecular typing 
methodologies and model-based (spatial) studies for source tracking within and 
beyond the healthcare setting (using a ‘One Health’ approach). 
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Dutch summary 
Clostridium difficile infectie (CDI) is sinds het veelvuldig gebruik van antibiotica 
in de gezondheidszorg uitgegroeid tot de meest voorkomende zorg-gerelateerde 
infectie in Noord-Amerika en Europa. Bij patiënten met een verstoorde darmflora 
(hoofdzakelijk door antibiotica) kan de bacterie hevige diarree en soms een 
levensbedreigende darmontsteking veroorzaken door de vorming van ‘toxines’ 
(gifstoffen). In Nederlandse ziekenhuizen treden 3 CDI gevallen per 10.000 
verpleegdagen op. Bij mensen met gezonde darmflora en afweer geeft de darm-
bacterie geen klachten. Circa 14% van de patiënten met een CDI sterft binnen 30 
dagen na het stellen van de diagnose, waarvan 4% (deels) door de directe gevolgen 
van de darminfectie (HOOFDSTUK 4 EN 5). C. difficile is een bekende oorzaak van 
diarree-uitbraken in ziekenhuizen en verpleeghuizen, maar ook buiten zorg-
instellingen is C. difficile alom in onze leefomgeving aanwezig. Uit recente studies 
blijkt dat meer dan de helft van de ziekenhuispatiënten met CDI de bacterie 
waarschijnlijk elders heeft opgelopen, maar het brononderzoek is zeer complex. 
Sinds 2005 zijn een groot aantal Nederlandse zorginstellingen getroffen door CDI 
uitbraken van een meer antibioticaresistent C. difficile subtype dat zich vanuit 
Canada en de Verenigde Staten naar Europa heeft verspreid. Patiënten met CDI 
bleken ernstiger ziek te worden en vaker aan de infectie te overlijden dan voor-
heen bekend. Middels moleculaire typering werd dit subtype aangeduid als ‘PCR 
ribotype 027’. In Nederland werd, net als in andere Europese landen, een natio-
naal referentielaboratorium opgezet ter ondersteuning van de infectiebestrij-
ding middels moleculaire typering en surveillance onderzoek. In de loop van 
2006 werd er een grote afname van PCR ribotype 027 waargenomen, alhoewel 
uitbraken bleven voorkomen. In 2009 voerde het referentielaboratorium een 
doorlopend nationaal surveillanceprogramma in een deel van de Nederlandse 
ziekenhuizen in (‘Sentinel surveillance’). Hiermee werd beoogd het voorkomen 
van CDI in Nederland beter te monitoren en uitbraken sneller te kunnen opmer-
ken en bestrijden.  
Sinds de verspreiding van PCR ribotype 027 in Europa roept het ‘European Centre 
for Disease Prevention and Control’ (ECDC) op tot nationale surveillance in 
alle Europese landen. In 2011 bleken slechts 14 van de 31 Europese landen (45%) 
surveillance toe te passen en met beperkt gebruik van moleculaire typering. 
Berekeningen van de incidentie en ziektelast van CDI in Europa waren niet goed 
mogelijk door het gebruik van uiteenlopende en vaak suboptimale laboratorium-
diagnostiek-, typerings- en surveillancemethoden. Signalen van internationale 
uitbraken of verspreiding van subtypes met een toegenomen ziektelast waren 
hierdoor lastig te herkennen. In 2010 initieerde ECDC een vierjarig project 
genaamd ‘European CDI Surveillance network (ECDIS-Net)’ om de diagnostiek en 
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surveillance op Europese schaal te verbeteren. Het eerste deel van dit proefschrift 
omvat twee studies van ECDIS-Net om de (mogelijkheden tot) standaardisatie van 
laboratoriumdiagnostiek,  typerings- en surveillancemethoden voor C. difficile te 
onderzoeken.
De laboratoriumdiagnostiek van CDI dient te bestaan uit het uitvoeren van 
meerdere testen in een ‘algoritme’. Door één enkele test te gebruiken of een 
incorrecte combinatie van testen kan CDI worden gemist of juist onterecht 
worden vastgesteld. HOOFDSTUK 2 van dit proefschrift beschrijft dat slechts 46% 
van de ECDIS-Net laboratoria in 2014 een optimaal algoritme gebruikte om CDI te 
diagnosticeren. In 2011 was dit percentage 19%. De studie gaf meer inzicht in de 
barrières voor het implementeren van optimale laboratoriumdiagnostiek in 
Europese laboratoria, welke werd gebruikt bij de totstandkoming van een nieuwe 
Europese richtlijn voor de diagnostiek van CDI in 2016. Surveillanceprogramma’s 
kunnen het gebruik van optimale laboratoriumdiagnostiek stimuleren en statis-
tische methoden toepassen om vertekening (bias) door diagnostische variabiliteit 
zo goed mogelijk te corrigeren. 
 
Met moleculaire typering kunnen thans ongeveer 600 verschillende PCR ribo-
typen van C. difficile onderscheiden worden. Door het genetisch materiaal van 
C. difficile bij verschillende ziektegevallen te vergelijken, krijgt men inzicht in de 
verspreiding van de bacterie binnen een zorginstelling, tussen zorginstellingen 
of op grotere schaal. HOOFDSTUK 2 laat zien dat de Europese capaciteit voor PCR 
ribotypering tussen 2011 en 2014 toenam van 65 tot 72%. De capaciteit voor een 
internationaal gestandaardiseerde vorm van PCR ribotypering met een verbeterd 
onderscheidend vermogen (‘capillaire’ PCR ribotypering) steeg van 23 tot 50%. 
Optimale toepassing van bestaande en verbeterde moleculaire typeringsmetho-
den is belangrijk, maar niet vanzelfsprekend door de beperkte middelen en 
bezuinigingen in verschillende Europese landen. De ontwikkeling en toepassing 
van nieuwe typeringsmethoden, zoals bijvoorbeeld ‘whole-genome sequencing’ 
met gebruik van nagenoeg het complete bacteriële genoom, vindt slechts in 
enkele laboratoria plaats.  
 
ECDIS-Net leidde tot de realisatie van een gestandaardiseerd Europees surveil-
lanceprotocol met ondersteuning van moleculaire typering, om de infectie-
bestrijding van CDI op grotere schaal te kunnen verbeteren. In HOOFDSTUK 3 van 
dit proefschrift werd dit surveillanceprotocol getest in 14 Europese landen in 
2013. Implementatie van het protocol was haalbaar in alle deelnemende landen 
met een acceptabele en bruikbare hoeveelheid data. Opvallend was het hoge aan-
tal patiënten met symptomen van CDI bij ziekenhuisopname (49%) en de hoge 
prevalentie van PCR ribotype 027 (30%). Ook een andere studie toonde aan dat 
er nog steeds grote uitbraken van PCR ribotype 027 plaats vinden, met name 
in Oost-Europa. Na afronding van deze studie heeft het ECDC het Europese 
surveillanceprogramma van CDI verder geoptimaliseerd en toegankelijk ge-
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maakt voor alle Europese landen. In 2017 namen ziekenhuizen in minstens 
21 landen deel. Verdere aandacht is nodig voor verbetering van gebruikte surveil-
lance definities, het verkrijgen van een representatieve populatie en het valide-
ren van verkregen data.  
In het tweede deel van dit proefschrift werden gegevens van het Sentinel surveil-
lanceprogramma in Nederlandse ziekenhuizen en een patiënt-controle onder-
zoek in de huisartsenpraktijk gebruikt om veranderingen in de epidemiologie 
van CDI in Nederland te bestuderen. Hierbij lag de nadruk op recente ontwikke-
lingen, zoals de prevalentie van CDI bij kinderen, de verspreiding van C. difficile 
vanuit de vee/varkenshouderij of andere mogelijke bronnen van CDI buiten het 
ziekenhuis. 
De afgelopen jaren werd er een toename van CDI bij kinderen in de Verenigde 
Staten gerapporteerd. Het Sentinel surveillanceprogramma registreert kinderen 
vanaf 2 jaar met CDI, omdat de betekenis van C. difficile bij kinderen jonger dan 
2 jaar onduidelijk is. HOOFDSTUK 4 van dit proefschrift beschrijft de analyse van 
klinische en microbiologische surveillancegegevens van kinderen met CDI in 
Nederlandse ziekenhuizen. Er bleek geen toename van het aantal CDI meldingen 
bij kinderen (3% van alle CDI) in 26 Nederlandse ziekenhuizen in 2009-2015. 
Ongeveer een derde van de kinderen had een ernstige infectie, maar slechts 
3% had complicaties en geen van de kinderen stierf aan de gevolgen van CDI. 
Kinderen waren relatief vaak besmet met PCR ribotype 265 vergeleken met 
volwassenen (15 versus 1%). Een specifieke moleculaire analyse middels Multiple- 
locus variabele-number tandem-repeat analyse (MLVA) toonde aan dat driekwart 
van de ribotype 265-stammen van kinderen genetisch gerelateerd waren aan die 
van volwassenen. Ribotype 265 bleek bij navraag zeer zeldzaam of afwezig 
in verschillende landen ter wereld behalve in het naburige België (ook bij jonge 
kinderen). Het bleef onduidelijk hoe dit type zich kan hebben verspreid. Het 
uitbraak-geassocieerde PCR ribotype 027 werd niet gevonden bij kinderen. Deze 
verschillen behoeven verdere opheldering.   
Na bestrijding van PCR ribotype 027 in Nederland ontstond er een hoge ziektelast 
van C. difficile PCR ribotype 078 (13% van alle CDI), wat mogelijk van dier op mens 
overdraagbaar is. Uit eerdere studies bleek dat een kwart van de geteste 
Nederlandse varkensboeren positief testte op ribotype 078 en dat varkens en hun 
omgeving vaak verontreinigd zijn met dit type. Er werden genetisch identieke 
bacteriën in varkens en mensen aangetroffen middels whole-genome sequen-
cing. In HOOFDSTUK 5 van dit proefschrift onderzochten we of een verhoogde 
dichtheid aan varkens leidt tot een hogere incidentie van ribotype 078 CDI in de 
daar gelegen ziekenhuizen. Er bleek echter geen verband tussen de ziekenhuis-
incidentie van ribotype 078 en de provinciale varkensdichtheid. Tevens zochten 
we naar geografische clustering van CDI ziektegevallen die opgenomen werden 
in het ziekenhuis maar voor opname klachten hadden gekregen. Er werden geen 
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geografische clusters gevonden. Patiënten met PCR ribotype 078 hadden wel een 
verhoogd sterfterisico in vergelijking met andere CDI patiënten (relatief risico 
1.35) zoals eerder vastgesteld. Om verspreiding van CDI verder te onderzoeken 
zal dus nog breder moeten worden gekeken. Momenteel worden infecties in 
toenemende mate onderzocht in de context van een ecologisch systeem tussen 
mens, dier en omgeving; het zogenaamde 'One Health'-concept.  
HOOFDSTUK 6 van dit proefschrift beschrijft onderzoek naar geografische cluste-
ring en omgevingsrisicofactoren (met name blootstelling aan vee) van CDI buiten 
het ziekenhuis. Hierbij hebben we gebruikgemaakt van data van een eerder afge-
rond patiënt-controle onderzoek in de huisartsenpraktijk. De hypothese was dat 
clustering van CDI buiten het ziekenhuis zou kunnen wijzen op nog niet eerder 
gedetecteerde omgevingsbronnen van C. difficile, zoals veehouderijen. Er werden 
echter geen geografische clusters gevonden en blootstelling aan vee verhoogde de 
kans op CDI niet (Odds Ratio 0.99). Mogelijk wordt vindt verspreiding van CDI dus 
plaats via wijdverspreide bronnen (zoals dragers van C. difficile zonder klachten) 
en niet door plaatselijke omgevingsbronnen. Momenteel loopt een nieuw onder-
zoek naar de risicofactoren en besmettelijkheid van dragers van C. difficile bij 
ziekenhuisopname. 
CDI blijft vooralsnog de meest voorkomende zorg-gerelateerde infectie in Europa 
met een aanzienlijke sterfte. Hoewel de incidentie van CDI in Nederland al jaren 
stabiel is, blijven uitbraken voorkomen. Er zijn aanvullende maatregelen nodig 
om CDI verder te bestrijden, waarbij de belangrijkste aanbevelingen vanuit dit 
proefschrift zijn: i) verbetering van op onderzoek berustende infectiepreventie in 
ziekenhuizen, ii) het realiseren van optimale laboratoriumdiagnostiek voor CDI 
in alle ziekenhuizen, iii) meer aandacht voor de rol van dragers bij de versprei-
ding van C. difficile, iii) continue monitoring van de ziekenhuisincidentie van 
CDI in alle ziekenhuizen als indicator voor patiëntveiligheid, iv) toepassing 
van hoog-onderscheidende moleculair typeringsmethoden in een 'One Health’ 
context om het brononderzoek van CDI te laten slagen.
Concluderend biedt dit proefschrift verschillende opties voor verbetering van 
surveillance en infectiebestrijding van CDI.
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